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ABSTRACT
The cellular response to DNA damage is an evolutionarily conserved process mediated
by Ser/Thr kinases that results in the formation of multiple protein-protein complexes
designed to control the cell cycle. The assembly of those multi-protein complexes is
often triggered by the phosphorylation of a protein generating a short phospho-motif that
is subsequently recognized by a downstream phospho-binding domain. To gain a better
understanding of the exact mechanisms by which kinases signal through their substrates
to phospho-binding domains in the DNA damage signaling process, we used two
complementary proteomic screening approaches to identify novel kinase substrates and
new phospho-binding domains. First, to explore the p38/stress-activated protein kinase
(SAPK) axis of DNA damage signaling, we determined the optimal phosphorylation
motifs of mammalian p38/SAPK and MAPKAP Kinase-2. The optimal substrate
phosphorylation motif for MAPKAP Kinase-2 closely matches the 14-3-3-binding site on
CDC25B/C, and we show that MAPKAP Kinase-2 is directly responsible for CDC25B/C
phosphorylation and 14-3-3-binding both in vitro and in response to UV-induced DNA
damage within mammalian cells. Using RNA interference we demonstrate that down-
regulation of MAPKAP Kinase-2 eliminates both the G2/M and intra S-phase
checkpoints. We show that MAPKAP Kinase-2, more aptly named CHK3, is new
member of the DNA damage checkpoint kinase family that functions in parallel with
CHK1 and CHK2 to integrate DNA damage signaling responses and cell cycle arrest in
mammalian cells. Second, to identify phospho-binding domains functioning downstream
of the kinases ATM/ATR, we developed a high-throughput chemical proteomic screening
approach to isolate phospho-binding domains that interact with the [Ser/Thr]-Gln motifs
phosphorylated by ATM/ATR. We identified the tandem BRCA1 carboxy-terminal
(BRCT) domains as novel phospho-specific binding domains regulating PTIP and
BRCA1 function and show that the phospho-binding function of BRCA1 is lost in many
BRCA1-BRCT mutations that predispose women to breast and ovarian cancer. Together
with our 1.85A X-ray crystal structure data of the phosphopeptide bound BRCA1 BRCT
domains, we provide a molecular rational as to how these mutations disrupt some
BRCA1 functions. In combination, our discoveries expand the molecular understanding
as to how kinases signal to phospho-binding domains in the DNA damage response
signaling network, provide insight into cancer development and as well as identify novel
targets for the development of chemosensitizing therapeutic agents.
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Chapter 1
Signaling and Protein Phosphorylation in the DNA
Damage Response Network
6
The DNA Damage Response Signaling Process
Most cancers exhibit genetic instability [1]. This instability occurs at both
the nucleotide level and at the chromosome level [2]. In many cases,
chromosomal instability results in the loss or gain of whole chromosomes [1].
While, the DNA damage signaling and repair pathway is necessary to maintain
genomic integrity, we have only a skeletal understanding of how the DNA
damage checkpoint functions to maintain genomic stability. Several types of
DNA damage can trigger the different DNA damage checkpoints, which will
temporarily halt cell division and allow for the repair of damaged DNA or, if the
extent of damage is beyond the capacity of repair, the activation of apoptosis [2].
Protein complexes that recognize different types of DNA damage, such as
lesions commonly caused by ionizing radiation (IR) and ultraviolet light (UV),
initiate the activation of the kinases ataxia-telangiectasia mutated (ATM) and
ataxia-telangiectasia- and RAD3-related (ATR) [1]. One protein complex thought
to scan DNA for distortions and activate ATR is the Rad9/Radl/Husl
heterotrimeric checkpoint sliding clamp complex, which is similar to the
proliferating cell nuclear antigen (PCNA) homotrimeric sliding clamp. Another
protein complex, consisting of Mrel 1/Rad50/Nbsl, is thought to localize to sites
of double stranded DNA breaks and subsequently increase the activation of ATM
[2]. ATM and ATR transduce the signal of DNA damage that engages the DNA
damage checkpoint and have overlapping functions as substrates common to
both kinases have been identified. Activation of ATM and ATR leads to the
phosphorylation and activation of several downstream substrates, including p53
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and the Ser/Thr checkpoint kinases CHK1 and CHK2. One way in which both
CHK1 and CHK2 regulate cell cycle progression is through their phosphorylation
of the phosphatase CDC25B on Ser 309 and CDC25C on Ser 216. For the cell
cycle to proceed to mitosis, CDC25B/C must translocate to the nucleus, where it
activates Cdkl/cyclin B by reversing inhibitory phosphorylation events [3]. When
CDC25BI/C is phosphorylated on Ser 309 and Ser 216 respectively, it is bound by
the phospho-specific binding protein 14-3-3, which sequesters CDC25B/C in the
cytosol, thereby inhibiting the transition into mitosis [4, 5].
Simplistically, the DNA damage response signaling network can be
thought of as a network comprised of sensors and tranducers. Sensors, such as
the Rad17-RFC and 9-1-1, and Mrell1-Rad50-Nbs1, are thought to directly
associate with various forms of damaged DNA (and the damage repair
complexes at those sites) to help serve as activation complexes that modulate,
recruit, and localize specific signaling proteins such as kinases. Transducers
include protein kinases that, when activated by the presence of sensor
complexes and DNA damage, initiate a signal transduction cascade that
propagates and amplifies the damage signal to ultimately cause cell cycle arrest
or cell death.
There exists a need to identify additional kinase substrates of these DNA
damage responsive kinases and to determine how kinase phosphorylation
modulates these newly phosphorylated proteins. Therefore, the goals of my
thesis are to identify new kinase substrates in the DNA damage response
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pathway as well as identify new phospho-binding domains in the DNA damage
response pathway that facilitate DNA damage signaling and repair.
Signaling and the Protein Kinase
Protein kinases are a fundamental component of almost all mammalian
signaling pathways. Despite there fundamental roles, most kinases have relativity
few, if any, identified substrates. Analysis of the human genome indicates that
protein kinase catalytic domains are contained within ~1-2% of all potential open
reading frames, and over 400 of these are thought to be either Ser/Thr or dual-
specificity protein kinases [6]. In addition, 30% or more of all intracellular proteins
are likely to be phosphorylated at some point in time during the lifetime of the
cell. Protein phosphorylation often functions to regulate substrate binding and
catalytic activity primarily by inducing allosteric changes in protein tertiary
structure. However signal transduction by protein kinases also results in the
directed assembly of multi-protein complexes at specific locations within the cell
[7]. This process is particularly evident following DNA damage, where activation
of DNA damage kinases results in the formation of protein-protein complexes at
discrete foci within the nucleus [1]. In many cases, kinases directly control the
formation of these multi-protein complexes by generating specific
phosphorylated-motif sequences; modular binding domains then recognize these
short phospho-motifs to mediate protein-protein interactions. Determining which
protein kinases are responsible for phosphorylating particular protein substrates
is critical for mapping signal transduction cascades that regulate the growth,
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division, differentiation and death of a cell. To enhance our knowledge of the
DNA damage signaling process, part of my thesis work focuses on the
identification of additional kinase substrates in the DNA damage signaling
network.
Determination of the optimal kinase phosphorylation motif by
oriented peptide library screening
Oriented peptide library screening is a powerful method for the
determination of the optimal kinase phosphorylation motif and for the
identification of potential kinase substrates. Recent advances in mass
spectrometry and the increasing use of phospho-motif-specific antibodies has
now made it possible to experimentally identify phosphorylated substrates and
simultaneously map the likely sites of phosphorylation [8, 9]. Despite the power
of these approaches, however, both techniques have limited sensitivity for
detecting phosphoproteins that are present at low levels within the cell. Many of
these low abundance proteins include critical transcription factors and protein
"control nodes" that lie near the top of signal amplification cacades. Thus
additional approaches will be necessary to fully define kinase-dependent
signaling networks. Oriented peptide library screening combined with
bioinformatics-based searches of protein sequence databases offers an
alternative strategy for identifying substrates - including low abundance
substrates - of particular protein kinases, [10, 1 1].
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In oriented peptide library screening, 107-1013 peptides are synthesized
simultaneously by solid phase peptide synthesis, with all of the peptides
containing either a single fixed Ser, Thr, or Tyr residue at an "orienting" position
within the peptide sequence. The orienting residue in the peptides serves as the
phospho-acceptor during an in vitro phosphorylation reaction with the protein
kinase of interest and is flanked by a series of degenerate positions which
contain a mixture of all possible amino acids. Only those peptides which contain
favorable amino acids surrounding the fixed Ser, Thr, or Tyr residue will be
preferentially phosphorylated by the kinase of interest. This subset of
phosphorylated peptides can then be separated from the bulk of non-
phosphorylated peptides using immobilized metal affinity chromatography (IMAC)
[11, 12]. The recovered phosphopeptides, without any further separation, are
sequenced in bulk by Edman degradation. By comparing the amount of each
amino acid at each position flanking the fixed Ser, Thr, or Tyr in the
phosphorylated peptides to the amount of each amino acid in the starting peptide
library mixture, the affinity of the kinase for each amino acid in each position in
the sequence is revealed [11]. The end result of this process is a matrix of
selection values that describes, in quantitative terms, the relative importance of
each amino acid at each position within the kinase substrate motif as well as the
optimal peptide substrate sequence for that kinase. The matrix of kinase
selectivity values can be used to search protein sequence databases and identify
potential substrate proteins that contain the closest matches to the optimal
protein kinase phosphorylation motif [10]. These putative substrates can then be
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examined in vitro and in vivo to determine whether they are, in fact, kinase
substrates after DNA damage. In addition, the optimal substrate peptide can be
synthesized and used as a substrate to measure kinase activity in vitro, for
example in an immunoprecipitation kinase assay to measure the change in
kinase activity after DNA damage, or in a high-throughput screen for protein
kinase inhibitors.
Signaling and the Phospho-Binding Domain
How does protein phosphorylation in response to DNA damage lead to
DNA repair, cell cycle arrest, or cell death? In many cases, kinases control the
orchestration of these complex cellular events that require the timely assembly of
multi-molecular signaling or repair complexes at specific locations within the cell.
The temporal and spatial control by these kinases is often achieved through
phosphorylation-dependent binding and activation. Prior to the discovery of SH2
domains, protein phosphorylation was thought to regulate substrate binding and
catalytic activity primarily by inducing allosteric changes in protein tertiary
structure. A new view emerged with the observation that binding of SH2
domains to proteins occurred only when they carried a phosphotyrosine (pTyr)
residue, introducing the idea that phosphorylation could function as a direct
regulatory switch for protein-protein interactions. Because the first two
phosphopeptide-binding modules that were recognized, SH2 and PTB domains,
bound specificially to pTyr-containing sequences this view was not immediately
applied to serine/threonine kinase signaling involved in cell cycle progression
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[13-15]. However, the finding that 14-3-3 proteins recognize phosphorylated
serine and threonine-based motifs on molecules involved in cell cycle
progression started to support the idea that phospho-binding is more widespread.
Recently, a number of additional modular domains that specifically recognize
short pSer/pThr-containing sequences have been identified, including WW
domains, FHA domains, the C-terminal domain of Polo-like kinases, and BRCT
domains [16-20]. All of these pSer/pThr-binding domains participate in cell cycle
regulation and the cellular response to genotoxic stress. These domains
comprise a diverse structural group, and all recognize phosphoserine or
phosphothreonine within a unique consensus motif directing specificity of ligand
binding. The continued discovery of new domains has led to an increased
appreciation of the role phosphopeptide recognition domains play in regulating
the reversible assembly of multi-protein complexes. There most likely
existsadditional phospho-binding domains that are involved in mediating protein-
protein interactions in the DNA damage signaling process.
14-3-3 proteins
14-3-3 proteins are found in all eukaryotic cells and were the first family of
pSer/pThr-binding molecules to be identified. Investigation of the optimal 14-3-3
binding motif by in vitro peptide library screening led to the identification of two
optimal phosphoserine/threonine-containing motifs - RSX(pS/T)XP and
RXXX(pS/T)XP - that are recognized by all seven 14-3-3 isotypes [21]. The 14-
3-3 family of proteins play critical roles in several cellular processes [22-24],
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including the DNA damage checkpoint response pathway. 14-3-3 proteins
interact with phosphatases, apoptotic factors, transcription factors, cell surface
receptors, ion channels, cytoskeletal proteins, and metabolic proteins to regulate
the function of a ligand by increasing or decreasing the ligand's catalytic activity,
facilitating or blocking molecular interactions between the ligand and other
molecules, or regulating the subcellular localization of the bound protein [5, 25].
In one important example 14-3-3 proteins regulate subcellular localization by
inducing the cytoplasmic sequestration of the CDC25 family of phosphatases
upon phosphorylation by CHKI or CHK2 in response to DNA damage [26, 27]. In
this case, the cytoplasmic retention of the CDC25 phosphatases prevents the
activation of CDC2-Cyclin B by CDC25 and thereby inhibits mitotic entry [28, 29].
FHA domains
FHA (Forkhead Associated) domains were originally identified through
sequence profiling as a region of homology in forkhead transcription factors [30].
The phospho-binding function of FHA domains emerged from studies in
Arabidopsis showing that a region encompassing the FHA domain of the protein
KAPP (kinase-associated protein phosphatase) bound specifically to the
phosphorylated form of the protein kinase RLK5 [31]. Oriented peptide library
screening to determine the consensus motifs for phosphothreonine peptide
binding has allowed a tentative grouping of FHA domains into discrete classes on
the basis of specificity at the pThr+3 position (3 residues carboxy terminal to
phosphothreonine) [32]. FHA domain-containing proteins have been most
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extensively investigated in the context of cell cycle control and the cellular
response to genotoxic damage. The mammalian kinase CHK2 contains a single
FHA domain amino terminal to its kinase domain and mediates cell cycle arrest
at multiple checkpoints in response to DNA damage. CHK2 causes cell cycle
arrest by phosphorylating multiple substrates: the transcription factor p53 to
induce G1 block, the phosphatase CDC25B/C whose phosphorylation results in
14-3-3 binding and G2/M arrest, and the G1 phosphatase family member
CDC25A to trigger its degradation and cellular S-phase delay [33, 34]. One
function of the FHA domain of CHK2 appears to be the regulation of the trans
autophosphorylation of its kinase domain by mediating direct homo-dimerization
through interaction with ATM-phosphorylated T68 of CHK2 [35, 36]. It is unclear
how the FHA domain may target CHK2 to its substrates, and in some cases an
additional surface is necessary, in conjunction with the phosphopeptide binding
surface, for binding as with BRCA1 [37].
Identification of novel phospho-binding domains
To help elucidate the DNA damage signaling processes downstream of
kinase activation, part of my thesis work focuses on the identification of additional
phospho-binding domains that function to integrate the DNA damage signaling
and repair process. Common screens to identify novel protein-protein
interactions are often incapable of isolating interactions that require a post-
translational modification, such as phosphorylation. The Yaffe lab recently
designed a library versus library screen to identify new phospho-binding domains
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downstream of cyclin-dependent kinases [18]. To perform this screen, proteins
from a human brain cDNA library are in vitro translated (IVT) and labeled with
[35S]methionine then assayed for phospho-specific binding to oriented peptide
libraries. Peptide libraries are synthesized as a biotin-tagged phospho and non-
phospho peptides designed to represent the optimal phosphorylation motif of the
kinase of interest, as determined by oriented peptide library screening discussed
above. By using the biotin-tagged peptide library bound to streptavidin-
conjugated agarose beads, proteins that bind to the phosphorylated form of this
peptide, but not with the non-phosphorylated form, can be isolated, run on an
SDS-PAGE gel and exposed to a phosphoimager plate for quantification. The
ratio of phospho-specific binding to non-phospho binding can then be evaluated.
Part of my thesis project not only involves the identification of phospho-
binding domains that interact with ATM and ATR substrates, but also involves
improving upon the initial phospho-binding screen. The major drawback to the
initial approach is the amount of time required to screen the cDNA library. The
original cDNA library contained 26,000 clones that were translated in pools of
-100 cDNA clones per pool. Therefore 260 different IVT reactions and assays
are required to screen the cDNA library. Furthermore, once a phospho-
dependent interaction is discovered, the sub-fractionation of the cDNA pool to
isolate the interaction is very time intensive and sometimes the initial observed
interaction is never recovered. We therefore adapted the IVT screen to a 96 well
format to greatly accelerate the screening process. Screening in 96 well format
allowed a four fold larger library to be screened in ten rounds, with each round
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requiring two days for completion followed by a two-week exposure to a
phosphoimager plate. After identifying a pool that contains a phospho-
dependent interaction, the cDNA from that pool is transformed into bacteria and
plated on agar plates. Single colonies are then picked and their DNA isolated for
re-screening. Performing the DNA mini-preps and re-screens in 96 well format
allowes for a greater coverage of the cDNA pool, further decreasing the chance
the positive clone will be lost.
Following isolation of the phospho-binding domain, the optimal phospho-
binding motif can be determined using oriented peptide library screening [16]. In
this approach the phospho-peptide library is incubated with a GST-phospho-
binding domain fusion protein bound to GSH-agarose beads. After thorough
washing, the bound peptides are eluted and sequenced, allowing for the
determination of the optimal binding motif and the construction of a position
specific scoring matrix [10]. After the construction of a matrix, Scansite
<http://scansite.mit.edu> is used to search the entire human database for
proteins containing the optimal binding motif [38]. Isothermal titration calorimetry
is often used to confirm the results obtained from the peptide library screening
and to determine the binding affinity of the optimal phosphopeptide to the
phospho-binding domain. Common approaches to confirm the selection of the
likely in vivo interacting proteins include pull-down assays and in vivo co-
association studies.
The elucidation of undiscovered kinase substrates and phospho-binding
domains in the DNA damage response pathway could provide molecular insight
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into a number of DNA damage responsive cellular processes, examples of which
are discussed below.
DNA Repair Pathways and Cell Cycle Checkpoints
The five major DNA repair pathways
The five major DNA repair pathways involved in maintaining genomic
integrity are base excision repair (BER); homologous recombinational repair
(HRR); mismatch repair (MMR); non-homologous end joining (NHEJ); and
nucleotide excision repair (NER). Proteins associated with these types of DNA
repair processes are well positioned to act as the first sensors of DNA damage,
recruit the Radl7-RFC and 9-1-1 and Mrell11-Rad50O-Nbsl complexes, activate
the DNA damage checkpoint kinases, and trigger cell cycle arrest and apoptosis.
Base excision repair
BER is involved repairing single-base DNA damage caused by
methylating and oxidizing agents, and the large number of spontaneous
depurinations that occur (about 10,000 per cell per day) [39]. BER is activated
through two different pathways depending on the type of DNA damage; one
pathway involves single nucleotide BER and the other pathway involves long
patch BER which removes 2-15 nucleotides. In BER, a DNA glycosylase binds
the altered deoxynucleoside and catalyzes cleavage of the base-sugar bond to
remove a damaged base [40]. Glycosylase activity generates an
apurinic/apyrimidinic site (AP site). BER can also occur at a site of spontaneous
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depurination. Ref-1, an AP endonuclease, then makes a 5' nick in the DNA
backbone. This nicking is followed by poly(ADP-ribose) polymerase-1 (PARP-1)
acting as a DNA nick surveillance protein by binding to the nicked DNA [41].
Repair patch synthesis and DNA ligation complete the BER process [39].
Ref-1 is gaining attention in the field because it has been shown to be
elevated in a variety of cancers, indicating that during cancer progression
enhanced BER may provide a growth advantage [41]. Ref-1 in addition to playing
a role in BER, is also a regulator of cell cycle arrest and apoptosis [41].
PARP-1 is another protein gaining interest in the field. DNA damage
increases the activity of PARP-1, which is activated by binding to single- or
double-strand breaks in DNA. PARP-1 is also involved in long patch BER
through the recruitment of DNA repair enzymes to the vicinity of a DNA lesion.
PARP-1 catalyzes the synthesis of poly(ADP-ribose) onto substrate proteins in
the vicinity of the damaged DNA [40]. The attachment of the negatively charged
ADP-ribose polymers to proteins most likely creates a region of negative charge
around the DNA break, thus further opening up the chromatin and allowing
access of additional repair proteins to the site of DNA damage. Treatment of cells
with PARP inhibitors can sensitize cells to apoptosis [40, 42]. Therefore at low
levels of DNA damage, PARP activity may protect against apoptosis. In fact it
has been suggested that, depletion of NAD+ and eventually ATP by PARP-1
utilization may provide a linkage between excessive DNA damage and the
triggering of apoptosis [41]. Furthermore, p53 undergoes extensive poly(ADP)
ribosylation in the apoptotic program suggesting that PARP-1 may activate p53
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function in apoptosis. PARP-1 is also cleaved by caspase-3 suggesting that
PARP-1 mediated BER is counterproductive once a cell is committed to
apoptosis [40].
Homologous recombinational repair
HRR allows for the physical exchange of a DNA segment from a
homologous intact DNA strand to restore DNA sequence information that is
destroyed due to damage [43]. HHR is a preferred way to repair DNA double
strand breaks because it is very accurate. However, because HHR requires a
template daughter strand to assist in the repair process, it cannot be performed
until after the damaged DNA strand has been replicated, and thus HHR is not
possible in G1 and early S-phase [44, 45]. The major proteins involved in HHR
are BRCA1, ATM, ATR, c-Abl, Werner syndrome gene (WRN), Bloom syndrome
gene (BLM), p53, Rad51, and the breast cancer-associated gene 2 (BRCA2) [46,
47].
BRCA1 is involved in the assembly of the BRCA-associated genome
surveillance complex (BASC), which includes the proteins MSH2, MSH6, MLH1,
ATM, BLM, and the RAD50-MRE11-NBS1 [48]. BASC is thought to act as a
scaffold and sensor for DNA damage. The role for each protein in this complex or
in the strand exchange reactions of HRR is not well understood [49]. BRCA1
interacts with Rad51 and participates with Rad51 in HRR of double-strand breaks
and interstrand crosslinks caused by cisplatin [2, 46, 50, 51]. BRCA1, BRCA2
and RAD51 interact and co-localize in nuclear foci in the nucleus during S-phase
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and mutations in BRCA2 give rise to phenotypic effects similar to those arising
from mutations in BRCA1, suggesting that the proteins have related functions
[51]. Despite the similarity in function of BRCA1 and BRCA2, the two genes are
not related by sequence [51].
Mismatch repair
The post-replication correction of nucleotide mismatches involves a highly
conserved set of MMR proteins including MLH1, PMS2, MSH2, MSH3, and
MSH6 [52]. The MMR repair process involves the detection of the mismatch by
the MSH2/MSH6 heterodimer, which leads to the recruitment of the MLH1/PMS2
heterodimer. The MSH2/MSH6 heterodimer is also part of the BASC complex
and thus it may also be involved in HRR to correct base mismatches or other
abnormalities that can arise from the strand exchange reactions of HRR [46, 48,
51].
Defects in the MMR process give rise to increased DNA mutations and a
predisposition to cancer. Furthermore, mutations in MMR are implicated in the
development of a wide variety of sporadic tumors [52]. The MMR system is
involved in the cellular response to a variety of DNA damaging agents. MMR
mutants defective in repair would be expected to exhibit increased cytotoxicity
after treatment with DNA damaging agents, however these mutants are observed
to be resistant to the normally cytotoxic effects of alkylating and methylating
agents [52]. For example, MMR deficient cells are less sensitive to the induction
of apoptosis by methylating agents which appears to be triggered by secondary
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lesions, possibly double-strand breaks, caused by MMR processing. Methylating
agents lead to p53 phosphorylation on several residues, and these
phosphorylation events depend on the presence of functional MMR proteins [52].
This positions the MMR proteins as a proximal step of DNA damage signaling
and in the activation of the DNA damage checkpoint.
Non-homologous end joining
HRR and NHEJ are two main processes for repairing double-strand
breaks. Unlike HHR, NHEJ is regarded as largely inaccurate because it involves
end-joining reactions with junctions containing deletions back to regions of semi-
homology [53]. Despite this inaccuracy, recent data indicates that mammalian
cells repair the majority of double-strand breaks by NHEJ, although there is
emerging evidence that NHEJ may be coupled to HRR to generate accurate
repair of double-strand breaks [46, 49]. Either way, the two pathways HRR and
NHEJ can be thought of as complementary processes as double mutant cells
defective in both HRR and NHEJ are profoundly more sensitive to IR than either
mutant alone [46, 54]. The NHEJ processes are initiated by DNA-PK and DNA
binding proteins Ku70 and Ku80. After binding to DNA ends of a double-strand
break, Ku recruits the catalytic subunit of DNA-PK (often denoted as DNA-PKcs).
DNA-PKcs is an inactive protein kinase which is activated upon association with
Ku at DNA ends [42, 54]. The active complex of Ku and DNA-PK is able to
position the ends of the double-strand break and allow their ligation by DNA
ligase IV to complete NHEJ-mediated DNA repair [50].
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Nucleotide excision repair
NER is responsible for the repair of DNA damage that contains large helix-
distorting lesions. Common lesions repaired by NER include the UV-induced
cyclobutane pyrimidine dimers and 6-4 photoproducts, as well as the adducts
produced by chemotherapeutic agents like cisplatin [55, 56]. When DNA helix-
distorting damage is produced by UV, the levels of p53 are increased to help
activate NER. NER is a very complicated repair process though it has been
reconstituted in vitro with purified components. The proteins involved in the NER
process, including XPD, XPB, p53 and p331NGlb, are responsible for many
steps of NER including the recognition of the DNA damage, the recruitment of
repair complexes to the lesion, the modification of the DNA for helicases-
mediated repair, the incision and release of the damage DNA in a single-strand
fragment ranging from 24-32 nucleotides in length, the repair of the gap by DNA
synthesis, and the DNA ligation to form the final phosphodiester bond [55, 56].
Like the BER pathway, the NER pathway consists of two subpathways: global
genomic repair (GGR) and transcription coupled repair (TCR) [55, 57]. As
expected, these pathways function differently, with GGR acting on damage in the
non-transcribed regions of DNA and TCR acting on damage in actively
transcribed DNA [40]. However, after activation, most enzymatic steps utilize the
same enzymes and enzyme complexes [58].
The XPD helicase function is essential for NER, and mutations in XPD
have been shown to alter stabilization and function of the transcription factor
complex TFIIH. TFIIH is a nine-subunit complex that acts in NER. XPD and XPB
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are members of this complex whose helicase activities are required for NER, as
they allow the opening of DNA around the site of damage during the GGR
subpathway of NER [59]. During the TCR subpathway of NER, it is thought that
stalling of RNA pol II at a site of DNA damage recruits the TFIIH complex, with its
XPD subunit, to participate in NER [55, 58]. When the XPD helicase function is
lost due to alterations in its ATP hydrolysis region, neither the 5' to 3' incision
around a DNA adduct can be detected. Various mutations in XPD display
different defects in DNA repair, RNA transcription and apoptosis as well as cause
diseases such as xeroderma pigmentosum, Cockayne's syndrome or
trichothiodystrophy [40]. The XPB helicase also acts also within the TFIIH
complex necessary for transcription and NER as well as for p53-dependent
apoptosis [46, 59]. The few XPB mutations known each have different levels of
deficiency with respect to repair of cyclobutane pyrimidine dimers and
pyrimidine(6-4)pyrimidine dimmers [59, 60].
The induction of NER and apoptosis after UV damage in mouse
fibroblasts is observed only in p53"/+ and not in p53'- cells, indicating that both
stress response functions are dependent on wild-type p53 function [55, 59, 60].
Thus UV-induced apoptosis is not only dependent on XPB and XPD function, but
also requires p53 function [46].
UV-induced DNA damage and the Radl7-RFC and 9-1-1 complex
Genetic screens to identify genes that affect sensitivity to genotoxins led
to the identification of the Rad9, Husl, and Radl orthologs. This complex is a
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heterotrimeric ring composed of Rad9, Husl, and Radl, termed the 9-1-1
complex [61, 62]. These proteins are required for activation of checkpoint
signaling pathways and interact in a stable complex in cells in a manner to the
sliding DNA clamp PCNA [63]. The PCNA clamp serves as a sliding platform that
tethers replication proteins and polymerases to the DNA. PCNA is loaded onto
DNA by the ATPase replication factor C (RFC) complex [64]. In contrast, the 9-1-
1 clamp interacts with and is loaded by a separate clamp loader that contains the
checkpoint protein, Rad17. Rad17 interacts with four replication factor C subunits
(Rfc2, Rfc3, Rfc4, Rfc5) to form a pentameric structure, referred to as the Rad17-
RFC complex [64, 65]. These complexes of proteins are presumed to act in
concert with one another. In a similar fashion to the loading of the PCNA sliding
clamp complex, it is thought that during a checkpoint response the Rad17-RFC
complex may recognize damage and load the 9-1-1 sliding clamp onto DNA [64].
Association of Rad17-RFC and the 9-1-1 heterotrimer has been identified in vitro,
and each complex is inferred to bind to sites of DNA damage in vivo as the
Rad17-RFC complex binds preferentially to DNA with primer-template-like
structures; however loading of the 9-1-1 complex onto DNA by Rad17-RFC has
not yet been shown in cells [2]. Once loaded, the 9-1-1 complex may serve to
recruit DNA damage response proteins and enhance damage signaling to other
checkpoint components [66].
For example, in response to genotoxic stresses such as DNA damage
caused by alkylation or UV light the 9-1-1 complex is loaded onto chromatin to
help activate the checkpoint signaling pathways [63]. The Rad17-RFC complex
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together with the 9-1-1 complex is thought to help activate the ATR/CHK1
pathway and may recruit substrates of these kinases, including BRCA1 and its
associated proteins, for phosphorylation by ATR [61]. Following DNA damage,
ATR/ATRIP is recruited to chromatin in a reaction that does not require the 9-1-1
complex. Independently of ATR, the 9-1-1 clamp is loaded onto chromatin by the
Rad17 clamp loader. The chromatin-bound 9-1-1 complex then facilitates the
ATR-mediated phosphorylation and activation of CHK1. The ATR/ATRIP and
Rad17-RFC clamp loader complexes are most likely not the actual sensors of
DNA damage. After the replication fork encounters a lesion and stalls, extensive
regions of single-stranded (ssDNA) are produced. ssDNA is also a common
intermediate generated in the DNA repair process and it is a potential ATR/CHK1
pathway activator [63]. Exposed ssDNA is coated with the ssDNA-binding protein
RPA, which is required for checkpoint activation. RPA-coated ssDNA directly
recruits ATR/ATRIP and stimulates the Rad17-dependent loading of the 9-1-1
onto DNA. Studies in Xenopus egg extracts suggest that other intermediates also
participate in the assembly of the ATR/ATRIP and 9-1-1 complexes onto
chromatin at stalled replication forks [64]. Activated CHK1 plays critical roles in
cellular checkpoint responses by stabilizing stalled replication forks, and blocking
the firing of late origins of replication, and arresting cells in G2/M [67].
The 9-1-1 complex members are key participants in the Chkl activation
pathway. In this regard, studies have shown that HuslT- and Rad9T cells have
CHK1 activation defects and disruption of Rad9, Husl, or CHK1 produces a
phenotypically similar response [46, 67]. Cells deficient for the 9-1-1 components
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continue DNA replication after DNA damage, a phenomenon known as
radioresistant DNA synthesis (RDS) that indicates defective checkpoint signaling
during S-phase [65]. A major question is how the chromatin-bound 9-1-1 clamp
complex promotes CHK1 activation. Recent work has shown that a unique
feature of Rad9 is its "tail" that is required for this function. Unlike Husl and
Radl, Rad9 possesses an approximately 120-amino acid C-terminal tail region
that is phosphorylated on several serine and threonine sites [60, 64]. The tail is
not required for interaction with Husl and Radl, interaction of the clamp with
Rad17, or loading of the clamp onto chromatin, demonstrating that the tail is not
required to form a functional clamp [64]. One of these phosphorylation sites is a
consensus PIKK "SQ" site that is phosphorylated by ATR and ATM in response
to DNA damage [2, 64]. It is unknown which kinases phosphorylate the other
sites. Surprisingly, the PIKK consensus site is not required for CHK1 activation,
instead as least one of the other sites is essential for Rad9 activation of CHK1 [2,
64, 68]. This data suggest an model where the phosphorylated Rad9 tail, in the
chromatin-bound 9-1-1 complex, help recruits signaling proteins to the DNA
lesions and facilitates the and activation of CHK1 [2, 64, 67].
IR-induced DNA damage and the Mre 1-Rad5O-Nbsl complex
The Mre11-Rad50-Nbs1 (MRN) complex localizes to sites of double-
strand breaks (DSB) in vivo and plays vital roles in DNA metabolism, including
DSB repair, meiotic recombination, and telomere maintenance [69]. NBS1 (also
termed nibrin) is the product of the gene mutated in the human chromosomal
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instability disorder, Nijmegan breakage syndrome [70, 71]. The clinical features
of NBS show considerable but not complete overlap with those features
displayed by A-T patients. Treatment of cells with IR induces the rapid formation
of nuclear foci containing the NBS1-Mre11-Rad50 complex and the foci
assembly in close proximity to DNA DSB [72, 73]. Nbsl contains an FHA domain
and an adjacent BRCT domain, both of which are involved in targeting this
complex to nuclear DNA damage foci [73, 74]. Cells deficient in Mrel1 or Nbsl
continue DNA replication after IR, an RDS phenotype, and display errors in other
cell cycle checkpoints [2, 75]. The overlapping clinical phenotypes of A-T and
NBS prompted speculation that the two proteins might be functionally
interconnected. This prediction was validated by reports that ATM
phosphorylates NBS1 on up to three serine residues (Ser 343, Ser 397, and Ser
615), and that Ser to Ala substitutions at any one of these sites generates a
mutant NBS1 protein that fails to complement the checkpoint defects in NBS
cells [1, 75]. Exactly how the MRN complex signals through ATM in the
checkpoint signaling process in not well understood though it appears to involve
both protein localization and ATM kinase activation. [42].
Additional damage sensors: BRCA1
The breast-cancer susceptibility gene product, BRCA1, plays important
roles in cell cycle control, transcriptional regulation, chromatin remodelling, and
the response to DNA-damage [51, 76]. BRCA1 is a large, modular protein of
1863 amino-acid residues containing an N-terminal RING domain, a central
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region rich in SQ/TQ dipeptide pairs, and tandem BRCT (Brcal C-terminal)
domains. BRCA1 appears to function in multiple points in checkpoint signaling
perhaps by linking checkpoint arrest to DNA damage repair [76]. BRCA1 is
thought to enhance cancer progression by allowing excessive DNA damage
through insufficient DNA repair and loss of cell cycle arrest in the presence
unrepaired DNA damage. Recent findings position ATM and ATR as critical
upstream modulators of BRCA1. However, BRCA1 has also been sown to be
required for ATM activation after DNA damage, placing BRCA1 both upstream
and downstream of ATM [76]. Early in the DNA damage signaling response,
BRCA1 becomes phosphorylated and initiates activation of checkpoint kinases
and the localization of additional substrates for kinase phosphorylation [47, 77-
79]. Once phosphorylated, BRCA1 may activate downstream protein kinase
cascades, aiding in amplification of the damage signal by recruiting additional
phosphorylation substrates [80]. BRCA1 also colocalizes with a number of
proteins involved in DNA repair and/or replication, including Rad51, PCNA,
Mrel 1-Rad50-Nbs1, histone deacetylases, the DNA helicase BLM (mutated in
Bloom's Syndrome), and mismatch repair proteins [51, 81]. Consistent with these
associations, BRCA1 affects homologous recombination, mismatch repair, and
transcription-coupled repair [51]. Studies of the DNA damage responses in
BRCAl-deficient cells are focusing increasing attention on the role of BRCA1 in
promoting high fidelity DNA repair through homologous recombination between
sister chromatids [51, 82]. BRCA1 also is involved in the regulation of
centrosome duplication. In cell deficient in BRCA1, improper amplification of
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functional centrosomes leads to the formation of multiple spindle poles within a
single cell [83]. These abnormalities directly result in the unequal segregation of
chromosomes, abnormal nuclear division and aneuploidy.
BRCA1 is the classic member of a family of checkpoint repair proteins that
contain the conserved BRCT domains, which have recently been shown to be
phosphospecific binding domains involved in the signaling process from the
induction of the G2/M cell cycle checkpoint to the repair of damaged DNA [51,
84-86]. In addition to BRCA1, other members of this BRCT domain-containing
family have recently been identified as substrates for ATM and are likely
substrates of ATR as well. Both MDC1 and p53 binding protein 1 (53BP1) are
large nuclear BRCT domain-containing proteins that rapidly localize to sites of
DNA damage in cells treated with IR or other DNA-damaging agents [87, 88],
although the functions of MDC1 and 53BP1 remain unclear. Within minutes
following ionizing radiation, MDC1 associates with the MRN complex and with
numerous other DNA damage response proteins including 53BP1 and BRCA1.
Nbsl, BRCA1, 53BP1 and MDC1 all form nuclear foci that colocalize with H2AX
foci induced by DNA damage. The exact role of how BRCA1 and its BRCT
domains function to control the DNA damage response remains unclear.
Damage transducers: ATM, ATR, CHK1 and CHK2
The ATM/CHK1 and ATR/CHK2 pathways are responsible for regulating
several points within cell cycle progression. Despite the importance of these
pathways, there most likely remains unidentified substrates and phospho-binding
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domains functioning downstream of these kinases. ATM and ATR are members
of the phosphoinositide 3-kinase related kinases (PIKKs) and regulate several
proteins within the same pathway, often by phosphorylation of proteins
substrates on a common [Ser/Thr]-Gln motif, to control the cell cycle progression
[2, 89]. CHK1 and CHK2 are serine-threonine kinases that are required for cell
cycle arrest in response to DNA damage [90]. As downstream kinases, CHK1
and CHK2 are phosphorylated by ATM/ATR-dependent processes and potentiate
phosphorylation of additional downstream targets [89, 91]. This pattern of dual
regulation of substrate phosphorylation by ATM and ATR in cells exposed to
different forms of genotoxic stress has become a recurrent theme in the
checkpoint-signaling field. Of the PIKK family members, ATM represents the
primary responder to IR or radiomimetic agent-induced DNA damage. In the
absence of ATM, or in normal cells that incur a high level of IR-induced DNA
damage, ATR serves mainly as a backup kinase for ATM [92, 93]. On the other
hand, ATR takes on the front-line signaling responsibilities when cells are
challenged with other forms of genotoxic stress, such as UV light exposure or
treatment with agents that interfere with DNA replication (aphidicolin and
hydroxyurea) [2]. ATR is essential for cell viability and ATR has been shown to
form a heterodimer with the associated protein ATRIP, which is required for ATR
stabilization and the checkpoint signaling pathway [2, 93, 94]. Though the
mechanism of ATR-ATRIP activation remains elusive it is probable that, like the
PIKK family member DNA-PK, kinase activity is activated upon association with
additional protein partners at the sites of damaged DNA, such as single-stranded
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DNA [2]. In fact, ATR and ATRIP colocalize to intranuclear foci after DNA
damage or inhibition of replication [94]. Though ATR's essential function is not
yet fully defined, it is likely to be critical for repairing the DNA damage sustained
that occurs on a continuous basis. Furthermore, cells may require ATR for the
constant monitoring to ensure viability [94]. Recent data clearly demonstrates
that ATM, ATR and DNA-PK are required to associates with protein partners at
the sites of DNA damage for efficient phosphorylation of their targets [42].
The ATM protein kinase has been studied more extensively than ATR for
two reasons. First, ATM was identified as the gene defective in the syndrome
ataxia-telangiectasia (AT), and little association between ATR deficiency and a
disease yet exists (ATR has reciently been shown to be involved in Seckel
syndrome [95]). Second, unlike ATR, ATM is not essential for cell viability [93,
96]. Cells lacking ATM display chromosomal instability, a RDS phenotype, and
extreme sensitivity to IR and radiomimetic drugs. AT cells are defective for cell
cycle checkpoints at GU/S, S, and G2/M phase transitions in response to
radiation-induced damage [1]. For example, the topoisomerase inhibitor,
camptothecin, induces double-strand breaks predominantly in replication forks,
and ATM mutant cells are defective in repair of this particular subclass of double-
strand breaks [46]. In response to DNA damage, the E2F1 protein is
phosphorylated by ATM and ATR at a site in its amino terminus. This
phosphorylation stabilizes E2F1, which transcriptionally activates the p73
promoter. Accumulation of p73 leads, in turn, to induction of apoptosis. ATM is
also required for IR-induced apoptosis and is largely dependent on BAX, a
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member of the Bcl-2 family of cell death regulators, which promotes apoptosis
[97, 98]. At DSBs, ATM may associate with the MRN complex of proteins, which
could then serve to recruit ATM substrates for phosphorylation much like the 9-1-
1 and Radl7-RFC complexes do for ATR [1]. Again, the fact that ATM and MRN
act together at DSBs is inferred from the fact that cells from patients with
mutations in NBS1, presenting as Nijmegan breakage syndrome, also exhibit
radiosensitivity and chromosomal fragility like AT cells, and patients with
mutations in MRE11 present with clinical symptoms and cellular defects much
like those seen in AT, thus giving rise to the name "AT-like disorder" [91, 99]. In
one example of ATM mediated signaling, ATM activates CHK2 by
phosphorylating an amino terminal Thr residue (Thr 68) [100, 101], and CHK2, in
turn, phosphorylates yet another amino-terminal Ser residue (Ser 20) in p53
[102-105]. Unlike the Ser 15 modification, which increases p53 transcriptional
activity, phosphorylation at Ser 20 interferes directly with the binding of p53 to
MDM2, thereby favoring p53 accumulation in response to IR-induced DNA
damage. In another example, ATM directly phosphorylates BRCA1 after
activation by DSB caused by ionizing radiation, although the consequences of
this phosphorylation are unknown [2]. Additionally, activated CHK2, downstream
of ATM, also phosphorylates BRCA1 on another site that is required for the
dissociation of BRCA1 and CHK2 [79]. This pattern of dual kinase
phosphorylation mediated regulation of proteins is evident throughout the cell
cycle and DNA damage response pathways making it difficult to unambiguously
order specific kinases within these types of signaling networks. If fact, once a
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kinase phosphorylation site is identified on a protein, it would be prudent to
identify other kinases that are activated during the process of interest, as they will
likely also phosphorylate this protein.
Damage transducers: p38 MAPK and MAPKAP Kinase-2
DNA damage, and other cellular stress, triggeres the activation of the
mitogen-activated protein kinase signaling pathways (MAPKs) [91, 106].
Normally, MAPKs are involved in regulating several cellular processes such as
development, growth, differentiation, proliferation, and programmed cell death
[27, 107]. MAPK signaling is required for preventing UV-induced DNA damage
and tumorigenesis by initiating cell cycle arrest and apoptosis [52, 91, 108]. The
MAPK pathway is comprised of three levels of kinases that are sequentially
activated by phosphorylation of specific amino acid residues within the activation
loop [109-111]. Ras can also play an important role as upstream activators of the
MAPK pathways, a role facilitated via several MAPK enzymes. For example,
DNA damage may first trigger activation of the serine/threonine MAP kinase
kinase kinases (MAPKKKs) such as MEKK1/2/3, MTK1 (MEKK4), MLK2,
ASK1/2, TAK1, and Tlp2. Active MAPKKKs in turn will phosphorylate serines in
the activation loop of MAPKKs (MEK1/2, MKK3/4/6/7) [106, 111-113].
Subsequently, active MAPKKs will phosphorylate [Thr-Xxx-Tyr] motifs within the
activation loop of MAPKs (p38s, JNKs, ERKs), which ultimately phosphorylate
proteins and effector MAPKAP kinases (MAPKAPKs) [91, 110, 114, 115].
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Just like the ATM and ATR pathways, a great deal of cross talk exists
between MAPK pathways, p38s, c-Jun N-terminal kinases (JNKs), and
extracellular signal-regulated kinases (ERKs) constitute the three main arms of
the MAPK signaling pathway [91, 116]. They also constitute evolutionarily
conserved pathways and are comprised of multiple isoforms. p38 MAPK has four
isoforms (a, , and 8); JNK has three isoforms (1/2/3); and ERK has two
isoforms (1/2) [106, 116]. For the most part, JNK and p38 MAPKs are activated
in response to genotoxic stresses while ERKs are activated in response to
mitogenic signals [27, 107, 116].
MAPKs regulate key oncogenes and tumor suppressors implicated in the
pathogenesis of cancers, such as ras, p53, APC/13-catenin, and p1 6 INK4a (p16)
[27, She, 2002 #1040, 116]. JNK and p38 MAPKs can either block cell
proliferation or promote cell death when activated by DNA damage through the
regulation of p53 and Cdc25A/B/C [27, 91, 117, 118]. MAPKs are also known to
phosphorylate p53 to increase its stability and activity [27, 91]. p38 will modulate
p53 activity by directly targeting Ser33 and Ser37 for phosphorylation [108, 119].
Furthermore, the MAPK signaling pathways contribute to cell cycle regulation by
controling p21 and Gadd45a [2, 46]. p21 can directly block Cdk4/6/cyclin D1 and
Cdk2/cyclin E, while Gadd45a's effects contrubite to p53 activation [111, 120].
Parallel to p53, UV-induced activation of MAPK increases the expression of the
Cdk inhibitor p16 [91, 111, 121]. Like p21, p16 blocks Cdk4/6/cyclin D activity
and prevents cells from progressing into S-phase.
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The p38 MAPK pathway was originally described as a mammalian
homologue to a yeast osmolarity sensing pathway [106, 111]. It was soon
discovered that many cellular stresses activated the p38 MAPK pathway [107].
There are several protein kinases downstream of p38 MAPK enzymes that are
activated following phosphorylation by p38 including MAPKAP Kinase-2 (MK2)
and MSK1/2 [111, 122, 123]. For example MK2 phosphorylates and activates
heat-shock protein 27 (HSP27), while MSK1/2 can phosphorylate and activate
transcription factors that regulate survival [106, 111, 116, 122].
MAPKs can also regulate proteins that are part of the WNT/P-catenin
signaling pathway. The Wingless/INT-1 (WNT) signaling pathway regulates
cytoplasmic 1-catenin accumulation by blocking the activity of the adenomatous
poliposis coli (APC) destruction complex, which phosphorylates -catenin and
targets it for degradation [111, 124, 125]. The APC complex is composed of
several factors, including APC protein, protein phosphatase 2A (PP2A), glycogen
synthase kinase 3 (GSK33) and Axin [126-128]. WNT signaling can promote the
accumulation -catenin under certain conditions, however, UV-induced p38
MAPK signaling has been reported to suppress WNT signaling and allow the
APC complex to remain active [2, 46, 52, 91,124].
As stated above, activation of MAPK is achieved not only through
activation of the MAPKKK/MAPKK/MAPK pathway, but also through the Ras
family of G proteins [129-131]. Ras activation can elicit varying responses [129,
132]. Initially, activated Ras activates MEK1/2 that specifically targets ERK1/2.
The MEK/ERK signaling cascade will promote cell growth [129]. However,
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sustained Ras/MEK/ERK activation will eventually induce MKK3/6 MAPKK
activation, leading to p38 activation and expression of p53 and p16 that most
likely counteract ERK [128, 129, 131, 133]. In response to DNA damage, p38
activation is critical for Ras-induced senescence, and interestingly its activation
may be blocked with the MEK inhibitor U0126, supporting the idea that MEK
activation is necessary for eventual MKK3/6/p38 activation [128, 129, 131, 133].
Cytokine regulation also involves p38 MAPK signaling [130]. The p38/MK2
pathway plays an important role in regulating the expression of many genes by
modulating events ranging from transcriptional and translational control to mRNA
stability [106, 123]). For example, IL-1 and TNFa, protein levels are regulated at
the transcriptional level while IL-6 levels are dependent on mRNA stability
induced in part by IL-1 [121, 130]. p38 inhibitors can suppress TNFa expression
without altering mRNA levels, which is indicative of regulation at the translational
level [106].
Complicating the issue it that fact that the exact role of p38 MAPK
signaling is dependant on the cell type and stimulus. p38 MAPK signaling has
been shown to both promote cell death as well as enhance cell growth and
survival in different cells and under various conditions [27, 116, 118, 122]. For
example, the ability of ionizing radiation to regulate p38 MAPK activity appears to
be highly variable with different groups reporting either no activation, weak
activation or strong activation [27, 116, 118, 122]. In the studies where p38
MAPK activation has been observed following exposure to ionizing radiation it
has been required for causing the G2/M arrest [27, 46, 111]. Interestingly in
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these studies, p38 signaling was dependent on expression of a functional ATM
protein. In support of this finding, overexpression of constitutively active MKK6
also enhanced cell numbers in the G2/M phase [52, 91].
Recent finding have show that p38 also plays a role in the UV-induced
G2/M arrest [107]. Specifically, this group claimed that p38 was the kinase
directly responsible for the phosphorylation of the 14-3-3 binding site on
CDC25B/C. The growing idea that p38 and ERK directly contribute to the
function of p53 (by phosphorylation of Ser15) and CDC25A/B/C (by
phosphorylation of multiple residues, including the 14-3-3 binding sites) is
puzzling. Based on preliminary data from our lab, the sequence motifs
phosphorylated by these kinases do match the phosphorylated residues on p53
and CDC25A/B/C [91, 106, 108, 111]. Furthermore, JNK1/2 has been reported to
phosphorylate Ser20, despite the fact that the p53 site is not a match for the
JNK1/2 phosphorylation motif [91, 106, 108, 111]. In addition to the identification
of ATR/CHK1 and ATM/CHK2 dependent processes, it is necessary to identify
how activation of these MAPK pathways with different stimuli or at different points
within the cell cycle, can alter the downstream processes and determine cell fate.
Part of my thesis project will involved the determination which kinases are
responsible for some of the identified known phosphorylation events.
The cell cycle checkpoints
The exact roles of the proteins described above depend on the stage in
the cell division cycle the cell is when DNA damage occurs.
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The GI checkpoint
Most eukaryotic cells that experience DNA damage in G1 exhibit a delay
prior to entering S-phase. This arrest in G1 allows time for DNA repair, thus
preventing replication of a damaged DNA template. The exact role of the G1
checkpoint is often the subject of debate because it is very different in higher and
lower eukaryotes. In mammalian cells, the key process may well be the series of
events that lead to the stabilization of the tumor suppressor p53. An intricate web
of protein kinases and phosphatases, as well as histone acetylases and
ubiquitin-conjugating enzymes, regulates the accumulation and transcriptional-
activating functions of p53 [134, 135]. Although p53 exerts a pervasive influence
on checkpoint functions during the mammalian cell cycle, the G1 checkpoint
represents the only case in which loss of p53 leads to total checkpoint abrogation
[134-136]. The G1 delay mechanism involves ATM/ATR and CHK2/CHK1 but
can take up to several hours to initiate because regulation for this block to S-
phase entry occurs at the transcriptional level. Here ATM/ATR and CHK2/CHK1
activate and stabilize p53, causing transcriptional induction of p21 which then
inhibits the Cdk2/cyclin E complex [2, 46, 137, 138]. In addition to p21, the
activated form of p53 stimulates the expression of a large panel of genes, which,
depending on the cellular context and type of initiating insult, may modulate
intracellular redox status or induce the host cell to undergo apoptosis [2, 46].
As we now know, one well defined role for ATM and ATR is the regulation
of p53 where these kinases utilize several means to stabilize the p53 protein.
However, determining the functional consequences of p53 phosphorylation after
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DNA damage was far more challenging than discovering the phosphorylation
site. The location of Ser 15 at the p53 amino terminus suggested that
modification of this residue might trigger the dissociation of p53 from MDM2, a
protein that targets p53 for ubiquitination, nuclear export, and proteosomal
degradation [2, 46]. It turns out, however, that Ser 15 phosphorylation is not
sufficient to disrupt the p53/MDM2 interaction and instead this modification
stimulates the transactivating function of p53 by enhancing the binding of this
protein to the transcriptional coactivator, p300 [139]. While this phosphorylation
by ATM probably causes p53 transcriptional activation, it is the phosphorylation
of p53 at Ser 20 by CHK2 acting downstream of ATM that appears to reduce the
ability of ubiquitin ligase MDM2 to bind p53, thus promoting its stabilization [2,
46, 136]. The physiological relevance of CHK2 in the regulation of p53 is
underscored by the finding that loss-of-function mutations in CHK2 can give rise
to a variant form of Li-Fraumeni syndrome, a heritable, cancer-prone disorder
typically associated with germ-line mutations in p53 [102, 140].
It is unclear how a parallel ATR/CHK1 or p38 pathway also drives p53
accumulation in cells that have incurred IR or UV light-induced DNA damage. It
will be interesting to determine if these kinases further ensure p53 stabilization by
phosphorylating MDM2 and preventing export of p53 to the cytoplasm where it is
degraded. Also undetermined is whether these two checkpoint cascades can
occur independently or whether cascades are always activated together,
regardless of the extent of damage [2]? Whether G1 arrest or apoptosis is more
important in mammalian cells in preventing cancer is as yet unresolved. If both
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mechanisms function to remove damaged cells from cycling, then both may play
prominent roles in cancer evasion.
The S-phase checkpoint
The traditional view for the S-phase checkpoint is predominantly based on
studies in budding and fission yeast. S-phase cells activate one of two very
similar checkpoint pathways (which may in fact be integrated into one pathway)
to signal DNA damage through the intra-S checkpoint or aberrant replication
forks through the replication checkpoint [141]. The first step in S-phase
checkpoint activation is stalling of replication forks owing either to the depletion of
dNTPs or to the presence of DNA damage on the template strand [2, 142].
Fortunately, DNA damage detected during S-phase is likely to be repaired
precisely via homologous recombination mechanisms involving sister chromatids
[143]. Nonhomologous repair mechanisms also play a very prominent role in
DNA DSB repair during all phases of the cell cycle; however, these mechanisms
are inherently less precise and therefore confer an increased risk that
inaccurately repaired DNA will be carried forward into M phase. The canonical
checkpoint defect displayed by A-T cells is radioresistant DNA synthesis [144]. In
normal cells, exposure to IR provokes a rapid but reversible decrease in DNA
synthesis, which reflects decreases in the rates of both replication origin firing
and DNA strand elongation [144]. In the absence of ATM, the IR-induced
decrease in DNA synthesis is dampened significantly, giving rise to the RDS
phenotype.
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Activation of ATM/CHK2 and ATR/CHK1 leads to phosphorylation of
CDC25A, thereby priming it for ubiquitination and proteasome destruction [117,
145, 146]. Loss of CDC25A inhibits Cdk2 by maintaining its inhibitory
phosphorylation on Tyr 15 and inhibiting its association with cyclin E, an
association necessary for progression into S-phase and possibly progression
[147]. CDC25A also regulates Cdk4 activity and, as indicated by a much earlier
study performed with UV treatment, destruction of CDC25A results in
maintenance of the Tyr 17 inhibitory phosphorylation on Cdk4 that also prevents
S-phase entry or progression [148]. IR exposure during S-phase activates CHK2
which then phosphorylates Ser 123 in CDC25A; this modification targets
CDC25A for ubiquitin-dependent degradation. Interestingly, mutant CHK2 alleles
associated with a variant form of Li-Fraumeni syndrome [102] failed to bind
and/or phosphorylate CDC25A [149], which implies that genetic lesions in the
RDS pathway could promote genome instability and cancer development.
The G2/M checkpoint
The final gatekeeper that blocks the entry of DNA-damaged cells into
mitosis is the G2/M checkpoint. Though well characterized in pombe systems,
the details of G2/M arrest in higher eukaryotic cells are still being determined.
The picture thus far supports that fission yeast and higher eukaryotes both target
Cdc2 to maintain its inhibitory phosphorylations as a principal means to block the
G2/M transition. Targeting of Cdc2 is achieved by various parallel pathways,
including the phosphatases that promote mitosis, the kinases that block Cdc2
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function, and other proteins that control these regulators, which all converge to
regulate Cdc2 activity. DNA damage causes the activation of several different
downstream kinases that independently block the activity of CDC25B/C, the
phosphatase that promotes mitosis by removing phosphates at Cdc2 inhibitory
sites. By one mechanism, activation of ATR by damage leads to CHK1
phosphorylation [150]. CHK1 then negatively regulates CDC25B/C by
phosphorylating it at Ser 309 or Ser 216, respectively [4, 151]. This
phosphorylation of CDC25B/C creates a binding site for 14-3-3 proteins, and the
bound state renders CDC25B/C either catalytically less active, sequestered in
the cytoplasm, or both [152, 153], as discussed previously. In additional to
activation by ATR, CHK1 may need to be further activated by BRCA1 to induce a
G2/M arrest, although this additional activation has yet to be confirmed [80]. By a
second mechanism, ATM activation by DNA damage in G2 leads to Chk2
activation that also phosphorylates CDC25B/C at Ser 309 or Ser 216 to block its
function [154-156].
Studies of the G2 checkpoint in A-T cells have led to conflicting results, at
least until the emergence of ATR, and possibly now p38 as a parallel initiator of
checkpoint signaling [107]. When A-T cells are exposed to IR during G1 or S-
phase, any cells that reach G2 phase are effectively arrested before they initiate
mitosis. In fact, these cells show a more protracted G2 arrest than do ATM-
expressing cells. On the other hand, if A-T cells are irradiated while in G2 phase,
then the cells fail to arrest, and proceed into mitosis [92, 157, 158]. These results
indicate that ATM is dispensable for activation of checkpoint-mediated G2 arrest
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unless the DNA damage occurs during G2 itself. The ATM-independent pathway
that initiates G2 arrest in cells that have experienced a genotoxic insult before G2
phase has not been defined. However, it is still unclear what role ATR/CHK1 and
p38 will play in this alternative pathway of G2 checkpoint activation [27, 117,
118].
The critical role of CHK1 in the implementation of the G2 checkpoint is
supported by the finding that Chkl-T embryonic stem cells display a substantial
reduction in G2 arrest following IR exposure [96]. The current G2 checkpoint
model positions ATR as the upstream activator of CHK1 in human cells. In light
of the ATR/CHK1 pathway outlined earlier, how do we explain the fact the ATM-
deficient cells fail to activate the G2 checkpoint when DNA damage occurs during
G2 phase? One possibility is that ATM also contributes to the inhibition of
CDC25B/C activity, particularly in IR-damaged cells, by activating CHK2, which is
capable of phosphorylating Ser 216 of CDC25C, at least in vitro [159]. In cells
that express both ATM and ATR, ATM may activate CHK2 to reinforce the block
to cyclin B/CDC2 activation imposed by the ATR/CHK1 pathway. A defect in the
maintenance of the checkpoint induced G2 arrest has been observed in Chk2-
embryonic stem cells [103]. Hence the ATM/CHK2 pathway may play a
secondary role in G2 checkpoint activation when cells incur DNA DSB during G1
or S-phase.
The exact role each of the aforementioned pathways play and the
interplay between the pathways under various cellular stresses will most certainly
be the focus of intense study in coming years. For my thesis project, I have
44
focued on the identifcation new kinases substrates in the DNA damage response
pathway phosphorylated by the CHK1, CHK2 and p38 arms of DNA damage
signaling, as well as identification of new phospho-binding domains the recognize
proteins phosphorylated by ATM and ATR that may facilitate DNA damage
signaling and repair.
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Chapter 2
MAPKAP Kinase-2 is a Cell Cycle Checkpoint Kinase
that Regulates the G2/M Transition and S-phase
Progression in Response to UV Irradiation
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Summary
The cellular response to DNA damage is mediated by evolutionarily
conserved Ser/Thr kinases, phosphorylation of CDC25 protein phosphatases,
binding to 14-3-3 proteins, and exit from the cell cycle. To investigate DNA
damage responses mediated by the p38/stress-activated protein kinase (SAPK)
axis of signaling, the optimal phosphorylation motifs of mammalian p38a SAPK
and MAPKAP Kinase-2 were determined using oriented peptide library
screening. The optimal substrate motif for MAPKAP Kinase-2, but not for p38
SAPK, closely matches the 14-3-3-binding site on CDC25B/C. We discovered
that MAPKAP Kinase-2 is directly responsible for CDC25B/C phosphorylation
and 14-3-3-binding in vitro and in response to UV-induced DNA damage within
mammalian cells. Down-regulation of MAPKAP Kinase-2 eliminates DNA
damage-induced G1, intra S-phase, and G2/M checkpoints. We propose that
MAPKAP Kinase-2, more aptly named CHK3, is a new member of the DNA
damage checkpoint kinase family that functions in parallel with CHK1 and CHK2
to integrate DNA damage signaling responses and cell cycle arrest in
mammalian cells.
Contributions:
Andy Elia, Mike Yaffe, and Mary Stewart preformed the p38 kinase experiments shown in Figure
2.1 and discussed in the text. Dan Lim preformed the structural modeling experiment shown in
Figure 2.6 and played a major role in the construction of Figure 2.7. Ancho Nguyen played a
major role in the generation of the FACS data shown in Figures 2.4/2.5.
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Introduction
The maintenance of genomic integrity is essential for the health of multi-
cellular organisms. DNA damage checkpoints constitute a mechanism where
cell division is delayed to allow repair of damaged DNA or if the extent of DNA
damage is beyond repair, induce apoptosis. The three major DNA damage-
responsive cell cycle checkpoints are the G1/S checkpoint, intra S-phase
checkpoint, and the G2/M checkpoint [46].
Signal transduction events controlling the DNA damage response are
mediated by evolutionarily conserved Ser/Thr kinases and
phosphoserine/threonine-binding domains. Distinct types of genotoxic stress
converge to trigger a limited repertoire of DNA damage checkpoint responses,
presumably by funneling specific protein complexes that recognize different types
of DNA damage into a few common pathways. For example, lesions commonly
caused by IR and UV initiate the activation of the upstream kinases ATM and
ATR [2]. These kinases transduce the signal that directly engages the DNA
damage checkpoint.
ATM and ATR appear to have partially overlapping functions since some
common Ser/Thr-Gln-containing substrates of both kinases have been identified.
ATM responds primarily to double strand breaks whereas ATR responds to many
types of DNA damage, including the bulky DNA lesions caused by UV. Once
activated, ATM phosphorylates the downstream effector kinase CHK2 on Thr68,
and ATR phosphorylates the downstream effector kinase CHKI on Ser317 and
Ser345 [2, 160]. In addition, studies in both Xenopus egg extracts and
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mammalian cells have pointed to the existence of a checkpoint pathway that is
independent of ATR/CHK1 and ATM/CHK2 [107, 120, 161-163].
A major mechanism by which CHK1 and CHK2 control the DNA damage
response is through the phosphorylation-dependent inactivation of members of
the CDC25 family of phosphatases, which are positive regulators of Cyclin/Cdk
complexes [164]. The CDC25 family consists of three different isoforms:
CDC25A, CDC25B (variants 1,2, and 3) and CDC25C. CDC25A and CDC25B
are thought to be oncogenes since they are upregulated in many forms of human
cancer [165, 166]. CDC25A controls both progression through S-phase and entry
into, and maintenance of, mitosis [167, 168]. In response to DNA damage,
CDC25A is phosphorylated on several sites including Ser78 and Ser123,
targeting it for ubiquitin-mediated degradation [167]. CDC25B and CDC25C, on
the other hand, are primarily involved in regulating mitotic entry through their
activation of the cyclin-dependent kinase CDC2/CyclinB [164]. In response to
DNA damage, CDC25B1/CDC25B2 and CDC25C become sequestered away
from the nuclear pool of CDC2/CyclinB by phosphorylation on Ser-309/Ser-323
and Ser216, respectively, leading to 14-3-3 binding and cytosolic retention [169-
172]. The exact roles of different CDC25 family members in establishing this
G2/M checkpoint, however, remain a matter of active debate [173, 174].
In contrast to the IR-induced DNA damage checkpoint, the UV responsive
checkpoint is less well understood. It was recently shown that, in addition to the
ATR/CHK1 pathway, the p38 SAPK pathway is also required for full activation of
the DNA damage response following UV irradiation [107]. We discovered that
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MAPKAP Kinase-2, a direct downstream target of p38 SAPK is directly
responsible for phosphorylating CDC25B and C and maintaining the G1, S, and
G2/M checkpoints in response to UV-induced DNA damage. Thus, MAPKAP
Kinase-2 constitutes a third checkpoint kinase, in addition to CHK1 and CHK2,
involved in coordinating the DNA damage response of higher eukaryotic cells.
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Results
Defining the optimal phosphorylation motif for p38 SAPK
To identify substrates and targets of the p38 SAPK signaling pathway
involved in DNA damage responses, the optimal substrate phosphorylation motif
for p38ca SAPK was determined using oriented peptide library screening [11].
Efficient peptide phosphorylation by p38 SAPK required a fixed Pro residue in the
Ser+1 position (data not shown), consistent with the known identification of p38
SAPK as a Pro-directed MAP kinase. Screening performed with a library
containing the degenerate sequence X-X-X-X-Ser-Pro-X-X-X-X (X denotes all
amino acids except Cys, Ser, Thr, and Tyr) displayed strongest selection for Pro
in the Ser-2 position with weaker selection for other aliphatic residues (Figure
2.1A). Additional selection was also observed at the Ser-3, Ser-1 and Ser+2
positions.
To further refine the optimal phosphorylation motif, a secondary screen
was performed based on results from the initial screen by using a library with Pro
fixed in both the Ser-2 and Ser+1 positions, and Ser, Thr, and Tyr included in the
X positions. This revealed selection for Gin, Met, and Gly in the Ser-1 position,
along with slightly weaker selection for Pro, Ser and Thr (Figure 2.1A). Gly was
the preferred residue in the Ser-3 position, along with lie, Val, and Tyr.
Hydrophobic residues, particularly aromatic and P-branched amino acids, were
selected at the Ser+2 position. The resulting optimal motif for p38a SAPK
determined by oriented peptide library screening closely matches the sequence
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of mapped p38 MAPK phosphorylation sites on most, though not all, known
substrates (Figure 2.1A) [112, 113, 175-179]
A peptide containing the optimal p38 SAPK consensus phosphorylation
motif GPQSPI, "p38tide", was synthesized for kinetic analysis. This peptide was
readily phosphorylated by p38 SAPK in vitro, however, it failed to display
saturable Michaelis-Menton-type kinetics (Figure 2.1B). Instead, the initial
velocity increased linearly with increasing p38tide concentration up to1400 FtM.
This finding suggests that additional interactions besides an optimal
phosphorylation motif are likely to be involved in optimizing p38 SAPK-substrate
binding, such as MAP kinase docking sites [180].
To search for potential p38 SAPK substrates, particularly those relevant to
DNA damage signaling, the Swiss-Prot database was queried with the p38 SAPK
consensus phosphorylation motif using Scansite [181]. Other than GADD153, a
known p38 SAPK substrate, we were unable to identify any DNA damage
response proteins in the top 250 hits. Database searching did, however, reveal
two tandem near-optimal p38 SAPK phosphorylation sites (Ser-345 and Ser-348)
in p47phox, a cytosolic component of the NADPH oxidase enzyme. A peptide
containing this sequence, PGPQSPGSPL, "p47tide", was strongly
phosphorylated by p38 SAPK, but like p38tide, the isolated peptide displayed
linear non-saturable kinetics (Figure 2.1B).
Wild-type and mutant versions of GST-tagged full-length p47phox protein,
rather than isolated peptides, were then used as substrates for in vitro
phosphorylation reactions. The wild-type full-length p47phox protein was rapidly
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phosphorylated by p38a SAPK (Figure 2.1C, D). Mutation of Ser-345--Ala had a
more pronounced effect on p47phox phosphorylation than mutation of Ser-
348-Ala, in excellent agreement with the observation that the Ser-345 site is a
better match for the optimal p38 SAPK consensus motif than the Ser-348 site.
Simultaneous mutation of both Ser-345 and Ser-348 to Ala eliminated
phosphorylation of p47phox by p38 SAPK altogether. Kinetic analysis revealed
classical Michaelis-Menton behavior for p38 SAPK phosphorylation of the wild-
type p47phox with a Km of 6.0 IM and a Vmax of 36.6 nmol/min/tg. Mutation of
Ser-345 to Ala both increased the Km and reduced the Vmax, while mutation of
Ser-348 to Ala primarily increased the Km (Figure 2.1 E).
This data from isolated peptides and intact proteins argues that efficient
substrate phosphorylation by p38 SAPK requires sequences with reasonable
matches to the optimal substrate motif determined by oriented peptide library
screening, and that additional interactions involving MAPK docking sites are
likely to be critical for strong kinase-substrate interactions. Several docking motifs
have been identified for p38 SAPK, particularly a short cluster of positively
charged amino acid residues often flanked by hydrophobic amino acids [106,
111]. Two sequences corresponding to this type of docking motif are present
near the p38SAPK phosphorylation sites in p47 phox, 311IHQRSRKRLSQ 3 21 and
329VRFLQQRRRQA3 3 9. Mutation of 335RRR337 to LLL in the latter motif
decreased the rate of p38a SAPK phosphorylation of p47phox by over 70%. The
contribution of amino acids 311-321, or involvement of alternative p38 SAPK
docking site(s) [112] is not yet known.
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Bulavin et al. [107] implicated p38 SAPK in the DNA damage-response
pathway and reported that p38 SAPK was directly responsible for generating a
14-3-3-binding site on CDC25B (Ser-323 in CDC25B2; Ser-309 in CDC25B1) in
response to UV-C-induced DNA damage. Like p47phox, CDC25B contains a
potential p38 SAPK docking motif, 345 PVQNKRRRSV354, however the sequence
flanking Ser-323, LXRSPSMP lacks a Pro in the Ser+1 position, and does not
resemble the optimal p38 SAPK motif shown in Figure 2.1A. As shown in Figure
2.2A, recombinant p38 SAPK readily phosphorylated bacterially produced
CDC25B in vitro. However, this phosphorylation did not induce 14-3-3-binding,
and a Ser-323->Ala mutant form of CDC25B was phosphorylated by p38 SAPK
equivalently to the wild-type CDC25B protein. This data argues that while
CDC25B may be a p38 SAPK substrate, this phosphorylation event is not
responsible for the 14-3-3-binding event that results in a G2/M checkpoint.
Defining the optimal phosphorylation motif for MAPKAP Kinase-2
A number of Ser/Thr kinases are activated downstream of p38 SAPK
including MAPKAP kinases-2, and -3, MNK1 and MNK2, MSK1 and MSK2, and
PRAK [116]. In response to UV-B-induced DNA damage, She et al (2002)
reported that MAPKAP kinase-2 could phosphorylate p53 on Ser-20, the same
site that is phosphorylated by two well-established checkpoint kinases, CHK1
and CHK2. Both CHK1 and CHK2 can also phosphorylate CDC25 family
members to create 14-3-3 binding sites, suggesting that MAPKAP Kinase-2
might share a similar motif. The optimal substrate phosphorylation motif for
54
MAPKAP kinase-2 was therefore investigated using oriented peptide library
screening.
Efficient peptide phosphorylation by MAPKAP Kinase-2 was only
observed with a library containing a fixed Arg in the Ser-3 position (X-X-X-X-R-X-
X-S-X-X-X-X, where X denotes all amino acids except Cys, Ser, Thr, or Tyr). A
critical step in determining protein kinase phosphorylation motifs by peptide
library screening involves purification of the phosphorylated peptides from the
non-phosphorylated peptide background. In the case of MAPKAP Kinase-2, this
was dramatically improved by conversion of all Glu and Asp residues to their
methyl esters prior to metal-affinity chromatography and sequencing [12]. This
resulting motif revealed clear amino acid selection at almost all degenerate
positions (Figure 2.3A). MAPKAP Kinase-2 displayed strong selection for the
hydrophobic residues Leu, Phe, lie, and Val in the Ser-5 position, and the Ser+1
position. Strong selection was also observed for Gin in the Ser-2 position, and
modest selection for Leu in the Ser-1 position. The motif determined for
MAPKAP Kinase-2 using oriented peptide library screening is in remarkably good
agreement with the sequence of mapped MAPKAP Kinase-2 phosphorylation
sites on known substrates (Figure 2.3A, bottom) [110, 182-188], which primarily
contain Leu, lie or Phe in the Ser-5 position, Arg in the Ser-3 position, Gin, Ser,
or Thr in the Ser-2 position, Leu, Val or Pro in the Ser-1 position, and
hydrophobic residues along with Glu in the Ser+1 position. The preference for
polar residues Ser and Thr in addition to Gin in the Ser-2 position in known
55
MAPKAP Kinase-2 substrates would not have been detected by oriented peptide
library screening since Ser and Thr were not present in the library.
To verify the peptide library screening results, individual peptides
(MK2tides) containing the optimal MAPKAP Kinase-2 consensus motif LQRQLSI,
or mutant versions with Ala substituted at each position in the motif, were
synthesized and used for kinetic analysis (Figure 2.3B, C). The optimal MK2tide
displayed a Km value two-fold lower than the best MAPKAP kinase-2 peptide
substrate known to date, a sequence derived from HSP27 [188]. Substitution of
Ala at each position in the motif affected Km and Vmax differently with some
positions showing primarily a K effect (i.e. Arg in the Ser-3 position), while
others revealed a primary effect on Vmax (i.e. Leu in the Ser-5 position) (Figure
2.3C). The rank order of importance of key residues is Arg-3 > Leu-5 - Ile+1 >
Gln-3. The optimal MK2tide had neither the lowest Km nor the highest Vmax, but
rather had the highest Vmax/Km ratio, consistent with the fact that the peptide
library screening approach selects substrates on the basis of optimal Vmax/Km,
rather than low Km or high Vmax alone [189]. Combining the data from oriented
peptide library screening, known substrate sequences, and our kinetic studies,
the optimal MAPKAP Kinase-2 phosphorylation motif is (Leu/Phe/lle)-(Xxx)-(Arg)-
(Gln/Ser/Thr)-(Leu)-(Ser/Thr)-(Hyd rophobic).
The optimal MAPKAP Kinase-2 substrate motif is an excellent match for
the known Ser-323 phosphorylation/14-3-3 binding motif in CDC25B, as well as
the Ser-216 phosphorylation/14-3-3-binding site in CDC25C (Figure 2.3A). Initial
experiments focused on CDC25B, since unlike CDC25C, CDC25B can be
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produced in modest quantities in bacteria, and the Ser-323 site in CDC25B had
been previously reported to be a direct p38 SAPK site. Incubation of
recombinant CDC25B with purified MAPKAP Kinase-2 resulted in significant
CDC25B phosphorylation and strong binding of the phosphorylated protein to 14-
3-3 (Figure 2.2A). Mutation of Ser-323-Ala substantially reduced the ability of
MAPKAP Kinase-2 to phosphorylate CDC25B, and completely eliminated the
ability of CDC25B to bind to 14-3-3 (Figure 2.2A). These in vitro results strongly
suggest that MAPKAP Kinase-2 is the critical CDC25/14-3-3 checkpoint kinase
downstream of DNA damage signals relayed by the p38 SAPK pathway.
MAPKAP Kinase-2 is critical for the G2/M checkpoint following UV-
induced DNA damage
The importance of MAPKAP Kinase-2 in DNA damage checkpoint function
was investigated in U20S cells. Activation of MAPKAP Kinase-2 in response to
UV-C irradiation-induced DNA damage (Figure 2.4A) was monitored by its
reduced mobility on SDS-PAGE gels, and by immunoblotting using a phospho-
specific antibody against pThr-344, a site phosphorylated by p38 and required for
MAPKAP Kinase-2 activation [177]. As shown in Figure 2.2B, MAPKAP kinase-2
was activated within 1 hr of irradiation, and remained activated for the 8 hr
duration of the experiment. The kinetics of MAPKAP Kinase-2 activation
paralleled the ability of CDC25B from these cells to bind to 14-3-3. Based on
these data, a 2 hr time point was chosen for use in further studies.
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RNA interference was used to confirm a direct role for endogenous
MAPKAP Kinase-2 in the UV-induced DNA damage response. Treatment of
U20S cells with MAPKAP Kinase-2-specific siRNA oligonucleotides, but not with
control GFP siRNA oligonucleotides, resulted in a substantial reduction of
MAPKAP Kinase-2 to nearly undetectable levels by 48 hr after transfection
(Figure 2.2C). No reduction in the levels or UV-C-induced activation of p38
SAPK, CHK1 or CHK2 was observed in these cells. Despite the presence of
these other active kinases, siRNA-mediated knock-down of MAPKAP Kinase-2
caused a loss of both CDC25B- and CDC25C-binding to 14-3-3 after UV-C
exposure (Figure 2.2C).
Cell cycle progression in the control GFP and MAPKAP Kinase-2 knock-
down cells following UV-C-irradiation was studied using FACS (Figure 2.4). In
these experiments, cells were irradiated with 20 J/m2 of UV-C radiation, allowed
to recover for 2 hr, then placed in nocodazole-containing media for an additional
16 hr to cause any cells progressing through the cell cycle to arrest in mitosis,
where they can stained for the mitotic marker phosho-histone H3. Under these
conditions, un-irradiated cultures of asynchronous GFP siRNA-transfected cells
accumulated in a 4N-DNA-containing peak, with prominent levels of phospho-
histone H3 staining (Figure 2.4B, C), consistent with a nocodazole-mediated M-
phase arrest. In response to UV-irradiation, control cells displayed a prominent
G1, S, and G2 distribution, with near-complete loss of phospho-histone H3
staining, indicating intact G1, S, and G2 checkpoints (Figure 2.4D, E).
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The behavior of the MAPKAP Kinase-2 siRNA transfected cells was
dramatically different. In the absence of UV irradiation, MAPKAP kinase-2 siRNA
transfected cells, like control GFP siRNA-transfected cells, accumulate in a 4N
DNA-containing peak with high levels of phospho-histone H3 staining (Figure
2.4F, G). Following UV-induced DNA damage, however, the MAPKAP Kinase-2
knock-down cells failed to arrest cell cycle progression. Instead, these cells
proceeded to enter mitosis to the same extent as un-irradiated cells, as shown by
a comparable 4N-DNA peak and similar levels of phosho-histone H3 staining as
those observed in un-irradiated cells (Figure 2.4H, I). Together with the
CDC25B/C:14-3-3 results in Figure 2.2C, this FACS data demonstrates that
MAPKAP Kinase-2, is critical for the UV-induced G2/M checkpoint in response to
UV-irradiation. In contrast to the UV response, summarized in Figure 2.4J, the
G2/M checkpoint response to ionizing radiation in MAPKAP Kinase-2 knock-
down cells is intact (Figure 2.4K).
MAPKAP Kinase-2 is critical for the S-phase checkpoint and G1
arrest following UV-induced DNA damage
The MAPKAP Kinase-2 knockdown cells in Figure 2.4 also showed a loss
of the G1 and S-phase checkpoints following DNA damage, since UV-irradiation
of asynchronous cultures resulted in accumulation of the cells in a 4N DNA-
containing peak when the cells were transferred to nocodazole-containing
medium. To investigate the direct role of MAPKAP Kinase-2 in S-phase
checkpoint function, control or MAPKAP Kinase-2 knock-down U20S cells were
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UV-irradiated, allowed to recover for 30 min, and then labeled with BrdU for
various times. In the absence of irradiation, 42% of the control siRNA-
transfected cells showed substantial BrdU incorporation after 12 hr, compared
with 53% of the MAPKAP Kinase-2-siRNA transfected cells (Figure 2.5A, B).
When the cells were irradiated with 20 J/m2 of UV light prior to BrdU labeling,
only 3.5% of the control siRNA transfected cells showed BrdU incorporation at 12
hr. In marked contrast, 48% of the MAPKAP Kinase-2-knock-down cells
continued to incorporate substantial amounts of BrdU. A similar difference in
BrdU uptake between control siRNA-treated cells and MAPKAP Kinase-2-knock-
down cells was also seen at shorter times after irradiation (Figure 2.5B).
Examination of the FACS profiles 12 hr following UV-irradiation revealed a
dramatic decrease in the G1 population in the MAPKAP Kinase-2-knock-down
cells compared with the control GFP siRNA-transduced cells (Figure 2.5A, right-
most upper and lower FACS profiles). This loss of the G1 peak, together with the
increased percentage of cells showing BrdU incorporation at 12 hr versus 2 hr of
labeling, implies that endogenous MAPKAP Kinase-2 plays important roles in
both the inhibition of DNA synthesis following damage (S-phase checkpoint
function), and in the damage-induced arrest of cells in G1 prior to S-phase entry
(G1/S checkpoint function). Loss of the G1/S and S-phase checkpoints in
MAPKAP kinase-2 knock-down cells was associated with higher levels of
CDC25A, decreased levels of p53, and reduced phosphorylation of p53 on Ser-
20 following UV-irradiation compared with control siRNA-treated cells (Figure
2.2C).
60
The fate of S-phase control or MAPKAP Kinase-2 siRNA-treated cells in
response to UV-C-induced DNA damage was examined by using FACS. In this
experiment, asynchronous cells were mock-treated or irradiated with 20 J/m2 of
UV-C radiation and then pulse-labeled with BrdU. The ells showing BrdU uptake
were subsequently analyzed 10 and 20 hr later (Figure 2.5C). In both non-
irradiated control and MAPKAP Kinase-2 knock down cells, the BrdU pulse-
labeled population showed a late S and G2/M distribution at 10 hr, and a re-
appearance of a G1 peak at 20 hr, indicating full transit through the cell cycle. In
response to UV-C irradiation, control siRNA-treated cells failed to show
significant BrdU uptake upon which to gate for FACS analysis (Figure 2.5C,
lower left panel). In contrast, the large population of MAPKAP Kinase-2 siRNA
treated cells, which had lost the S-phase checkpoint and incorporated BrdU,
went on to display a greatly reduced G1 peak at 20 hr with many cells showing
DNA staining > 4N (Figure 2.5C, bracket in lower right panel), consistent with
mitotic death and exit from the cell cycle.
MAPKAP Kinase-2 Depleted Cells are More Sensitive to DNA
Damage-Induced Cell Death
The experiments in Figures 2.4 and 2.5A-C indicate that MAPKAP Kinase-
2 is involved in each of the cell cycle checkpoints triggered by UV-induced DNA
damage. To determine the effect of MAPKAP Kinase-2 depletion on cell survival,
cells were transfected with control siRNA or MAPKAP Kinase-2 siRNA for 48 hr,
trypsinized, re-plated, and analyzed for colony formation in response to various
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doses of UV-C irradiation 12 hr after re-plating. As shown in Figures 2.5D and E,
MAPKAP Kinase-2 knock-down cells displayed a significant reduction in colony
formation when compared to control-treated cells at all doses of UV-C irradiation
examined. This difference in survival after UV-C exposure was most
pronounced at low to moderate UV doses.
A structural model for MAPKAP Kinase-2 substrate selectivity
The optimal phosphorylation motif determined for MAPKAP Kinase-2 is
strikingly similar to that determined for two other checkpoint kinases, CHK1 and
CHK2 (Figure 2.6A; [90] and data not shown). All three of these CAMK
superfamily members - MAPKAP Kinase-2, CHK1, and CHK2 - strongly select for
aliphatic residues in the Ser-5 position, Arg in the Ser-3 position, and
aromatic/aliphatic residues in the Ser+1 position, along with additional less
stringent selection for particular amino acids in other positions (Figure 2.6A). In
contrast, members of the AGC kinase superfamily such as Akt/PKB and
conventional protein kinase C superfamily members preferentially phosphorylate
sequences containing Arg residues in both the Ser-5 and Ser-3 positions, and
play important roles in anti-apoptotic signaling and other signaling events unique
to differentiated cell function, rather than critical roles in cell cycle control.
To investigate the structural basis for substrate motif selection, we
performed molecular modeling studies of activated MAPKAP Kinase-2, using the
published MAPKAP Kinase-2:ADP co-crystal structure [190] as a base model.
The optimal substrate peptide Leu-Gln-Arg-Gln-Leu-Ser-lle-Ala was modeled into
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the kinase active site in an extended conformation (Figure 2.6D), and the
kinase:substrate complex compared with the structures of Akt/PKB:AMP-
PNP:GSK3-peptide ternary complex [191] (Figure 2.6C) and the CHK1 crystal
structure containing a modeled CDC25C peptide [192] (Figure 2.6E). Strong
selection for Arg in the Ser-3 position for MAPKAP Kinase-2, Akt/PKB and CHK1
is rationalized by the presence of a conserved glutamate residue at a similar
location in all three kinases (Glu-145 in MAPKAP Kinase-2, Glu-236 in Akt/PKB
and Glu-91 in CHK1), which in Akt/PKB forms a bidentate salt bridge with the
Ser-3 arginine guanidino group on GSK3-peptide [191]. Similarly, selection for a
hydrophobic residue at the Ser+1 position is explained by a hydrophobic pocket
that is conserved at this position in all three kinases. The pocket is lined by Phe-
310, Pro-314, Leu-317 and Phe-359 in Akt/PKB and by Met-167, Leu-171, Val-
174, Leu-178 and Leu-179 in CHK1. The corresponding Ser+1 pocket in
MAPKAP Kinase-2 is lined by Pro-223, Pro-227, Val-234 and Leu-235. Within
this region, Gly-312 in Akt/PKB and Gly-169 in CHK1 are replaced by Tyr-225 in
MAPKAP Kinase-2, which may reduce the depth of the MAPKAP Kinase-2
hydrophobic pocket and explain selection for branched chain aliphatic residues in
this position compared with Phe selection by Akt/PKB and CHK1.
The marked contrast between Arg selection at the Ser-5 position in
Akt/PKB with the corresponding selection for hydrophobic residues at this
position by MAPKAP Kinase-2 and CHK1 is accounted for by the presence of
Glu 342 in Akt/PKB at the base of the Ser-5 pocket. This residue is not
conserved in MAPKAP Kinase-2 and CHK1, and is instead substituted by lle-255
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in MAPKAP Kinase-2 and by Ala-200 in CHK1. Additional residues, notably Phe-
147, Pro-189, Pro-261 and Leu-342 in MAPKAP Kinase-2, and similarly Phe-93,
lle-96, Pro-98, Pro-133 and Leu-206 in CHK1, contribute a significant
hydrophobic character to this region.
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Discussion
In this study we have defined the optimal substrate motifs within the p38
SAPK/MAPKAP Kinase-2 axis of signaling using oriented peptide library
screening. Our elucidation of the optimal phosphorylation motif for MAPKAP
Kinase-2 expands considerably upon, and is in good agreement with, a more
preliminary motif for this kinase determined previously [110]. Similarly, the
optimal motif determined for p38 SAPK is in reasonable agreement with many
mapped phosphorylation sites on p38 SAPK substrates. As with all consensus
phosphorylation motifs, bona-fide substrates match the optimal motif at some,
but not necessarily at all positions. Nearly all in vivo p38 MAPK substrates
contain at least a minimum core SP motif, though Cohen and colleagues have
recently identified TAB1 as a novel in vivo substrate of p38 SAPK in which one of
the three mapped p38 SAPK phosphorylation sites lacks the Ser+1 Pro residue.
This suggests that alternative phosphorylation and docking motifs may be
present on some p38 SAPK substrates, and/or that local avidity effects may be
important in some cases.
Our data suggests that a crucial role of p38 SAPK in response to UV-
induced DNA damage is the phosphorylation and activation of MAPKAP Kinase-
2, leading to MAPKAP Kinase-2-directed phosphorylation of CDC25 family
members to induce 14-3-3-binding and subsequent cell cycle arrest. In this way,
MAPKAP Kinase-2 performs similar functions after UV-C induced DNA damage
as those performed by CHK1 and CHK2 after exposure of cells to ionizing
radiation [193]. Recent data suggest that p38 SAPK (and therefore MAPKAP
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Kinase-2) may play a similar role in certain types of chemotherapy-induced DNA
damage [118, 120, 163].
Our finding that MAPKAP Kinase-2 is a central checkpoint kinase involved
in DNA damage responses triggered by UV irradiation allows a different
interpretation of the results of Bulavin et al [107], who demonstrated that
inhibition of p38 SAPK by the chemical inhibitor SB202190, or reduction of p38
SAPK levels using anti-sense oligonucleotides blocked the G2/M checkpoint
response in cells that received the same dose of UV-C radiation as the cells used
in our study. The authors reported that p38 SAPK directly phosphorylated
CDC25B and C to generate a 14-3-3 binding site. However, the experiments in
that study were performed using Flag-tagged p38 SAPK that was
immunoprecipitated from UV-irradiated cells. p38 SAPK and MAPKAP Kinase-2
form a tight complex within cells, and in response to cellular stress, p38 SAPK
phosphorylation of MAPKAP Kinase-2 is required for the co-transport of the p38
SAPK:MAPKAP Kinase-2 complex from the nucleus to the cytoplasm [122, 123].
Thus, the p38 SAPK immunoprecipitates used in that study likely contained
significant amounts of MAPKAP Kinase-2. Furthermore, the activity of MAPKAP
Kinase-2 would have been strongly reduced by treatment with any p38 SAPK
inhibitor.
MAPKAP Kinase-2 undergoes initial activation in the nucleus with
subsequent export of the active kinase to the cytoplasm [122]. Thus, MAPKAP
Kinase-2 is well positioned to function as both a nuclear initiator of CDC25B/C
phosphorylation in response to DNA damage, and as a maintenance kinase that
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keeps CDC25B/C inhibited in the cytoplasm. A unified model for kinase-
dependent DNA damage checkpoints is presented in Figure 2.7. In response to
ionizing radiation, ATM activation of CHK2 and ATR activation of CHK1 leads to
phosphorylation of CDC25 family members on related sequences corresponding
to the checkpoint kinase core "motif' LxRxx[S/T](. Similarly, in response to UV-
induced DNA damage, ATR activates CHK1 and p38 SAPK activates MAPKAP
Kinase-2, leading to phosphorylation of the same core motif on CDC25 family
members. The exact role that different checkpoint kinases play in
phosphorylating different CDC25 phosphatases remains incompletely
understood. The major role of CHK1 appears to involve phosphorylation of
CDC25A after IR ([167] and references therein), whereas CHK2 appears to
phosphorylate all three CDC25 family members. In the absence of CHK2, CHK1
appears to be able to subsume at least part of this function [193]. Our data now
suggests that MAPKAP Kinase-2 is the primary effector kinase that targets
CDC25B/C after UV-C exposure. MAPKAP Kinase-2 may also be involved in
CDC25A phosphorylation, since we observed that the G1 and S-phase
checkpoints were eliminated in the MAPKAP Kinase-2 knock-down cells.
Given the convergence of optimal substrate motifs for MAPKAP Kinase-2,
CHK1 and CHK2, the structural similarity between the substrate-binding cleft in
CHK1 and MAPKAP Kinase-2, and the functional overlap between these 3
kinases in response to DNA damage, MAPKAP Kinase-2 could equivalently be
referred to as "CHK3". Whether MAPKAP Kinase-2 plays a similar critical
checkpoint role in the cellular response to altered chromatin topology and
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chemically-induced DNA damage as that described here in response to UV-
irradiation is not known. However, recent reports that p38 MAPK participates in
checkpoint activation following Topoisomerase II inhibition, adriamycin-induced
double-strand breaks [120], and temozolomide-induced DNA damage mismatch-
repair [163], is consistent with such a model. Experiments to test this are
currently in progress. In summary, our data implicate MAPKAP Kinase-2 as a
third checkpoint kinase that functions in parallel with CHK1 and CHK2 to
coordinately regulate the DNA damage response.
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Experimental Procedures
Protein Production and Purification
Recombinant 14-3-3E/,-MBP (maltose binding protein), 14-3-3p/-GST
(glutathione-S-transferase) and p47phox-GST proteins were produced as
described previously [21]. A vector encoding CDC25B2-GST was a gift from B.
Gabrielli (University of Queensland, Australia). Point mutations were generated
using the Stratagene Quick Change Mutagenesis Kit and confirmed by
sequencing the entire coding regions.
Kinase Motif Screening with Oriented Peptide Libraries and In Vitro Kinase
Assays
Combinatorial peptide library screening was performed using recombinant
purified p38a SAPK, MK2, CHK1 and CHK2 as previously described [11] with
minor modifications. Kinase reactions were performed in 30 g1 of kinase reaction
buffer (20 mM HEPES, pH 7.5, 10 mM MgCI2, 3 mM 2-mercaptoethanol, 100
pg/ml BSA, 50 p.M ATP, 10 RCi 32 P-y-ATP) containing 2.0 pg of recombinant p47
or CDC25B substrate protein or the specified amount of peptide and 0.10 pg of
recombinant p38a SAPK or 0.03 pg of recombinant MAPKAP Kinase-2 at 30° C
for the indicated time.
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Tissue Culture and Transfections
U20S cells were maintained and propagated in DMEM supplemented with
10% fetal bovine serum (FBS), L-glutamine and penicillin/streptomycin. siRNA
oligonucleotides corresponding to MAPKAP Kinase-2 sense strand
5'-UGACCAUCACCGAGUUUAUdTdT-3' and anti-sense strand
5'-AUAAACUCGGUGAUGGUCAdTdT-3' and to GFP sense strand
5'-UCCCGGCUAUGUGCAGGAGdTdT-3' and anti-sense strand
5'-CUCCUGCACAUAGCCGGGAdTdT-3' were purchased from Dharmacon.
siRNAs were used according to the manufacturer's suggested protocol and
transfected into cells using Lipofectamine 2000 (Gibco Invitrogen).
14-3-3 pull-down assays, Immunoblotting, and Immunofluorescence
U20S cells were lysed in lysis buffer: 50 mM Tris/HCI, pH7.8, 150 mM
NaCI, 1.0% NP-40, 5 mM EDTA, 2 mM DTT, 8 pg/mL pepstatin, 8 pg/mL
aprotinin, 8 pg/mL leupeptin, 2 mM Na3VO 4, 10 mM NaF, 1 pM microcystin for 20
min at 40C. Clarified lysates (0.5-2mg protein) were incubated with 20 pL
glutathione beads or amylose beads containing 10-20 pg 14-3-3- GST or 14-3-3-
MBP, respectively, for 120 min at 40C. Following washing, lysates and bead-
bound proteins were analysed by SDS-PAGE, followed by transfer to PVDF
membranes and immunoblotted with the indicated antibodies. For
immunofluorescence experiments, U20S cells were seeded onto 18mm2
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coverslips, irradiated or mock-treated, fixed, extracted, and immunostained as
described previously [86].
FACS Analysis
UV irradiation was performed at 254 nm (UV-C) using a Stratalinker 2400
(Stratagene). U20S cells were fixed in 70% ethanol overnight at -200C,
permeabilized with PBS containing 0.2% Triton X-100 for 20 min at 40C, blocked
with 2% FBS in PBS and incubated with 1 ig of anti-phospho-histone H3 per 106
cells for 60 min on ice. Following washing, cells were incubated with FITC-
conjugated goat anti-rabbit antibody (diluted 1:500) for 30 min on ice, washed,
and resuspended in PBS containing 50 [tg/ml PI for 20 minutes immediately prior
to FACS analysis.
For BrdU incorporation experiments, cells were incubated with 30 EM
BrdU for the indicated times, then fixed and permeabilized as above. Cells were
denatured in 2N HCI for 20 min at room temperature, neutralized with 0.1M
Na2B 40 7 (pH 8.5), blocked with 2% FBS in PBS and incubated with a murine
anti-BrdU antibody for 60 min on ice. Following washing, cells were incubated
with FITC-conjugated goat anti-mouse antibodies and PI as above. Analysis was
performed using a Becton Dickinson FACS machine with CellQuest software.
Structural Modeling
Activated MAPKAP Kinase-2 (phosphorylated on Thr 222) was modeled
using the crystal structure of the ADP complex [190] with the activation loop
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(residues 213 to 241) deleted and rebuilt using the corresponding region
(residues 299 to 328) from the structure of activated Akt/PKB in complex with
AMP-PNP and GSK3-peptide [191] as a template. An optimal peptide (Leu-Gln-
Arg-Gln-Leu-Ser-lle-Ala) was modeled in the active site based on the GSK3-
peptide. A substrate peptide (Leu-Tyr-Arg-Ser-Pro-Ser-Met-Pro-Leu, residues
211-219 of human CDC25C) in the CHK1 active site was similarly modeled using
the GSK3-peptide as a template and manually adjusted to resemble the
published model [192]. Structures were superimposed using ALIGN [194] and
SUPERIMPOSE [195]. Manual adjustments of the models were made using
XFIT from the XtalView suite [196].
Antibodies and Reagents
Anti-MAPKAP Kinase-2, anti-phospho-MAPKAP Kinase-2 (pT344), anti-
p38, anti-phospho-p38 (pT180/pY182), anti-CHK1 and anti-phospho-CHK1
(pS345), anti-CHK2 and anti-phospho-CHK2 (pT68), anti-phospho(Ser/Thr)
ATM/ATR substrate antibody, and anti-phospho-p53 (pS20) antibodies were
purchased from Cell Signaling. Anti-CDC25B antibody was purchased from BD
Transduction Labs. Anti-p53, anti-CDC25a, and anti-CDC25C antibody were
purchased from Santa Cruz. Anti-phospho-histone H3 was purchased from
Upstate Biotech, Inc. Anti-5-bromo-2-deoxyuridine (BrdU) was purchased from
Sigma-Aldrich, Inc. Propidium Iodide (PI) was purchased from Calbiochem,
amylose beads were purchased from New England Biolabs, Ni-NTA agarose
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were purchased from QIAGEN, and glutathione beads and BrdU were purchased
from Sigma-Aldrich.
Purification of Recombinant Proteins
Constructs encoding GST- and MBP-fusion proteins were transformed into
DH5a or BL21(DE3) strains of E. coli and recombinant proteins obtained by
inducing late log phase cells with 0.4 mM IPTG at 37oC for 3-5 hr. Cells were
lysed by sonication in lysis buffer containing 50 mM Tris-HCI (pH 7.5), 250 mM
NaCI, 1 mM DTT, 8 pg/mL pepstatin, 8 pg/mL aprotinin, and 8 pg/mL leupeptin.
Fusion proteins were purified from cell lysates by using amylose or glutathione
beads. After being extensively washed with PBS containing 0.5% NP-40 and a
final wash with PBS, fusion proteins were eluted from the beads with HEPES (pH
7.2), containing 40 mM maltose or 20 mM glutathione, followed by exchange into
PBS using duplicate Sephadex G-25 columns (NAP-10 columns, Pharmacia).
Protein concentrations were determined using the bicinchoninic acid assay
(Pierce) as recommended by the manufacturer, using BSA as the standard. Full-
length CHK1-GST or full-length CHK2-His6 in pFASTBAC was expressed in Sf9
insect cells. CHKl-expressing cells were lysed in buffer containing 50 mM Tris-
HCI (pH 7.5), 250 mM NaCI, 1 mM DTT, 1.0% NP-40, 8 pg/mL pepstatin, 8
pg/mL aprotinin, 8 g/mL leupeptin, 2 mM Na3VO4, 10 mM NaF, and 1 pM
microcystin, and CHK1 was purified using glutathione beads. CHK1 was eluted
from the beads with 10 mM glutathione in 50 mM Tris-HCI (pH 8.0) and dialyzed
into kinase buffer. CHK2-expressing cells were lysed in buffer containing 50 mM
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Tris-HCI (pH 7.5), 250 mM NaCI, 1 mM DTT, 1.0% NP-40, 8 pg/mL pepstatin, 8
pg/mL aprotinin, 8 pg/mL leupeptin, 2 mM Na3VO4, 10 mM NaF, and 1 pM
microcystin, and CHK2 was purified using Ni-NTA agrose beads. After being
washed extensively with lysis buffer containing 40 mM imidazole, CHK2 was
eluted from the beads with 100 mM imidazole in 50 mM Tris-HCI (pH 8.0) and
dialyzed into kinase buffer.
Kinase Motif Screening with Oriented Peptide Libraries
Combinatorial peptide library screening was performed using recombinant
purified p38a SAPK, MK2, CHK1, and CHK2. Briefly, 5.0 mg of recombinant
p38a SAPK, 3.0 mg MK2, 2.0 mg CHK1, and 2.0 mg CHK2 were incubated with
1 mg of each peptide library in 300 ml reaction volumes containing 20 mM
HEPES (pH 7.5), 10 mM MgCI2, 3 mM 2-mercaptoethanol, and 100 mM ATP
containing 2.5 mCi of 32P-g-ATP for 120 min at 30oC. Under these conditions,
approximately 1% of the peptide mixture was phosphorylated. The reaction
mixture was diluted by addition of 300 ml of 30% acetic acid, and the
phosphorylated peptides separated from unincorporated 32P-g-ATP by DEAE
column chromatography (1 ml bed volume) by using isocratic elution with 30%
acetic acid. The peptide mixture (both phosphorylated and unphosphorylated but
free of ATP) eluted within the first 1 ml following the 600 ml void volume of the
column. Samples were dried in a Speed-Vac apparatus.
For the p38a SAPK peptide library experiments, the sample was
resuspended in 200 ml of 50 mM MES (pH 5.5) containing 1 M NaCI. Separation
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of phosphorylated from nonphosphorylated peptides was achieved by IMAC
using ferric-iminodiacetic acid beads. A 0.5 ml iminodiacetic acid column was
charged with 2.5 ml of 20 mM FeCI3 and extensively washed with H20 and then
with 3 ml of 500 mM NH4HCO3 (pH 8.0), 3 ml of H20, and 3 ml of 50 mM MES
(pH 5.5)/1 M NaCI. The peptide mixture was applied, and the column was
developed with 3 ml 50 mM MES (pH 5.5) and 1 M NaCI followed by 4 ml of H20
to remove nonphosphorylated peptides. Phosphorylated peptides were then
eluted with 2 ml of 500 mM NH4HCO3 (pH 8.0) and dried in a Speed-Vac
apparatus and resuspended in 80 ml H20.
Peptide library screens using basophilic kinase-directed libraries are
complicated by a high background of nonphosphorylated Asp/Glu-rich peptides
that copurified with the phosphorylated peptides during the immobilized metal
affinity chromatography (IMAC) step prior to peptide sequencing, greatly
complicating the analysis. To overcome this problem, we developed a new
approach in which peptide libraries are first phosphorylated by the kinase of
interest and then treated with methanolic HCI to convert Asp and Glu residues to
their uncharged methyl esters. With this approach, the background of
nonphosphorylated peptides that adhere to the IMAC column was reduced to
insignificant levels. Furthermore, the Asp and Glu methyl esters were converted
back to their free acids during the sequencing reaction, allowing selection for
these residues, if present in the phosphorylation motif, to be accurately
measured.
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For the MAPKAP Kinase-2, CHK1, and CHK2 peptide library experiments,
40 ml of thionyl chloride was added drop wise in a hood to 1 ml of dry methanol.
This solution was then used to dissolve each of the dried peptide libraries
followed by stirring at room temperature for 1 hr. The peptide library was dried
down overnight and resuspended in 100 ml of a 1:1:1 mixture of
methanol/acetonitrile/water. A 0.5 ml iminodiacetic acid column was charged
with 2.5 ml of 20 mM FeCI3 and extensively washed with H20 and then with 3 ml
of 500 mM NH4HCO3 (pH 8.0), 3 ml H20, and 3 ml of 50 mM MES (pH 5.5) and
1 M NaCI. The peptide mixture was applied, and the column was developed with
4 ml of H20 followed by 3 ml NH4HCO3 (pH 8.0) to remove nonphosphorylated
peptides. Phosphorylated peptides were eluted with 2 ml of 500 mM NH4HCO3
(pH 11.0), dried in a Speed-Vac apparatus, and resuspended in 40-80 ml H20.
After IMAC purification, libraries (0.5-1.5 nmol) were subjected to
automated Edman sequencing using an Applied Biosystems model 477A peptide
sequencer. Data analysis was performed by normalizing the abundance (mol%)
of each amino acid in the phosphorylated peptide mixture to that present in the
starting libraries. The sums of the final preference ratios were normalized to the
total number of amino acids in the degenerate positions within the peptide
libraries so that a particular amino acid would have a preference value of one in
the absence of selectivity at a particular position. The degenerate peptide
libraries used for in vitro kinase screening with p38 MAP kinase, MK2, CHK1,
and CHK2 consisted of the sequences Gly-Ala-X-X-X-X-S-P-X-X-X-X-Ala-Lys-
Lys-Lys [SP library] where X denotes all amino acids except Cys, Ser, Thr, and
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Tyr; Gly-Ala-X-X-X-X-P-X-S-P-X-X-X-X-X-Ala-Lys-Lys-Lys [PxSP library] where
X denotes all amino acids except Cys; or Gly-Ala-X-X-X-X-R-X-X-S-X-X-X-X-Ala-
Lys-Lys-Lys [RxxS library] where X denotes all amino acids except Cys, Ser, Thr,
and Tyr. In all libraries, S denotes Ser, P denotes Pro, and R denotes Arg.
Kinase reactions were performed in 30 ml of kinase reaction buffer (20
mM HEPES [pH 7.5], 10 mM MgCI2, 3 mM 2-mercaptoethanol, 100 mg/ml BSA,
50 mM ATP, and 10 mCi 32P-g-ATP) containing 2.0 tg of recombinant p47 or
CDC25B substrate protein or the specified amount of peptide and 0.10 mg of
recombinant p38a SAPK or 0.03 mg of recombinant MAPKAP Kinase-2 at 30oC
for the indicated time. The sequences of the p38 optimal peptide and the
p47phox peptide were KKAZGPQGPQSPIE and KKAZGPQSPGSPLE,
respectively. For 14-3-3 pull-downs of CDC25B after in vitro phosphorylation by
p38 or MAPKAP Kinase-2, 2.0 mg of CDC25B was incubated with 10-fold excess
14-3-3-MBP and analyzed by autoradiography. For kinetic measurements, the
reactions were terminated by the addition of an equal volume of 0.5 percent
phosphoric acid and 5 ml was spotted onto p81 paper. The p81 paper was
washed 5' in 0.5 percent phosphoric acid and added to scintillation fluid for
scintillation counting. For in vitro phosphorylation reactions, the reactions were
terminated by the addition of an equal volume of sample buffer followed by
heating at 95oC for 3 min. Samples were analyzed by SDS-PAGE followed by
transfer to nitrocellulose for autoradiography and immunoblotting. The rate of
p38a phosphorylation of isolated peptides and full-length p47phox proteins was
determined by scintillation counting with peptide concentrations of 100, 400, and
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1400 FtM and protein concentrations of 1, 5, 10, and 15 AM with time points taken
at 5, 10, and 20 minutes. MAPKAP Kinase-2 phosphorylation of MK2tides was
performed with peptide concentrations of 5, 10, 20, 40, 80, 160, 320, 500, and
1000 WIM with time points taken at 3, 6, 9, and 12 min. From these enzymatic
studies, Km, Vmax, and Vmax/Km values were then ascertained. All kinetic
experiments were performed a minimum of three times. For each experimental
condition in the determination of the Km and Vmax values, we verified that the
reaction rates were linear with respect to time for all substrate concentrations and
that less than 10% substrate was phosphorylated.
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Figures
Figure 2.1. Substrate specificity and kinetic analysis of substrate
phosphorylation by p38a SAPK.
(A) p38 substrate specificity determined using oriented peptide library
screening.
Residues displaying the highest selectivity are shown; those with selection
values > 1.7 in bold. MEF2A, Myocyte Enhancer Factor 2; ATF2, Activating
Transcription Factor 2; 3PK1, MAP Kinase-activated Protein Kinase-3.
(B) Kinetics of in vitro phosphorylation of an optimal p38 peptide (p38tide) and
a peptide from p47phox (p47tide) by p38a kinase.
(C) Kinetics of in vitro phosphorylation of wild-type GST-p47phox, the Ser-
345-Ala mutant, and the Ser-348-Ala mutant. Typical data from n=3
experiments is shown.
(D) In vitro phosphorylation of full-length wild-type or mutant p47phox
proteins. Samples were analyzed by SDS-PAGE/autoradiography.
(E) Table of kinetic parameters for the reactions in panel C.
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Figure 2.2. Involvement of MAPKAP Kinase-2 in the phosphorylation of
CDC25B and CDC25C after DNA damage.
(A) Phosphorylation of full-length wild type CDC25B or a Ser-323-,Ala mutant
by p38a SAPK or MAPKAP Kinase-2. After phosphorylation, generation of a 14-
3-3 binding site on CDC25B was determined by a 14-3-3-MBP pulldown followed
by SDS-PAGE/autoradiography.
(B) Kinetics of MAPKAP Kinase-2 phosphorylation and generation of a 14-3-
3-binding site on CDC25B were measured in U20S cells following 20 J/m2 UV-
irradiation.
(C) Signaling events in the G2/M, G1, and S-phase checkpoint response were
analyzed in GFP siRNA- or MAPKAP Kinase-2 siRNA-treated U20S cells before
and 2 hrs after UV-induced DNA damage. Equal loading was determined by
western blotting for P3-actin.
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Figure 2.3. Substrate specificity and kinetic analysis of substrate
phosphorylation by MAPKAP Kinase-2.
(A) MAPKAP Kinase-2 substrate specificity was determined by oriented
peptide library screeing. HSP27, Heat Shock protein 27; 5-LO, 5-Lipoxygenase;
LSP1, Lymphocyte-specific protein; SRF, Serum Response Factor; GS,
Glycogen Synthase; TH, Tyrosine Hydroxylase.
(B) Kinetics of in vitro phosphorylation of the optimal MAPKAP Kinase-2
peptide (MK2tide) by MAPKAP Kinase-2.
(C) Table of kinetic parameters for MAPKAP Kinase-2 phosphorylation of wild-
type and mutant MK2tides.
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Figure 2.4. MAPKAP Kinase-2 is required for G2/M arrest following DNA
damage.
(A) UV-C irradiation induces DNA damage as revealed by nuclear foci
formation. U20S cells were mock irradiated or exposed to 20 J/m2 of UV-C
radiation and immunostained 2 hr later using an anti-phospho(Ser/Thr) ATM/ATR
substrate antibody.
(B-I) GFP siRNA- or MAPKAP Kinase-2-siRNA-treated U20S cells were
irradiated as in panel A, then placed in 50ng/ml nocodazole-containing media for
an additional 16 hours. Cells were analyzed by FACS for DNA content by PI
staining (panels B, D, F and H) and for phospho-histone H3 staining as a marker
of mitotic entry (panels C, E, G, and I).
(J-K) GFP siRNA- or MAPKAP Kinase-2-siRNA treated U20S cells were either
mock treated, exposed to 20 J/m2 of UV-C irradiation (J), or to 10 Gy of ionizing
radiation (K) and analyzed as in panels B-I. Representative results of each
experiment are shown.
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Figure 2.5. MAPKAP Kinase-2 is required for S-phase arrest and cell
survival following DNA damage.
(A) GFP siRNA- or MAPKAP Kinase-2-siRNA treated U20S cells were mock
treated or UV-irradiated and allowed to recover for 30 min. BrdU was added and
cells were fixed and analyzed by FACS for DNA content and BrdU-incorporation
12 hr later.
(B) Percentage of cells in panel A showing BrdU incorporation at 2 and 12 hr
following BrdU addition were measured.
(C) GFP siRNA- or MAPKAP Kinase-2-siRNA treated U20S cells were either
mock treated or UV-irradiated, allowed to recover for 30 min, then pulse-labeled
with BrdU for 30 minutes. At the indicated times after irradiation the distribution of
DNA content analyzed in the BrdU-positive population.
(D) GFP siRNA- or MAPKAP Kinase-2-siRNA treated U20S cells were either
mock-treated or irradiated at the indicated UV-C dose. Cells were stained with
Crystal Violet 48 hr later and visualized. Insets show a magnified view.
(E) Quantitative colony forming assays were performed by plating cells at a
density of -100 cells per 35 mm2 dish. Cells were treated as in panel D, and
assays performed in triplicate for each condition.
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Figure 2.6. Comparison of active site electrostatic potentials and
hydrophobicity for the substrate binding cleft of MAPKAP Kinase-2, Akt
and CHK1.
(A) Optimal substrate phosphorylation motifs for Akt/PKB, CHK1, CHK2 and
MAPKAP Kinase-2.
(B) Ribbons representation of the MAPKAP Kinase-2 kinase domain in a
similar orientation as that shown in panels C through E (upper), and in an
orthogonal orientation (lower) with stick representations of the substrate peptide
in the active site cleft. Figure created using Molscript [197] and Raster3D [198].
(C) Molecular surface representations of the Akt/PKB active site (PDB code
106K) using GRASP [199]. Electrostatic potentials (left) are colored red
(negative) and blue (positive). Hydrophobicity (right) is shaded grey, yellow and
green for low, medium and high hydrophobic potentials, respectively. The GSK3
substrate peptide Gly-Arg-Pro-Arg-Thr-Thr-Ser-Phe-Ala-Glu, with the phospho-
acceptor indicated in bold and underlined, is shown in stick representation.
(D) Molecular surface representations of the MAPKAP Kinase-2 active site
(PDB code 1NY3). Electrostatic and hydrophobic potentials are colored as in C.
The optimal substrate peptide Leu-Gln-Arg-Gln-Leu-Ser-lle-Ala is shown in stick
representation.
(E) Molecular surface representations of the CHK1 active site (PDB code
11A8). Electrostatic and hydrophobic potentials are colored as in C. Stick
representation of the modeled CDC25C substrate peptide (Leu-Tyr-Arg-Ser-Pro-
Ser-Met-Pro-Leu) is shown. The region corresponding to the Ser-5, Ser-3 and
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Ser+l1 positions of the substrate peptides in panels C, D and E is indicated by
dashed circles.
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Figure 2.6 Continued.
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Figure 2.7. A unified model of the kinase-dependent DNA damage
checkpoint.
Parallel pathways in the DNA damage checkpoint signal transduction network
converge on common substrates by signaling to downstream kinases with similar
phosphorylation motif specificities. indicates hydrophobic residues. The dashed
line from CHK1 to CDC25B/C indicates that this phosphorylation event remains
controversial in response to ionizing radiation.
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Figure 2.7 Continued.
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Chapter 3
BRCT Repeats as Phosphopeptide-
Binding Modules
Involved in Protein Targeting
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Summary
We used a proteomic approach to identify phosphopeptide-binding
modules mediating signal transduction events in the DNA damage response
pathway. Using a library of partially degenerate phosphopeptides, we identified
tandem BRCA1 carboxy-terminal (BRCT) domains in Pax transactivation
domain-interacting protein (PTIP) and BRCA1 as phosphoserine (pSer)- or
phosphothreonine (pThr)-specific binding modules that recognize a subset of
substrates phosphorylated by the kinases ataxia-telangiectasia mutated (ATM)
and ataxia-telangiectasia- and RAD3-related (ATR), in response to y-irradiation.
PTIP tandem BRCT domains are responsible for phosphorylation-dependent
protein localization into 53BP1- and phospho-H2AX (y-H2AX)-containing nuclear
foci, a marker of DNA damage. These findings provide a molecular basis for
BRCT domain function in the DNA damage response and may rationalize why
the BRCAI BRCT domain mutation M1775R, which fails to bind
phosphopeptides, predisposes patients to breast and ovarian cancer.
Contributions:
Andy Elia initially adapted the small pool IVT screening process, developed in other labs, to
identify phospho-binding domains. Katja Hoepker helped with the implementation and screening
of the 96,000 clone library that led to the identification of PTIP in Figure 3.1. Bob Grant helped
with BRCT domain protein purification for ITC analysis. Mike Yaffe assisted with the ITC analysis.
Timmy Ho helped with BRCT domain protein production and figure 3.1/3.2/3.3 construction.
Ancho Nguyen helped with the localization data shown in Figure 3.5/3.6. Drew Lowery cloned
several of the constructs, helped with DNA purification and westernblot analysis.
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Introduction
Signal transduction by protein kinases in eukaryotes results in the directed
assembly of multi-protein complexes at specific locations within the cell [7]. This
process is particularly evident following DNA damage, where activation of DNA
damage response kinases results in the formation of protein-protein complexes
at discrete foci within the nucleus [46].. In many cases, protein kinases directly
control the formation of these multi-protein complexes by generating specific
phosphorylated-motif sequences; modular binding domains then recognize these
short phospho-motifs to mediate protein-protein interactions [15, 17].
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Results
Identification of pSer- or p Thr-binding domains
We used a proteomic screening approach [18] to identify novel modular
pSer- or pThr-binding domains involved in the DNA damage response. In cells
exposed to IR, the kinases ATM and ATR phosphorylate transcription factors,
DNA repair proteins, protein kinases, and scaffolds on Ser-GIn and Thr-Gln
motifs [2]. We therefore constructed an oriented phosphopeptide library biased
to resemble the motif generated by ATM and ATR [89, 200] (Figure 3.1A). This
library and its non-phosphorylated counterpart were immobilized and screened in
a high-throughput multi-well format against -96,000 in vitro translated (IVT)
polypeptides (960 pools each containing -100 transcripts) (Figure 3.1A).
Pool EE11 contained the strongest phosphopeptide-binding clone, EE11-
9, encoding the C-terminal 70% of human PTIP (Figure 3.1B). PTIP, originally
identified as a transcriptional regulatory protein, appears to also play a critical
role in the DNA damage response pathway [201-203]. Human PTIP contains 4
BRCT domains, known protein-protein interaction modules present in many DNA
damage response and cell cycle checkpoint proteins [204]. A construct
containing only the tandem 3rd and 4 t h BRCT domains displayed strong and
specific binding to the (pSer or pThr)-Gln library (Figure 3.1B). Constructs of
PTIP lacking both of these domains either failed to bind or lacked
phosphopeptide discrimination. Furthermore, neither the 3rd nor the 4 th BRCT
domain alone bound to phosphopeptides, suggesting that the tandem C-terminal
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BRCT domains function as a single module that is necessary and sufficient for
phospho-specific binding.
The optimal phosphopeptide binding motif of BRCT Domains
BRCT domains are often found in tandem pairs, ((BRCT)2), or multiple
copies of tandem pairs, and the tandem BRCA1 BRCT domains behave as a
single stable fragment in limited proteolysis and X-ray crystallographic studies
[84]. Like those of PTIP, the tandem BRCT domains of BRCA1, but not the
individual BRCT domains alone, displayed phospho-specific binding (Figure
3.2A). However, little if any phospho-binding was seen for (BRCT)2 modules
from MDC1, 53BP1, S. cerevisiae Rad9p, or the PTIP N-terminal pair,
suggesting that the phosphopeptide-binding function is present in only a subset
of tandem BRCT domains.
We used oriented peptide library screening to determine the optimal
phospho-binding motifs for the C-terminal (BRCT)2 domains of PTIP and BRCA1
(Figure 3.2B and Table 3.1). PTIP- and BRCA1-(BRCT)2 displayed strongest
binding to similar, but not identical, motifs with extremely strong selection for
either aromatic or aliphatic residues, and aromatic residues, respectively, in the
(pSer or pThr)+3 position. More moderate selection was also observed at other
positions, particularly (pSer or pThr)+2 and +5. We defined an optimal (BRCT)2-
binding peptide (BRCTide) as Y-D-I-(pSer or pThr)-Q-V-F-P-F and verified motif
data using a solid-phase array of immobilized phosphopeptides (Figure 3.3). In
the filter-array experiments (Figure 3.3), substitution of pSer for pThr enhanced
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binding for both PTIP and BRCA1 BRCT domains, consistent with the ITC
results. (BRCT)2 domains are unusual in binding to pSer-containing peptides
more strongly than to pThr-containing peptides since 14-3-3 proteins, WW
domains, WD40 domains, FHA domains and Polobox domains either bind pThr-
peptides better than pSer-peptides, or do not bind to pSer-peptides at all [4].
Substitution of pTyr for pThr eliminated binding altogether, verifying that tandem
BRCT domains are pSer/pThr-specific binding modules. Replacement of pThr
with Thr, Ser or Tyr abrogated tandem BRCT domain binding. The pTQ oriented
blots on the left show strong selection at several positions for both PTIP and
BRCA1 BRCT domains; especially for Phe in the +3 position in agreement with
the oriented peptide library screening data. The pS oriented blots on the right
show that the +3 position is the most important position for peptide selection.
Isothermal titration calorimetry showed that the optimal pSer-containing
peptide bound to the C-terminal (BRCT)2 of PTIP with a dissociation constant of
280 nM, and to the (BRCT)2 of BRCA1 with a dissociation constant of 400 nM
(Table 3.2). Replacement of pThr for pSer reduced the affinity of the peptide for
the PTIP-(BRCT)2 though binding was still observed. Interestingly, ATM and ATR
prefer SQ to TQ motifs for phosphorylation suggesting a convergence of the
kinase phosphorylation motif and tandem BRCT domain binding motif.
Substitution of pTyr, Ser or Thr for pSer abrogated binding verifying that (BRCT)2
modules are pSer- or pThr-specific (Figure 3.3).
99
BRCT Domains interact with phosphoproteins after DNA damage
After treatment of U20S cells with 10 Gy of IR, both PTIP- and BRCA1-
(BRCT)2 bound distinct phospho-proteins, as detected by immunoblotting with a
phospho-specific antibody against the (pSer or pThr)-Gln motif generated by
ATM and ATR (Figure 3.3A, B, D). Binding to (BRCT)2 was inhibited by
incubation with specific phosphopeptides but not by non-phosphorylated
peptides. Pretreatment of the cells with caffeine to inhibit the activity of ATM and
ATR prior to irradiation also largely eliminated binding [205].
In response to IR, the DNA damage protein 53BP1 undergoes multi-site
phosphorylation by ATM and forms nuclear foci [87, 88, 206]. 53BP1 bound to
the C-terminal PTIP-(BRCT)2 only after IR, in a phosphorylation-dependent
manner (Figure 3.3C). In addition, in vivo association of full-length FLAG-PTIP
with HA-53BP1 increased after IR treatment.
BRCT Domains are responsible for PITP localization after IR
The binding of tandem BRCT domains to ATM- or ATR-phosphorylated
substrates could localize PTIP to sites of DNA damage in vivo. In the absence
of DNA damage, GFP-PTIP was diffusely nuclear with a small amount of
cytosolic staining (Figure 3.4). Two hours after IR, PTIP localized into discrete
nuclear foci with (pSer or pThr)-Gln phosphoepitopes, 53BP1 and y-H2AX
(Figure 3.4A). PTIP lacking the C-terminal (BRCT)2 did not form foci (Figure
3.4B). The isolated C-terminal (BRCT)2, however, while diffusely nuclear in the
absence of DNA damage, re-localized into these nuclear foci after IR (Figure
100
3.4C). Inhibition of ATM and ATR by caffeine prior to IR reduced the number and
altered the appearance of full-length PTIP foci, and caused loss of co-localization
with y-H2AX (Figure 3.7).
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Discussion
These findings strongly suggest that PTIP functions as a key component
of the DNA damage response network and may provide a molecular rationale for
the early embryonic lethality of PTIP knock-out mice with extensive unrepaired
DNA ends [202]. (BRCT)2 selection for aromatic and aliphatic residues in the
(pSer or pThr)+3 positions exceeds their selection for Gin in the +1 position.
Thus, only a subset of ATM and ATR phosphorylated substrates are likely to bind
with high affinity, and other kinases might also generate (BRCT)2-binding motifs.
The important role for (BRCT)2 domains as pSer- or pThr-binding modules is
emphasized by the finding that -80% of germline mutations in BRCA1 result in
C-terminal truncations involving the BRCT region, predisposing patients to breast
and ovarian cancer [204]. Interestingly, a BRCA1 cancer associated mutation in
the (BRCT)2 module that ablates critical BRCA1 protein interactions [51],
M1775R, fails to bind phosphopeptides (Figure 3.2A), despite the fact the
M1775R crystal structure is nearly identical to that of the wild-type (BRCT)2 [85].
Since interference with DNA damage signaling results in both tumorigenesis, and
presumably tumor cell death in the face of massive DNA damage by
chemotherapeutic agents, the phosphopeptide-binding pocket of (BRCT)2
modules may constitute a target for anti-cancer drug development.
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Experimental Procedures
ATM/ATR Phospho-Motif Screen for Phosphoserine/threonine Binding
Domains
An oriented (pSer/pThr) phosphopeptide library biased toward the
phosphorylation motifs for ATM/ATR kinases, and its non-phosphorylated
counterpart were constructed as follows: biotin-Z-Gly-Z-Gly-Gly-Ala-X-X-X-B-
(pS/pT)-Gln-J-X-X-X-Ala-Lys-Lys-Lys and biotin-Z-Gly-Z-Gly-Gly-Ala-X-X-X-B-
(Ser/Thr)-Gln-J-X-X-X-Ala-Lys-Lys-Lys where pS denotes phosphoserine, pT
phosphothreonine, Z indicates aminohexanoic acid , B represents a biased
mixture of the amino acids (Ala, lie, Leu, Met, Asn, Pro, Ser, Thr, Val) and J
represents a biased mixture of (25% Glu, 75% X), where X denotes all amino
acids except (Cys, Arg, Lys, His). The amino acids Arg, Lys, and His were
intentionally omitted from the degenerate positions in the peptide library to
decrease the likelihood of identifying phosphopeptide-binding domains such as
14-3-3 which target basophilic motifs generated by kinases such as AKT, PKA,
and PKCs. Streptavidin beads (Pierce, 75pmol/pL gel) were incubated with a
ten-fold molar excess of each biotinylated library in 50 mM Tris/HCI (pH7.6), 150
mM NaCI, 0.5% NP-40, 1 mM EDTA, 2 mM DTT and washed five times with the
same buffer to remove unbound peptide. The bead-immobilized libraries (10pL of
gel) were added to 10 pL of an in vitro translated [3 5 S]-labeled protein pool in 150
pL binding buffer (50 mM Tris/HCI (pH7.6), 150 mM NaCI, 0.5% NP-40, 1 mM
EDTA, 2 mM DTT, 8 pg/mL pepstatin, 8 pg/mL aprotinin, 8 pg/mL leupeptin, 800
pM Na3VO4, 25 mM NaF). Each pool consisted of 100 radiolabeled proteins
103
produced by the ProteoLink in vitro expression cloning system (Promega). After
incubation at 40C for 3 hours, the beads were washed three times 200 pL with
binding buffer prior to SDS-PAGE (12.5%) and autoradiography. Positively
scoring hits were identified as protein bands that interacted more strongly with
the phosphorylated immobilized library than with the unphosphorylated
counterpart. Pools containing positively scoring clones were progressively
subdivided and re-screened for phospho-binding until single clones were isolated
and identified by DNA sequencing.
Cloning, Expression, and Purification of PTIP and BRCA1
For deletion mapping of the PTIP and BRCA1 BRCT phospho-binding
region and for expression of MDC1, Rad9, and 53BP1 (Figure 3.1-2), fragments
were generated by PCR, cloned into pcDNA3.1 (Invitrogen), and subjected to in
vitro transcription and translation. The BRCA1 BRCT M1775R mutation was
generated using the Stratagene Quick Change Mutagenesis Kit. For production
of recombinant GST-PTIP BRCT domains and GST-BRCA1 BRCT domains,
residues 550-757 of PTIP and residues 1634-1863 of BRCA1 were ligated into
the EcoRI and Notl sites of pGEX-4T1 (Pharmacia) and subsequently
transformed into DH5a E. Coli. Protein induction occurred at 370C for 4 hrs or at
250C for 16 hrs in the presence of 0.2-0.4 mM IPTG. GST-PTIP BRCT domains
and GST-BRCA1 BRCT domains were isolated from bacterial lysates using
glutathione agarose, eluted with 40mM glutathione/50mM Tris/HCI (pH 8.1), and
dialyzed into 50mM Tris/HCI (pH 8.1)/300mM NaCI. For ITC experiments,
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purified GST-PTIP BRCT domains were dialyzed into cleavage buffer (25mM
Tris-HCI, 100mM NaCI, 2mM CaCI2), and cleaved in solution with thrombin
(Sigma). Free GST was removed by incubation with glutathione agarose and the
PTIP BRCT domains were further purified on a mono-Q column and eluted with a
NaCI gradient. The appropriate fractions were dialyzed into 25mM Tris/HCI (pH
8.1), 100mM NaCI. The GFP-PTIP constructs FL (residues 1-757), ABRCT
(residues 1-549), or (BRCT)2 (residues 550-757) were cloned into the EcoRI and
Sail sites of pEGFP-C2 (Clontech). All plasmid insert sequences were verified
by sequencing.
Peptide Library Screening
Phosphoserine and phosphothreonine oriented degenerate peptide
libraries consisting of the sequences Gly-Ala-X-X-X-B-(pS/pT)-Gln-J-X-X-X-Ala-
Lys-Lys-Lys, Met-Ala-X-X-X-X-pThr-X-X-X-X-Ala-Lys-Lys, Met-Ala-X-X-X-X-
pSer-X-X-X-X-X-Ala-Lys-Lys-Lys, and Gly-Ala-X-X-X-X-pSer-X-X-Phe-X-X-Ala-
Tyr-Lys-Lys-Lys, where X denotes all amino acids except Cys. In the (pS/pT)-
Gln library pS denotes phosphoserine, pT phosphothreonine, B represents a
biased mixture of the amino acids (Ala, lie, Leu, Met, Asn, Pro, Ser, Thr, Val) and
J represents a biased mixture of (25% Glu, 75% X), where X denotes all amino
acids except (Cys, Arg, Lys, His). Peptides were synthesized using N-a-FMOC-
protected amino acids and standard BOP/HOBt coupling chemistry. Peptide
library screening was performed using 125-250 pl of glutathione beads
containing saturating amounts of GST-PTIP BRCT or GST-BRCA1 BRCT
105
domains (1-1.5 mg) (Figure 3.3). Beads were packed in a mL column and
incubated with 0.45 mg of the peptide library mixture for 10 min at room
temperature in PBS (150 mM NaCI, 3 mM KCI, 10 mM Na2HPO4, 2 mm KH2PO4,
pH 7.6). Unbound peptides were removed from the column by three washes with
PBS containing 1.0% NP-40 followed by three washes with PBS. Bound
peptides were eluted with 30% acetic acid for 10 min at room temperature,
lyophilized, resuspended in H20, and sequenced by automated Edman
degradation on a Procise protein microsequencer. Selectivity values for each
amino acid were determined by comparing the relative abundance (mole
percentage) of each amino acid at a particular sequencing cycle in the recovered
peptides to that of each amino acid in the original peptide library mixture at the
same position.
Isothermal Titration Calorimetry
Peptides were synthesized by solid phase technique with three C-terminal
lysines to enhance solubility. Peptides were then purified by reverse phase HPLC
following deprotection and confirmed by MALDI-TOF mass spectrometry.
Calorimetry measurements were performed using a VP-ITC microcalorimeter
(MicroCal Inc.). Experiments involved serial 10pL injections of peptide solutions
(20pM-150pM) into a sample cell containing 15pM PTIP BRCT domains
(residues 550-757) or 15pM GST-BRCA1 BRCT domains (residues 1634-1863)
in 25-50mM Tris/HCI (pH 8.1), 100-300mM NaCI. Twenty injections were
performed with 240s intervals between injections and a reference power of 25
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pCal/s. Binding isotherms were plotted and analyzed using Origin Software
(MicroCal Inc.)
Peptide Filter Array
An ABIMED peptide arrayer with a computer controlled Gilson diluter and
liquid handling robot was used to synthesize peptides onto an amino-PEG
cellulose membrane using N-a-FMOC-protected amino acids and DIC/HOBT
coupling chemistry. The membranes were blocked in 5% milk/TBS-T (0.1%) for
1hr at room temperature, incubated with 0.025-0.1 M GST-PTIP BRCT domains
(residues 550-757) or GST-BRCA1 BRCT domains (residues 1634-1863) in 5%
milk, 50 mM Tris/HCI (pH 7.6), 150 mM NaCI, 2 mM EDTA, 2mM DTT for 1 hr at
room temperature and washed four times with TBS-T (0.1%). The membranes
were then incubated with anti-GST conjugated HRP (Amersham) in 5%
milk/TBS-T (0.1%) for 1 hr at room temperature, washed five times with TBS-T
(0.1%), and subjected to chemiluminescence.
PTIP BRCT Domains and BRCA1 BRCT Domains Binding to Cellular
Substrates
U20S cells were either treated with 10 Gy of ionizing radiation or mock
irradiated and allowed to recover for 30-120 min. Cells were subsequently lysed
in 50 mM Tris/HCI (pH7.6), 150 mM NaCI, 1.0% NP-40, 5 mM EDTA, 2 mM DTT,
8 pg/mL pepstatin, 8 g/mL aprotinin, 8 g/mL leupeptin, 2 mM Na3 VO4, 10 mM
NaF, 1 M microcystin. The lysates (0.5-2mg) were incubated with 20 IpL
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glutathione beads containing 10-20 pg of GST-PTIP BRCT domains (residues
550-757), GST-BRCA1 BRCT domains (residues 1634-1863) or GST for 120 min
at 40°C. Beads were washed three times with lysis buffer. Precipitated proteins
were eluted in sample buffer and detected by blotting with anti-ATM/ATR
substrate (pSer/pThr)Gln antibody (Cell Signaling), polyclonal anti-53BP1
(Oncogene), or monoclonal anti-HA (Covance). For peptide competition
experiments, GST-PTIP BRCT domains or GST-BRCA1 BRCT domains were
immobilized on glutathione beads and preincubated with 350 pM of BRCTtide-
(7pSer, 7pThr, 7Thr, 7Ser), (pSer/pThr)Gln-library, (Ser/Thr)Gln-library, or
pThrPro-library for 1 hr at 4°C and washed three times with lysis buffer. For the
phosphatase experiment the lysate was treated for one hour with lambda protein
phosphatase (Sigma) prior to incubation with glutathione beads containing GST-
PTIP BRCT domains.
Immunofluorescence and Microscopy
U20S cells were seeded onto 18mm2 coverslips and transfected with
GFP-PTIP constructs FL (residues 1-757), ABRCT (residues 1-549), or (BRCT) 2
(residues 550-757) using FuGene6 transfection reagent (Roche) according to
manufacturer's protocol. Twenty to thirty hours following transfection, the cells
were either treated with 10 Gy of ionizing radiation or mock irradiated and
allowed to recover for 30-480 minutes. Cells were fixed in 3%
paraformaldehyde/2% sucrose for 15 min at RT and permeabilized with a 0.5%
Triton X-100 solution containing 20 mM Tris-HCI (pH 7.8), 75 mM NaCI, 300 mM
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sucrose, and 3 mM MgCI2 for 15 min at RT. When necessary, cytosolic proteins
were extracted after IR treatment as described by O. K. Mirzoeva, J. H. Petrini,
Mol Cell Biol 21, 281 (2001). In brief: cells were incubated with cytoskeleton
buffer (10mM PIPES pH6.8, 100mM NaCI, 300mM sucrose, 3mM MgCI2, 1mM
EGTA, 0.5% Triton X-100) for 5 minutes on ice followed by incubation with
cytoskeleton stripping buffer (10mM Tris-Hcl pH 7.4, 10mM NaCI, 3mM MgCI 2,
1% Tween-40, 0.5% sodium deoxycholate) for 5 minutes on ice followed by
successive washes in ice cold PBS. Slides were stained with primary antibodies
at 40°C overnight, then stained with a Texas Red conjugated anti-mouse or anti-
rabbit secondary antibody for 60 min (Molecular Probes) at RT. Primary
antibodies used were rabbit polyclonal anti-53BP1 (Oncogene), mouse anti-y-
H2AX (Upstate), and rabbit anti-(pSer/pThr)Gln (Cell Signaling). Images were
either collected on a Deltavision microscope (Carl Zeiss, Thornwood, NY) and
digitally deconvolved using Softworx graphics processing software (SGI) or
captured using a spinning disk confocal detector mounted on a Nikon TE2000
microscope using OpenLab software (Improvision).
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Tables
Table 3.1. Phosphoserine and Phosphothreonine Peptide Motif Selection by
PTIP and BRCA1 Tandem BRCT Domains
PTIP
-4 -3 -2 -1 +1 +2 +3 +4 +5
X Y (1.5) G (2.3) L (2.6) pS/pT V F P (1.6) 1(2.9)
D (1.5) 1(2.5) (3.8) (7 0) F (2.7)
E (1.4) M (2.5) L (2.4)
v (1.9) v (2.0)
(4.3) Y (2.0)
............................................................................................................................................ 
...................................................................................
X X E (1.3) 1(1.4) pS F (1.7) V (1.8) X 1 (1.9)
M (1.4) 1(1.5) T (1.5) F (1.7)
V (1.4) Q (1.5) M (1.6)
............................ .. ..................................................................................................................................... 
.............. 
..... ......
G (1.6) Y (1.1) D (1.2) L (1.2) pS Q (1.3) V (2.1) F (2.3) P (1.2) Y (1.3)
E (1.1) 1(1.2) 1(1.3) 1(1.7) 1(2.3)
M (1.2) P (1.2) V (1.8)
L (1.7)
................................................................................................................. 
....( 1.) ...................................................................................................
X X X 1(2.1) pT Q (1.5) Y(1.4) 1(1.4) F (1.5) A
L (1.8) F (1.4) L (1.3) Y (1.4)
W 1(1.3) V (1.2) P (1.3)
(1.3)
BRCA1
-4 -3 -2 -1 +1 +2 +3 +4 +5
X F (1.7) D (1.2) 1(1.4) pS/pT V F V (1.5) F
Y(1.6) E(1.1) V(1.3) (3.1) (7.5) P(1.4) (4.5)
L (1.2) T (2.6) Y G (1.8)M (1.2) (5.2)
............................................................................................................................................................................S1
X R (1.5) E (1.3) V (1.4) pS F (2.1) T (1.9) X F (1.6)
Y (1.4) D (1.2) 1(1.3) Y (1.6) V (1.7) M (1.4)
M (1.3) 1(1.4) Y (1.3)
X Y ( 2 ) X p S 1 (1 .2 ) X....................... ........................................................................................................ ............................................................................................4 ) ...... .... ....
X X Y (1.2) X pS Q (14) V (1.2) F (2.4) 1(1.2) X
................................................................................................................................................................................
X E (1.5) D (1.9) 1(1.6) pT Q (1.5) D (1.5) F (1.9) D (1.4)
E (1.5) L (1.4) E (1.4) Y (1.3) Y (1.2) P (1.2)
F (1.3) 1(1.2)
A GST fusion of the PTIP or BRCA1 tandem BRCT domains was screened for binding to four
phosphopeptide libraries, which contained the sequences GAXXXB(pS/pT)QJXXXAKKK,
GAXXXXpSXXFXXAYKKK, MAXXXXpTXXXXAKKK, and MAXXXXSpXXXXXAKKK, where X indicates all
amino acids except Cys. In the library MAXXXB(pS/pT)QJXXXAKKK B indicates (A, I, L, M, N, P, S, T, V)
and J represents a biased mixture of (25% E, 75% X), while X indicates all amino acids except (C, R, K, H)
for all positions in this library. Residues showing strong enrichment are underlined [16].
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Table 3.2. Peptide Bindinq Affinities for the Tandem BRCT Domains
Peptide Sequence (BRCT) 2 Domain Kd
BRCTtide-7pS GAAYDI-pS-QVFPFAKKK PTIP 280 nM
BRCTtide-7pT GAAYDI-pT-QVFPFAKKK PTIP 14.3 pM
BRCTtide-7S GAAYDI- S-QVFPFAKKK PTIP N.D.B.
BRCTtide-7T GAAYDI- T-QVFPFAKKK PTIP N.D.B.
BRCTtide-7pS GAAYDI-pS-QVFPFAKKK BRCA1 400 nm
BRCTtide-7S GAAYDI- S-QVFPFAKKK BRCA1 N.D.B.
BRCTtide-7T GAAYDI- T-QVFPFAKKK BRCA1 N.D.B.
Isothermal titration calorimetry (ITC) was used to determine binding constants (Kd). All observed binding
stoichiometries were consistent with a 1:1 complex of protein and phosphopeptide. N.D.B indicates no
detectable binding by ITC for a tandem BRCT domain with a concentration of at least 150pM. pS and pT
denote phosphoserine and phosphothreoine, respectively.
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Figures
Figure 3.1. Identification of pSer/pThr-binding domains using an ATM/ATR-
motif library vs. expression library screen.
(A) An oriented (pSer/pThr) phosphopeptide library, biased toward the
phosphorylation motifs of ATM and ATR, was immobilized on Streptavidin beads.
The library [pSQ= biotin-ZGZGGAXXXB(pS/pT)QJXXXAKKK] and its non-
phosphorylated counterpart (SQ) were screened against in vitro translated 35S-
Met labeled proteins. (pS/pT) denotes 50% phosphoserine and 50%
phosphothreonine, Z indicates aminohexanoic acid, B represents a biased
mixture of the amino acids (A, I, L, M, N, P, S, T, V) and J represents a biased
mixture of (25% E, 75% X), where X denotes all amino acids except (C, H, K, R).
In each panel, the first and second lanes show binding of proteins within the pool
to the phosphorylated (pSQ) and non-phosphorylated (SQ) libraries, respectively.
Identification of PTIP, denoted by arrow and asterisk, occurred through
progressive subdivision of the EE11 pool to a single clone. The uppermost band
is a fusion artifact of PTIP with vector sequences resulting in translation initiation
at an upstream start codon in the vector.
(B) Deletion mapping of the phospho-binding domain of PTIP. Truncations of
PTIP were assayed for selective binding to the pSQ library as in panel A. BRCT
domain boundaries were determined from sequence alignments [207].
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Figure 3.2. Comparison of the tandem BRCT domains and determination of
the PTIP and BRCAI1 BRCT optimal phosphopeptide-binding motifs.
(A) PTIP, BRCA1, BRCA1 M1775R, MDC1, 53BP1 and Rad9p (BRCT) 2
domains were assayed for binding as in Figure 3.1A. The peptide libraries used
were pSQ (Figure 3.1A), pS= biotin-ZGZGGAXXXXpSXXXXXAKKK, pT=biotin-
ZGZGGAXXXXpTXXXXXAKKK, pSXXF=biotin-ZGZGGAXXXXpSXXFXXAYKKK,
where pS is phosphoserine, pT is phosphothreonine, Z indicates aminohexanoic
acid, X denotes all amino acids except Cys. Domain boundaries: PTIP as
indicated in Figure 3.1; BRCA1 BRCT1 and 2, aa 1633-1863; BRCT1 alone, aa
1633-1740; BRCT2 alone, 1741-1863; MDC1, aa 1874-2089; 53BP1, aa 1622-
1972; Rad9p, 985-1309.
(B) Strong selection by the PTIP- and BRCA1-(BRCT)2 domains for Phe at the
(pSer/pThr)-Gln +3 position (7.0 or 7.5), respectively (Table 3.1). Bar graphs
show the relative abundance of each amino acid at a given cycle of sequencing
compared to its abundance in the starting peptide library mixture [16].
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Figure 3.3. PTIP and BRCAI BRCT domains binding to a filter array of
phosphopeptides.
(A, B)Binding of GST-PTIP (A) and BRCA1 (B) tandem BRCT domains to a
filter array of peptide spots, comprising single point mutants of the optimal BRCT
domain phosphopeptide (left column). Bound GST-BRCT domains were
detected by blotting with HRP-conjugated anti-GST antibody. The resulting
consensus binding motif is indicated in the right column; X denotes no dominant
selection, denotes residues with aliphatic or aromatic side chains, and letters
enclosed in square brackets are specifically de-selected. The top row indicates
the amino acid that was substituted for the optimal amino acid.
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Figure 3.4. Association of tandem PTIP and BRCA1 BRCT domains with
DNA damage-induced phosphoproteins through their phosphopeptide-
binding pockets.
(A) Lysates from U20S cells before or 2 hours after 10 Gy of IR were
incubated with GST-PTIP-(BRCT) 2. Bound proteins were detected by
immunoblotting with an antibody to the (pSer/pThr)-Gln motif generated by ATM
and ATR. The interaction was disrupted by incubation with the pSQ peptide
library, but not with the SQ peptide library or an unrelated pTP library [18].
(B) Interaction of the PTIP-(BRCT)2 domain with phosphoproteins was
disrupted by treatment of U20S cells with caffeine (5 mM) before IR exposure or
by incubating the beads with BRCTtide (7pT) but not by its non-phosphorylated
counterpart (7T).
(C) Tandem BRCT domains of PTIP interact with 53BP1 following DNA
damage. Endogenous 53BP1 from IR treated U20S cells was precipitated with
GST-PTIP-(BRCT)2 and detected by immunoblotting with an antibody to 53BP1.
U20S cells were transfected with HA-tagged 53BP1 and the interaction with
GST-PTIP-(BRCT)2 was analyzed as in panels A and B. Treatment of the cell
lysates with lambda phosphatase also abolished the interaction.
(D) Lysates from U20S cells before or after IR were incubated with GST-
BRCA1-(BRCT)2 and analyzed as in panel B. In these experiments the pSer
version of BRCTtide (7pS) and its non-phosphorylated counterpart (7S) were
used.
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Figure 3.5. Full length PTIP forms DNA damage induced foci and co-
localizes with (pSer/pThr)-Gln proteins, 53BP1, and y-H2AX.
(A) U20S cells were transfected with a full length GFP-PTIP construct (PTIP-
FL residues 1-757).
(B) U20S cells were transfected with a PTIP deletion construct in which the
last two BRCT domains had been removed (PTIP-ABRCT, residues 1-550)
(C) U20S cells were transfected with a PTIP construct containing only the last
two BRCT domains ((BRCT)2, residues 550-757). In A-C, 24 hrs following
transfection cells were either treated with 10 Gy of ionizing radiation or mock
irradiated, allowed to recover for 2 hrs, stained, and analyzed by
immunofluorescence microscopy.
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Figure 3.6. Caffeine attenuates recruitment of PTIP to DNA damage foci in
response to ionizing radiation. U20S cells transfected with full-length GFP-
PTIP cDNA were mock treated or treated with 10mM caffeine for 70 minutes
before exposure to 10 OGy ionizing radiation.
(A) In reponse to IR, mock-treated U20S cells formed nuclear foci containing
PTIP (in green) and y-H2AX (in red); these two proteins co-localize at sites of
DNA damage (merge).
(B) In response to IR, caffeine treated U20S cells formed reduced numbers of
nuclear foci; PTIP was mislocalized and did not form discrete nuclear foci and
there were reduced numbers of y-H2AX containing foci; pretreatment with
caffeine effectively abolished co-localization of PTIP and y -H2AX (merge).
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Chapter 4
Structure and Mechanism of BRCA1 BRCT Domain
Recognition of Phosphorylated BACH1
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Summary
Germline mutations in the BRCA1 tumor suppressor often result in a
significant increase in susceptibility to breast and ovarian cancers. Although the
molecular basis of their effects remains largely obscure, many are known to
target the highly conserved C-terminal BRCT-repeats that function as a
phosphoserine/phosphothreonine-binding module. We report the 1.85A X-ray
crystal structure of the BRCA1 tandem BRCT domains in complex with a
phosphorylated peptide representing the minimal interacting region of the DEAH-
box helicase BACH1. The structure reveals the determinants of this novel and
important class of BRCA1 binding events. We show that a subset of disease-
linked mutations appear to act through specific disruption of phospho-dependent
BRCA1 interactions rather than through gross structural perturbation of the
tandem BRCT domains.
Contributions:
Julie Clapperton and Steve Smerdon (with the assistance of Mike Yaffe) solved the X-tal structure
and produced Figures 4.1, 4.2 and part of 4.4. Timmy Ho helped with the mutagenesis of BRCT
domain constructs as well as DNA purification. Drew Lowery helped with the mutagenesis of
several constructs, helped with DNA purification and westernblot analysis.
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Introduction
The breast-cancer susceptibility gene product, BRCA1, plays important roles
in cell cycle control, transcriptional regulation, chromatin remodelling, and the
response to DNA-damage[51, 76, 83, 208]. BRCA1 is a large, modular protein of
1863 amino-acid residues containing an N-terminal RING domain, a central
region rich in SQ/TQ dipeptide pairs, and tandem BRCT domains. BRCA1
interacts with a large number of protein partners at different stages of the cell
cycle, or following genotoxic stress. For example, BRCA1 interacts with the DNA
helicase BACH1 during S and G2 in normally cycling cells,[20, 209] whereas
BRCA1 interacts with a subset of ATM/ATR substrates in response to DNA
damage[19]. In both S-phase and irradiated/mutagen-treated cells, BRCA1
localizes to distinct nuclear foci thought to represent sites of DNA-damage[48,
78] where BRCA1 is thought to function, at least in part, as a scaffold for the
assembly of DNA-repair complexes.
Mutations in BRCA1 occur in 50% of women with inherited breast cancer and
up to 90% of women with combined breast and ovarian cancer[210-213]. Most
frameshift and deletion mutants truncate all or part of the BRCT repeats, while
more that 70 missense mutations lie within the BRCT domains themselves
(http://research.nhari.nih.aov/proiects/bic/). BRCT domains are a/ structures
that occur singly or as multiple repeats in a number of proteins in addition to
BRCA1 that are involved in cell-cycle regulation and DNA-damage
responses[204, 214]. Comprised of 80-100 amino acids, BRCT domains are
generally thought to function as protein-protein recognition modules[204]. The
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molecular basis underlying BRCA1 BRCT function, and how cancer-causing
mutations in the BRCT domains act at the structural level, however, remains
unresolved, despite significant structural, biochemical, and mutagenic
analysis[84, 85, 204, 215, 216]. It has been suggested that mutational effects are
manifested through structural destabilization, however a number of mutations are
located on the protein surface, indicating that they may specifically affect BRCT
interactions with other BRCA1-associated targets.
We recently discovered that a subset of tandem BRCT domains, including
those of BRCA1, function as phosphoserine/phosphothreonine (pSer/pThr)-
binding modules, suggesting that some BRCT-mediated interactions with
proteins involved in DNA-damage and cell-cycle control are regulated by protein
phosphorylation[19]. Oriented peptide library screening of tandem BRCT
domains revealed phospho-dependent binding specificity extending from the
pSer/pThr+1 to the pSer/pThr+5 position, with particularly strong selection for
aromatic or aromatic/aliphatic residues in the pSer/pThr+3 position. High affinity
phosphopeptides selected by in vitro oriented library screens were able to block
the interaction of the tandem BRCT domains of BRCA1 and the transcriptional
regulator PTIP with ATM/ATR-phosphorylated substrates[19]. Similar findings
were reported by Chen and colleagues who were able to demonstrate that the
BRCA1 BRCT domain repeat mediates interaction with the DEAH-box helicase
BACH1 through a specific phosphoserine 990 located within a region (888-1063)
previously shown to be sufficient for BRCA1-BACH1 binding[20, 209]. The tumor-
suppressor function of BRCA1 may directly depend on this interaction since its
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disruption is sufficient to abrogate the G2-M checkpoint following DNA
damage[20, 217].
To determine the structural basis for phosphopeptide binding and
phosphopeptide-motif selection, and investigate alternative structural
mechanisms underlying BRCA1 BRCT mutations and cancer predisposition, we
solved the high resolution X-ray crystal structure of the BRCA1 tandem BRCT
repeats bound to a BACH1 phosphopeptide. We now provide a molecular
rationale for phosphospecific binding, and show that a set of cancer-associated
BRCA1 BRCT mutations eliminate phosphopeptide binding in vitro and BACH1
phosphoprotein binding in vivo, or alter the phosphopeptide recognition motif for
the BRCA1 tandem BRCT domains, revealing a structural basis for mutation-
associated loss of BRCA1 function.
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Results
Structure of the BRCA BRCT:BACH1 Phosphopeptide Complex
The BRCA1 tandem BRCT domains bound to the interacting
phosphopeptide from BACH1 (residues 986-995) was crystallized and its
structure solved at 1.85A resolution by X-ray diffraction (Figure 4.1A, B). Phases
were determined by molecular replacement using the previously determined
structure of the un-liganded BRCA1 tandem BRCT domains (PDB ID 1JNX) as a
search model[84], (Table 1 and Methods). Difference Fourier maps revealed
well-defined electron density for the phosphopeptide allowing modelling of eight
residues corresponding to BACH1 Ser988 - Lys995. Each BRCT repeat forms a
compact domain (Figure 4.1) in which a central, four-stranded beta-sheet is
packed against two helices, al and a3, on one side and a single helix, a2 on the
other. The two domains pack together through interaction between a2 of BRCT1
and the al'/a3' pair of BRCT2. A linker region connecting the two BRCT domains
contains a -hairpin-like structure O3L and a short helical region, aL, that forms
part of the interface through interactions with a2 of BRCT1 and the N-terminal
end of a 3' from BRCT2. Overall, the structure of the tandem BRCT
domain:phosphopeptide complex is similar to that of the un-liganded domains
(rmsd 0.4A for all Ca atoms). However, superposition of the individual BRCT
repeats reveals that phosphopeptide-binding is associated with a slight relative
rotation of each BRCT domain and a translation of BRCT1 helix al towards the
cleft between the domains.
The BACH1 phosphopeptide binds in an extended conformation to a groove
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located at the highly conserved interface between the N- and C-terminal BRCT
domains (Figures 4.1A, 4.2A), consistent with the requirement of both domains
for efficient phosphopeptide binding[19, 217]. This mode of binding is distinct
from that observed in the phospho-independent interaction between p53 and the
tandem BRCT domains of 53BP-1, which occurs primarily through the linker
region[218, 219]. Our structure clearly shows that the phospho-dependent
interactions that are necessary and sufficient for formation of the BACH1/BRCA1
complex occur on the opposite side of the BRCT-BRCT interface from those
involved in the p53:53BP-1 interaction.
BRCA1 BRCT:Phosphopeptide Specificity
BRCA1 tandem BRCT domain binding to library-selected peptides in
vitro[19, 217], and to phosphorylated BACH1 in vivo[20] is dominated by the
presence of a phosphoserine/threonine and a phenylalanine three residues C-
terminal to it (Phe +3). This is now confirmed by our structure which shows that
the BACH1 pSer 990 phosphate moiety binds to a basic pocket through three
direct hydrogen-bonding interactions involving the side chains of Ser1655 and
Lys1702, and the main-chain NH of Gly1656 (Figure 4.3A). All three of these
residues are located in BRCT1 and all are absolutely conserved in BRCA1
homologues. Ser1655 and Gly1656 are situated within the loop preceding al and
are brought into proximity with the phosphate moiety as a result of the
conformational change that occurs upon phosphopeptide binding. Intriguingly, a
S1655F mutation has been identified in a single breast cancer patient, although
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its link to disease has not been confirmed. In addition to these direct
interactions, the phosphate, and some peptide main-chain atoms are also
tethered through networks of water molecules, many of which are tetrahedrally
hydrogen bonded (Figure 4.3A). Indirect protein-solvent-phosphate contacts are
unusual in phospho-dependent protein-protein interactions but have been
observed previously in structures of phosphopeptide complexes of the human
Plk1 Polo-box domain[220, 221].
The Phe +3 peptide side-chain fits into a hydrophobic pocket at the BRCT
interface consisting of the side chains of Phe1704, Met1775 and Leu1839
contributed from both BRCT domains (Figures 4.3A, 4.4A). This finding
rationalizes the strong selection for aromatic amino acids in the +3 position of the
binding motif seen in peptide library experiments[19, 217], as well as the
observation of Yu et al that mutation of Phe993 to Ala eliminates BRCA1 :BACH1
binding[20]. Additional hydrogen-bonds with the main-chain N and C=O atoms of
Phe +3 are supplied by main- and side-chain atoms from Arg1699, a site of
mutation also associated with cancer predisposition. The phosphorylated Ser990
of BACH1 is preceded by an Arg residue in the -3 position and followed by a
proline residue in the +1 position, suggesting potential Ser990 phosphorylation
by either basophilic and/or proline-directed kinases. The BRCA1 tandem BRCT
domains are also known to interact with pSQ-containing motifs characteristic of
PI 3-kinase-like kinases such as ATM and ATR[19]. In the tandem BRCT:BACH1
phosphopeptide co-crystal structure, there are no direct interactions between the
+1 Pro side chain and the BRCT domains. Instead, this residue participates in
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only a single water-mediated hydrogen bond involving its carbonyl oxygen
(Figure 4.3A), consistent with the idea that various types of protein kinases can
generate tandem BRCT phospho-binding motifs. The Lys +5 side chain makes
two salt-bridging interactions with residues in BRCT2 (Figure 4.3A), consistent
with the Lys selection observed in this position by spot blot and peptide library
experiments[19, 217].
Cancer-Associated BRCA I BRCT Mutations
Residues that form or stabilize the phosphopeptide binding surface, and
the domain-domain interface, are among the most highly conserved portions of
the molecule in BRCA1 orthologues from humans, primates, rats and mice
(Figure 4.2B). Interestingly, these regions correlate strongly with the location of
cancer-associated mutations (Figure 4.2A). Some cancer-associated mutations
may disrupt the global BRCT fold while others are more likely to specifically
interfere with ligand binding[85, 204, 215, 216, 218]. Approximately 80 tumor-
derived mutations have been identified within the BRCA1 tandem BRCT
domains, though only a few of these have been subsequently confirmed to result
in cancer predisposition including D1692Y, C1697R, R1699W, A1708E, S1715R,
G1738E, P1749R, M1775R, 53821nsC (a frameshift mutation that results in a
stop codon at position 1829), and Y1853X (which truncates the last 11 residues).
Most of these cluster at or near the phosphopeptide-interacting surface (Figure
4.2A). Two of these mutated residues, Arg1699 and Met1775, directly interact
with residues in the phosphopeptide (Figure 4.3A). Two others, Pro1749 and
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Gly1738, are located at the BRCT1/BRCT2 interface beneath the molecular
surface and their effects are likely to be mediated through alterations in the
relative orientation of the tandem BRCT motifs that our structure suggests is
necessary for phospho-dependent interactions with partner proteins.
To verify the phosphoserine phosphate interactions observed in the X-ray
structure and to investigate the effects of the most common tumor-derived point
mutations, we investigated the binding of a panel of site-directed mutant BRCA1
tandem BRCT domains to the interacting region of BACH1. Binding was
determined by measuring the ability of in vitro transcribed and translated proteins
to bind to either phosphorylated and non-phosphorylated biotinylated peptides
(Figure 4.3B). Wild-type BRCA1 tandem BRCT domains clearly bind to
phosphorylated but not non-phosphorylated peptides, while mutation of the
conserved Ser1655 and Lys1702, alone or in combination, completely abolished
the interaction. Five bona fide cancer-linked mutations, P1749R, G1738E,
M1775R, Y1853X and 53821nsC all result in complete loss of phosphopeptide
binding. A mutation R1699W is cancer-linked and a second, R1699Q, has been
detected in breast cancer patients but has not yet been directly related to
disease-predisposition. We surmised that the glutamine side-chain might still
participate in main-chain hydrogen bonding to the peptide and this is, indeed, the
only BRCA1 tandem BRCT domain mutant that retained a small degree of
binding in our assays. Somewhat surprisingly, however, the R1699Q mutant
largely loses phospho-specificity, and instead bound to both phosphorylated and
non-phosphorylated peptides.
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To investigate the in vivo binding of cancer-predisposing mutant BRCA1
tandem BRCT domains to endogenous BACH1, we transfected U20S cells with
a vector encoding the C-terminal 550 amino acids of BRCA1 containing a myc
tag and an SV40 nuclear localization sequence as described by Chen et al[222].
As shown in Figure 4.3C, interaction between the wild type BRCA1 tandem
BRCT domains with full-length BACH1 was easily detected. In contrast, no in
vivo interaction was observed between BACH1 and mutant BRCA1 tandem
BRCT domains that disrupt phosphate-binding or predispose to breast and
ovarian cancer. All of these cancer-associated mutant proteins were expressed
at comparable levels when transfected into mammalian cells[81] (Figure 4.3C),
suggesting that gross structural destabilization is unlikely to account for their
cancer proclivity.
Interpretation of the structural effects of the M1775R mutation is simplified
since the X-ray crystal structure of the M1775R tandem BRCT domain mutant
has been determined (PDB ID 1N50)[85], revealing a nearly identical structure
as the wild-type protein with an average rmsd of 0.35 A for all Ca atoms.
Superposition of the mutant structure with that of our BACH1 complex shows that
the guanidine portion of the substituent arginine side-chain extrudes into the
tandem BRCT cleft, where it occupies the binding site for the essential Phe +3 of
the phosphopeptide (Figure 4.4A, B). In this case, loss of phosphopeptide-
binding in vitro and BACH1 binding in vivo appear to be attributable to the severe
steric clash of the Arg1775 side-chain with an important determinant of
phospholigand specificity and affinity. The M1775R mutant protein does,
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however, bind weakly to a BACH1 phosphopeptide in which the +3 Phe is
mutated to Asp or Glu (Figure 4.4C). This is consistent with the introduction of a
basic residue at the pSer +3 binding site and with the observation that this
mutation creates new anion binding sites in the M1775R crystal structure[85].
Thus, in addition to disrupting the native BRCA1:BACH1 interaction, this
mutation may also result in the formation of inappropriate BRCA1 BRCT
interactions.
Phosphopeptide-Binding and Nuclear Foci Formation
Subcellular localization and nuclear foci formation by the wild type,
S1655A/K1702M phosphopeptide-binding mutant and the M1775R cancer-
associated mutant BRCA1 BRCT domains were studied before and after DNA
damage in unsynchronized U20S cells (Figure 4.5). To maximize visualization
of nuclear foci, the cells were permeabilized with buffers containing 0.5% Triton
X-100 prior to fixation and immunostaining[69]. In un-extracted cells the wild-
type BRCT domains and both of the mutant BRCT proteins showed equivalent
diffuse nuclear localization. Extraction of the un-irradiated cells prior to fixation
resulted in near complete loss of BRCT domain staining in all cases (Figure
4.5A). Under these conditions, less than 5% of the wild-type and M1775R
tandem BRCT-containing cells displayed 5 or more nuclear foci, and no foci were
observed with the S1655A/K1702M double mutant. When the cells were
irradiated with 10 Gy of y-irradiation, and 2 hrs later permeabilized, fixed, and
stained, nearly all of the cells containing the wild-type BRCA1 tandem BRCT
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domains demonstrated sharp punctate nuclear foci that largely co-localized with
the staining pattern of an anti-pSer/pThr-Gln epitope antibody that recognizes
ATM- and ATR-phosphorylated substrates (Figure 4.5). In contrast, the
S1655A/K1702M mutant protein displayed only faint staining with a very fine
granular pattern that completely failed to co-localize with pSer/pThr-Gln staining.
This failure of foci formation and pSer/pThr-Gln co-localization is strong evidence
that the phospho-binding function of the BRCA1 tandem BRCT domains is critical
for normal subcellular localization following DNA damage. The M1775R mutant
protein that binds weakly to phosphopeptides with a different specificity than the
wild-type BRCA1 BRCT domains also formed punctate nuclear foci, although
these were slightly reduced in number and showed less co-localization with
pSer/pThr-Gln staining foci than the wild-type protein. This localization might
result from synergistic weak binding to alternative non-optimal phosphorylated
ligands present in high abundance in nuclear foci following DNA damage, as has
been observed for other phosphopeptide-binding domain interactions[223].
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Discussion
The 1.85A BRCA1 tandem BRCT domain:phosphopeptide structure
described here is the highest resolution X-ray structure of any BRCT domain
structure solved to date, and provides an enhanced structural framework within
which the molecular basis of breast and ovarian cancer can be further
investigated. The structure reveals why tandem BRCT repeats, rather than single
BRCT domains, are required for binding to pSer- or pThr-containing
phosphopeptides with high affinity and specificity, since motif recognition is
mediated by residues contributed from both domains across the domain-domain
interface. In addition, the structure rationalizes the observation that the BRCA1
BRCT domains do not bind to pTyr-containing sequences[7], since the
phosphate recognition pocket appears too shallow to accept a bulky phenyl ring.
Despite the fact that not all tandem BRCT domains appear to bind
phosphopeptides, several residues involved in the binding are relatively
conserved. Structures of additional BRCT:phosphopeptide complexes will be
necessary to better understand negative determinants of binding.
The BRCA1 tandem BRCT:phosphopeptide structure, in combination with
biochemical and cell biological analysis, shows that some pro-oncogenic
mutations in the BRCA1 C-terminal domains directly disrupt phosphopeptide
binding or perturb the BRCT interface that forms the phospho-dependent binding
surface. Similar conclusions were reached by Williams et al [36] who report the
structure of the BRCA1 tandem BRCT domains bound to an alternative
phosphopeptide determined from oriented peptide library screening7 , and the un-
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liganded structures of the M1775R and V1809F mutants in an accompanying
paper in this issue.
Like the BRCT domains in PTIP, the BRCT domains in BRCA1 are sufficient
for nuclear foci formation in response to DNA damage, and the phospho-binding
function appears to be involved in this phenomenon. Four bona fide cancer-
linked mutations, P1749R, G1738E, 53821nsC, and Y1853X all result in loss of
phosphopeptide binding. A fifth mutation, M1775R, binds weakly to
phosphopeptides with altered motif specificity, and can still form nuclear foci after
DNA damage, however it completely loses the ability to interact with wild-type
BACH1. These effects of the Pro1749 and Met1775 lesions confirm the previous
observations that these mutations are sufficient to abrogate BRCA1-BACH1
interactions in vivo[209]. Since BACH1 mutations have also been shown to be
associated with the development of cancer[224], these findings suggest that the
loss of this critical BRCA1 M1775R:BACH1 interaction may be the critical event
responsible for cancer predisposition[20, 224].
Despite the fact that mutations in BRCA1 ultimately predispose women to
cancer, wild-type BRCA1 paradoxically constitutes a target for anti-cancer
therapy. Given the importance of BRCA1 in homologous recombination and DNA
repair[82, 208, 225, 226], disruption of the pSer-binding function would be
expected to result in enhanced sensitivity to chemotherapy and radiation[26], as
has been observed in BRCA1 null murine embryonic stem cells[82]. The
structural delineation of the pSer binding surface provides a new target for
rational drug design.
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Experimental Procedures
Protein Cloning, Expression, and Purification
For crystallization experiments, human BRCA1 BRCTs (residues
1646-1859) were expressed as glutathione S-transferase (GST) fusions in
pGEX-4T1 (Amersham Pharmacia Biotech) in Escherichia coil BL21 at 180C. The
GST was removed by 48-hour treatment with thrombin before gel filtration.
Synthetic peptides were prepared by W. Mawby, University of Bristol, U.K. A
BRCA1 BRCT clone (residues 1313-1863) in pcDNA3 containing a N-terminal
Myc-tag and a SV40 nuclear localization sequence was a gift from R. Scully and
D. Livingston[222], and was used for the co-immunoprecipitation and
immunofluorescence assays. Mutations were generated using the Stratagene
Quick Change Mutagenesis Kit, and verified by sequencing. The pGEX-BRCA1
BRCT clone (residues 1633-1863) was described previously [19] and was used
for the peptide filter array. Induction of recombinant GST-BRCA1 BRCT domain
protein was performed at 370C for 3 hrs in the presence of 0.4 mM IPTG. The
GST-BRCA1 BRCT domains were isolated from bacterial lysates using
glutathione agarose, followed by elution with 40mM glutathione, 50mM Tris/HCI
(pH 8.1), and dialysis into 50mM Tris/HCI (pH 8.1), 300mM NaCI.
Crystallization and Structure Determination
Crystals were grown at 180C by microbatch methods. The BACH1
phosphopeptide (SRSTpS99 0PTFNK) was mixed with the BRCA1 BRCTs in a
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1.5:1 stoichiometric excess and concentrated to 0.35mM in a buffer containing
50mM Tris-HCI (pH 7.5), 0.4M NaCI, and 3mM DTT. Crystals grew from 50 mM
MES (pH 6.5), 0.1 M (NH4 )2SO4, and 13% PEG 8K (w/v). Crystals belonged to
the trigonal space group P3221 (a = b = 65.8 A, c = 93.1 A, a = = 90.0 ° , y =
120.00) with one complex in the asymmetric unit. Data were collected from flash-
cooled crystals at 100K on a Raxis-ll detector mounted on a Rigaku RU200
generator. Diffraction data were integrated and scaled using DENZO and
SCALEPACK [227]. The structure was solved by molecular replacement using
the coordinates 1JNX.brk[84] as a model with AMORE[228]. Subsequent
refinement was carried out using REFMAC5[228] and manual model building in
0[229]. Figures were constructed using Pymol.
Peptide Binding
An optimal phosphopeptide for binding the BRCA1 BRCTs was
determined by oriented peptide library screening as described previously[19].
This peptide was synthesized in both its phosphorylated and non-phosphorylated
form with a biotin group at the N-terminus using N-a-FMOC-protected amino
acids and standard BOP/HOBt coupling chemistry. These peptides were
conjugated to streptavidin coated beads (Sigma-Aldrich). The wild-type and
mutant BRCA1 BRCT domain-containing constructs (residues 1313-1863) were
transcribed and translated in vitro in the presence of [35S]-methionine using the
TNT kit (Promega). The bead-immobilized peptides (10 pL of beads) were added
to 10 pL of the in vitro translated [35S]-labeled protein pool in 150 pL binding
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buffer (50 mM Tris-HCI (pH7.6), 150 mM NaCI, 0.5% NP-40, 1 mM EDTA, 2 mM
DTT, 8 pg/mL pepstatin, 8 g mL'1 aprotinin, 8 pg mL- 1 leupeptin, 800 pM
Na3VO4, 25 mM NaF). After incubation at 40C for 3 hours, the beads were
washed three times with 200 pL of binding buffer prior to analysis by SDS-PAGE
(12.5% (w/v)) and autoradiography.
Peptide Filter Array
An ABIMED peptide arrayer with a computer controlled Gilson diluter and
liquid handling robot was used to synthesize peptides onto an amino-PEG
cellulose membrane using N-a-FMOC-protected amino acids and DIC/HOBT
coupling chemistry. The membranes were blocked in 5% (w/v) milk in Tris-
buffered saline containing 0.1% (v/v) Tween-20 (TBS-T) for hr at room
temperature, incubated with 0.025pM GST-BRCA1 BRCTs or 0.25 pM GST-
BRCA1 BRCTs M1775R (residues 1633-1863) in 5% (w/v) milk, 50 mM Tris-HCI
(pH 7.6), 150 mM NaCI, 2 mM EDTA, 2mM DTT for 1 hr at room temperature
and washed four times with TBS-T. The membranes were then incubated with
anti-GST conjugated HRP (Amersham) in 5% (w/v) milk/TBS-T for 1 hr at room
temperature, washed five times with TBS-T, and binding analysed by ECL
(Perkin-Elmer).
Co-immunoprecipitation of BRCA1 BRCTs and BACH1
U20S cells were grown to 50% confluency in 100cm2 dishes and
transfected with the myc-tagged wild-type or mutant BRCA1 BRCT constructs
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(residues 1313-1863) using FuGene6 transfection reagent (Roche) according to
manufacturer's protocol. Cells were collected 30 hrs following transfection, lysed
in lysis buffer (50 mM Tris-HCI (pH7.6), 150 mM NaCI, 1.0% NP-40, 5 mM EDTA,
2 mM DTT, 8 g/mL AEBSF, 8 g mL-' aprotinin, 8 g mL-) leupeptin, 2 mM
Na3VO4, 10 mM NaF and the phosphatase inhibitors microcystin and okadaic
acid). Lysates containing equal amounts of protein (3 mg) was incubated with 3
pL of a mouse anti-myc antibody (Cell Signaling) for 2 hr at 40C and then 10 pL
of protein G-sepharose beads (Sigma-Aldrich) were added and samples
incubated for an additional 2 hr at 40C. Beads were washed four times with lysis
buffer, bound proteins eluted in SDS-PAGE sample buffer, analysed on 6%
polyacrylamide gels, transferred to PVDF membrane, and detected by blotting
with rabbit anti-BACH1 antibody (a gift from D. Livingston). A portion of the
lysates were also run and blotted with the anti-BACH1 antibody and the anti-myc
antibody to further ensure equal protein loading.
Immunofluorescence and Microscopy
U20S cells were seeded onto 18mm2 coverslips and transfected with the
BRCA1 BRCT construct (residues 1313-1863) and various mutants using
FuGene6 transfection reagent (Roche) according to manufacturer's protocol.
Thirty hours following transfection, the cells were either treated with 10 Gy of
ionizing radiation or mock irradiated and allowed to recover for 120 minutes.
Cells were fixed in 3% (v/v) paraformaldehyde/2% (w/v) sucrose for 15 min at RT
and permeabilized with a 0.5% (v/v) Triton X-100 solution containing 20 mM Tris-
142
HCI (pH 7.8), 75 mM NaCI, 300 mM sucrose, and 3 mM MgCI2 for 15 min at RT.
When necessary, proteins were extracted after IR treatment as described
previously [69]. In brief, cells were incubated with extraction buffer (10mM
PIPES pH6.8, 100mM NaCI, 300mM sucrose, 3mM MgCI2, 1mM EGTA, 0.5%
(v/v) Triton X-100) for 5 minutes on ice followed by incubation with extraction
stripping buffer (10mM Tris-HCI pH 7.4, 10mM NaCI, 3mM MgCI 2, 0.5% (v/v)
Triton X-100) for 5 minutes on ice followed by successive washes in ice cold
PBS. Slides were fixed as above, stained with primary antibodies at 370C for 20
min, then stained with a anti-mouse or anti-rabbit secondary antibody for 20 min
(Molecular Probes) at 370C. Primary antibodies used were mouse anti-myc (Cell
Signaling) and rabbit anti-(pSer/pThr)Gln (Cell Signaling). Images were collected
on a Axioplan2 microscope (Carl Zeiss) and processed using OpenLab software
(Improvision).
Coordinates
The atomic coordinates and structure factors have been deposited in the
Protein Data Bank (Accession code 1T15).
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Table 4.1. Summary of crystallographic analysis. Details of the crystallization and
structure determination are provided in the supplementary information. 'Rym =
Ij I (I) - li / X(I) where Ij is the intensity of the jth reflection and (I) is the average
intensity. Rwork = ZhkI I Fobs - Fcac I /hkl Fobs, where Rfree is equivalent to Rwrk but is
Data Collection:
Space group
Unit cell dimensions
Resolution range (A)
Completeness (%)
Total observations
Unique reflections
Average I/o()
Rsym (%)
P3 221
a = b= 65.8 A, c= 93.1 A,
a= 8= 90°, = 120°
15.0-1.85
93.9
165,151
19,219
35.6
5.4
Model refinement:
Resolution (A) 15.0-1.85
No. of reflections (free) 18,225 (911)
RworkIRfre § (%) 20.6/22.2
No. of protein atoms 1,750
No. of water atoms 157
rms deviations
bonds (A) 0.01
angles () 1.35
calculated for a randomly chosen 5% of reflections omitted from the refinement
process.
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Figures
Figure 4.1. Structure of the BRCA1 tandem BRCT domains:BACH1
phosphopeptide complex.
(A) Ribbons representation of the BRCA1 tandem BRCT domains in complex
with the pSer-containing BACH1 peptide shown as stick representation in yellow.
The BACH1 phosphopeptide binds at the interface between the two BRCT
repeats. The secondary-structure elements in BRCT2 are labelled 'prime' to
differentiate them from the secondary-structure elements in BRCT1. The BRCT
inter-domain liker is shown in green. Areas of 310-helix are not labelled.
(B) Electron density map (2Fo-Fc) covering the BACH1 phosphopeptide.
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Figure 4.1 Continued.
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Figure 4.2. BRCA1 BRCT cancer-linked mutations and sequence
conservation in relation to the BACHI phosphopeptide binding-site.
(A) A molecular surface representation of BRCA1 tandem BRCT domains
showing how the cancer-associated mutations S1655F, D1692Y, C1697R,
R1699Q, S1715R, M1775R and Y1853X cluster with respect to the
phosphopeptide binding-site. BRCT1 is colored blue, BRCT2 is colored grey,
and the mutations are colored red, except for S1655 which is colored green as its
cancer predisposition has not been confirmed by pedigree analysis.
(B) Comparison of the front and back views of the molecular surface showing
the clustering of residues (magenta) conserved in human, chimp, mouse, rat,
chicken and Xenopus BRCA1 tandem BRCT domains. The BACH1 peptide binds
in a conserved phosphopeptide binding-groove.
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Figure 4.2 Continued.
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Figure 4.3. Functional effects of tandem BRCT domain mutations.
(A) Schematic representation of protein-peptide contacts between BRCA1
tandem BRCT domains and the BACH1 phosphopeptide. Hydrogen bonds, Van
der Waals interactions and water molecules are denoted by dashed lines, pink
crescents, and green circles respectively.
(B) The wild-type and mutant myc-tagged BRCA1 tandem BRCT domain
constructs containing the indicated mutations were analysed for binding to a
bead-immobilized optimal tandem BRCT domain-interacting phosphopeptide,
YDIpSQVFPF, or its non-phosphorylated counterpart. The weak phospho-
independent binding of the R1699Q mutant was observed using 10-fold more
sample input than used in the other lanes.
(C) U20S cells transfected with wild-type and mutant myc-tagged BRCA1
tandem BRCT domain constructs were analysed for association with
endogenous BACH1.
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Figure 4.4. The Phe +3 position of the BACH1 phosphopeptide is essential
for BRCAI1 tandem BRCT domain binding-specificity.
(A) Residues Phe 1704, Met 1775, and Leu 1704 from BRCA1 tandem BRCT
domains form a hydrophobic pocket to accommodate the Phe +3 position of the
BACH1 phosphopeptide.
(B) Superposition of the crystal structure of BRCA1 M1775R tandem BRCT
domain mutant [85] with the wild-type:BACH1 phosphopeptide complex reveals
that this mutation occludes the BACH1 Phe +3 position.
(C) BRCA1 wild type tandem BRCT domains and the M1775R mutant binding
to a BACH1 phosphopeptide spot array. The M1775R mutant spot blot was
performed using 10 times the amount of protein and was exposed to film for a
significantly longer amount of time than the wild-type protein.
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Figure 4.4 Continued.
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Figure 4.5. Localization of the BRCA1-BRCT domains to nuclear
phosphoproteins.
(A) Localization of wild-type, M1775R, or K1702M/S1655A versions of myc-
tagged BRCA1 tandem BRCT domains in un-irradiated U20S cells prior to (left
panels) or following (right panels) extraction using Triton X-100-containing
buffers. Bars indicate 25 gm.
(B) Localization following Triton X-100 extraction as in (a) two hours following
exposure of cells to 10 Gy of y-radiation. Extracted cells were also stained using
an anti-pSer/pThr-Gln epitope antibody that recognizes the phosphorylation motif
generated by the DNA damage-response kinases ATM and ATR. Bars indicate
10 im.
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Figure 4.5 Continued.
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Chapter 5
Future Directions
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Multiple pathways in cellular responses to DNA damage
The results presented here have detailed independent discoveries of the
requirement of MK2 in the DNA damage signaling pathway and have identified
the PTIP and BRCA1 BRCT domains as a new class of phospho-binding
domains that interact with proteins phosphorylated by ATM and ATR in response
to DNA damage. In addition, the screening techniques developed will help
facilitate further advances in the kinase signaling field. The determination of the
optimal phosphorylation motif of kinases will continue to provide important data
on kinases of interest and help identify their potential downstream targets. The
kinase motif data will prove even more valuable as an increasing amount of
computational biology research is performed. The identification of
posttranslational modification specific binding domains will continue to be an
important and exciting area of research. The screen discussed here is one of the
only proven approaches to directly identify specific phosphorlyation dependent
interactions. Work is already in progress to modify our screen to isolate domains
that recognize additional posttranslational modifications, such as methyl arginine.
The relationship of the p38/MK2 pathway to the ATR/CHK1 and ATM/CHK2
pathways
It is not clear why cells have evolved three seeminly parallel pathways that
respond to DNA damage. If there are multiple parallel pathways functioning, as
the current data suggests, these pathways may not be active at similar locations,
times or intensities within the cell. Recent data have emerged that suggest both
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the p38/MK2 and the ATR/CHK1 pathways are required for the cellular response
to DNA lesions caused by UV light or chemotherapeutic agents [67, 107]. It will
be necessary to determine both the temporal and spatial kinetics for each of
these pathways. Do cells require activation of multiple pathways for the full
checkpoint response, or is the p38/MK2 pathway somehow inseparably
integrated with these other pathways where inhibition of one component could
affect the activation of other members? It appears more likely that the activation
of redundant pathways is required because the inhibition of p38 or MK2 does not
appear to affect CHK1 activation [107, 117, 118]. It remains unclear how CHK1 is
unable to regulate CDC25A levels and generate the 14-3-3 binding sites on
CDC25BI/C without active MK2. It is also unclear how MK2 is unable to regulate
CDC25A and generate the 14-3-3 binding sites on CDC25B/C without active
CHK1 [27, 117]. Based on the current motif data, the regulation of CDC25B/C
appears to be one convergent point for MK2 and CHK1 in the DNA damage
checkpoint signaling pathway. Before the discovery that MK2 plays a critical role
in DNA damage signaling, a significant amount of the CHK1 data was generated
by using UCN-01 to inhibit CHK1. In fact, UCN-01 inhibits MK2 in vitro at similar
concentrations to those used to inhibit CHK1, and it is likely that UCN-01 inhibits
MK2 in vivo (C. Reinhardt, unpublished data). Therefore, results obtained with
the use of UCN-O1 may have been misinterpreted [167]. Recently, however, a
few labs have used CHK1 RNAi experiments to reproduce some of the UCN-01
data, which supports the requirement of CHK1, as the UCN-01 data implied [91,
118].
157
However it is possible that CHK1 and MK2 are in the same pathway, and
that CHK1 is responsible for the activation of MK2. The best approach to resolve
this issue will require examining the activation and/or phosphorylation status of
the classic members involved in these pathways (as in Figure 2.2). By using
siRNA approaches that deplete MK2, CHK1, or both MK2 and CHK1 in an
epistasis study it might be possible to order these signaling events and place
them into discrete pathways. For example, if depletion of MK2 does not affect
CHK1 activation, but depletion of CHK1 alters MK2 activation, CHK1 would be
placed upstream of MK2. This result would explain some conflicting previous
work. However, one problem that arises in epistasis studies involving the RNAi
depletion of an enzyme, experimental results from a 90% reduction in protein
levels may not be sufficient to create the null phenotype required. In spite of this
potential problem, loss of the checkpoint when MK2 or CHK1 is RNAi depleted
indicates that the kinase activities are impaired and supports the idea that an
RNAi epistasis study could generate meaningful results. Additionally,
overexpression of MK2 or CHK1 in CHK1 or MK2 RNAi depleted backgrounds,
respectively, may reveal compensation that takes place and explain why the
activity of one kinase is not sufficient to trigger the checkpoint.
Other types of DNA damage may activate MK2
How does the p38/MK2 pathway respond to different types of DNA
damage? The p38/MK2 pathway is activated by cellular stress, but our data
suggest that this pathway may also be activated directly by DNA damage or
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sensor proteins that localize with damaged DNA. It is unclear how the p38/MK2
pathway is activated by DNA damage. However, in response to alkylating agents,
the MMR proteins are required for the activation of p38, and most likely MK2
[163]. p38 and MK2 exist in a heterotrimeric complex located within the nucleus
so these kinases are perfectly positioned to be proximal respondes to DNA
damage. The p38/MK2 pathway may sense and transmit signals in a similar
fashion to ATM/CHK2 and ATR/CHK1, or there may be different undiscovered
upstream activators. BRCA1 plays an important, but yet undefined, role in the
DNA damage induced activation of CHK1. BRCA1 also plays a role in the taxol
mediated activation of p38 [230]. Is BRCA1 also required for the DNA damage
dependent activation of p38/MK2? Are the MRN or 911 complexes involved in
the activation of p38/MK2? And if so, are ATM/ATR also involved in the p38
mediated activation of MK2? It would also be interesting to determine if there are
differences in MK2 activation or target phosphorylation based on the type of DNA
lesion encountered. Specific pathway activation data, after DNA damage, may
provide insight into what types of cancers depend more heavily on different repair
pathways or kinases for proliferation. Inhibiting critical nodes in these networks
may prove more tractable than the current approaches which may not sufficiently
account for redundant signaling mechanisms, thus making certain pathways
more sensitive to inhibition. In the future, answers to these questions may more
efficiently direct cancer treatment choices and improve patient survival rates.
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Additional MK2 functions and targets
What are the other targets of MK2 in the DNA damage response
pathway? MK2 appears to phosphorylate the same targets as CHK1 and CHK2
following DNA damage. However MK2 regulates multiple pathways at the
transcriptional level and there are only a few identified roles for CHK1 and CHK2
regulating gene expression after DNA damage. Recently, Ueda et al. [231] used
comparative mass spectrometry analysis of protein samples to identify substrates
of MK2. It would be interesting to use similar genomic and proteomic approaches
to identify additional transcriptional and protein targets of MK2, including those
that are p53 dependent and independent.
BRCA1 and the requirement of its BRCT domains
The understanding of the multiple roles BRCA1 plays in the cellular
response to DNA damage remains incomplete. BRCA1 appears to function both
upstream and downstream of ATM/CHK2 and ATR/CHK1. How is this possible?
One explanation is an autocatalytic activation loop, where a kinase reaches a low
level of activity due to DNA damage, which in turn activates BRCA1 and
facilitates further activation of the kinase. It is unknown how the phosphorylation
of BRCA1 is involved in its activation of the checkpoint pathways. A few non-
mutually exclusive ideas are that phosphorylation could alter the structure of
BRCA1 exposing important domains, increase the activity of the RING finger
domain or the BRCT domains of BRCA1, or improve the ability of BRCA1 to act
as a protein scaffold localizing substrates in proximity to the relevant kinases.
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Is the role of BRCA1 in checkpoint signaling dependent on the phospho-
binding function of its BRCT domains, as recent data suggests [19, 20, 217]? It is
unclear how BRCA1 uses its BRCT domains to propagate signals in the DNA
damage response. How do the cancer-associated mutations found in BRCA1
disrupt this as yet undefined role? While BRCA1 BRCT domain destabilization is
one way function is lost, clearly not all BRCA1 BRCT domain mutations
destabilize the protein [85, 86, 232]. What is the function of the BRCA1-BACH1
interaction that is lost in BRCA1 cancer-associated mutations? Highlighting the
importance of this BRCA1-BACH1 interaction, there are also cancer-associated
mutations detected in BACH1 [224]. It is not known how the cancer-associated
mutations that do not disrupt phospho-binding prevent BRCA1 BRCT domain
function. Is there another surface on the BRCT domains that is required for
certain protein-protein interactions? It is likely that the phospho-binding pocket of
the BRCT domains only provides some of the necessary requirements of ligand
specificity and binding. One BRCA1 BRCT domain mutation, M1775R, appears
to alter phospho-binding specificity. It is not clear what interactions are lost and
what new ligands result from this mutation [86]. In addition to ATM and ATR that
generate the phospho-motif recognized by the BRCT domains, the PTIP and
BRCA1 BRCT domains show phospho-binding selectivity towards a Pro in the +1
position. It is possible that p38 also phosphorylates BRCT binding partners, such
as BACH1, in the DNA damage response pathway.
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Multiple functions of BRCT domain-containing proteins
The identification and crystallization of the BRCA1 BRCT domains
provides another example of the growing family of pSer/pThr binding domains.
Interestingly these domains are all structurally distinct supporting the idea that
phospho-binding developed as a type of convergent evolution [9, 22]. Though
BRCT domains are known protein-protein interaction modules present in many
DNA damage response and cell cycle checkpoint proteins, based on
experimental data and crystal structure based sequence alignments, it appears
that only a subset of BRCT domain posses a phospho-binding capability [86,
233]. It is not known how the phospho-binding motifs differ between BRCT
domains and if the short phospho-motif is the only means by which BRCT
domains interact with proteins. As predicted from the sequence alignments, little
if any phospho-binding was detected for 53BP1 or the PTIP N-terminal pair,
further suggesting that the phosphopeptide-binding function is present in only a
subset of tandem BRCT domains. The functions of the nonphospho-binding and
phospho-binding BRCT domain proteins remain to be determined. For example
human PTIP contains 5 BRCT domains, only two of which posses a phospho-
binding function; the function of the other three is yet undefined. The BRCT
domains probably mediate nonphospho-dependent protein interactions as well,
just like the FHA domains [234]. Though BRCT domains often exist in tandem
pairs, there are multiple examples of proteins that contain only one BRCT
domain or several BRCT domains. Based on crystal structure data BRCT
domains can dimerize [86, 233]. As BRCT domains are commonly found in
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proteins that function in the cell cycle, one possibility is that the proteins use the
BRCT domains as a common adaptor to facilitate necessary interactions,
whether phospho-dependent or phospho-independent.
The role of PTIP in the DNA damage response pathway
PITP shares many similarities to other proteins in the DNA damage
response pathway; PTIP contains BRCT domains, PTIP interacts with other DNA
damage response proteins, PTIP forms nuclear foci following IR, and (like ATR,
CHK1 and BRCA1) the PTIP knockout mouse is not viable [202]. What is the
exact role for PTIP in the DNA damage response pathway? PTIP may be
involved with S-phase progression and the recovery of stalled replication forks,
like ATR and CHK1. Based on the data available, PTIP does appear to play an
essential role for progression into mitosis, but it is unclear if that role is in S-
phase or G2, as cells lacking PITP do not display an S-phase entry defect [202].
Recent data also suggest that PTIP may have multiple splice forms [165]. While
PITP interacts with 53BP1 to form nuclear foci following DNA damage, the
functions of this interaction in unknown [19]. In addition, in vivo association of full-
length FLAG-PTIP with HA-53BP1 increases after IR treatment. If PTIP is
involved in the S-phase response, what then is the role of 53BP1?
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Multiple pathways in cellular responses to DNA damage
While much has been learned during my time at MIT, several intriguing
opportunities exist to improve our understanding of how protein-protein
interactions function in the DNA damage signaling response network.
Determining the exact role of MK2 in the DNA damage response pathway and
understanding how the BRCT domain-containing proteins function in signal
transduction pathways will be crucial. Recently, much research has been focused
on the development of drugs that inhibit DNA repair as chemosensitizing
compounds [67]. Because our discoveries expand the molecular understanding
as to how kinases signal to phospho-binding domains in the DNA damage
response signaling network they also provide novel validated targets for the
development of chemosensitizing therapeutic agents.
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Summary
The cellular response to DNA damage is mediated by
evolutionarily conserved Ser/Thr kinaeses, phosphory-
iation of Cdc25 protein phosphatases, binding to 14-
3-3 proteins, and exit from the cell cycle. To investigate
DNA damage responses mediated by the p38/s -
activated protein kinse (SAPK) axis of signaling, the
optimal phosphorylation motifs of mammalian p38a
SAPK and MAPKAP kinase-2 were determined. The
optimal substrate motif for MAPKAP kinase-2, but not
for p38 SAPK, closely matches the 14-3-3 binding site
on Cdc25B/C. We show that MAPKAP kinase-2 Is di-
rectly responsible for Cdc25B/C phosphorylation and
14-3-3 binding in vitro and in response to UV-induced
DNA damage within mammalian cells. Downregulation
of MAPKAP kinase-2 eliminates DNA damage-induced
G9/M, 0G, and intra S phase checkpoints. We propose
that MAPKAP kinase-2 is a new member of the DNA
damage checkpoint kinase family that functions In
parallel with Chkl and Chk2 to integrate DNA damage
signaling responses and cell cycle arrest in mamma-
lian cells.
Introduction
The maintenance of genomic integrity is essential for
the health of multicellular organisms. DNA damage
checkpoints constitute a mechanism where cell division
is delayed to allow repair of damaged DNA or, if the
extent of DNA damage is beyond repair, induce apopto-
sis. The three major DNA damage-responsive cell cycle
checkpoints are the G,/S checkpoint, intra S phase
checkpoint, and the G,/M checkpoint (Zhou and Elldge,
2000).
Signal transduction events controlling the DNA dam-
age response are mediated by evolutionarily conserved
Ser/Thr knases and phosphoserine/threonine binding
domains. Distinct types of genotoxic stress converge
to trigger a limited repertoire of DNA damage checkpoint
responses, presumably by funneling specific protein
complexes that recognize different types of DNA dam-
age into a few common pathways. For example, lesions
commonly caused by ionizing radiation (IR) and ultravio-
let light (UV) initiate the activation of the upstream ki-
nases ataxia-telangiectasia mutated (ATM) and ataxia-
*Correspondence: myaffeOmit.edu
telangiectasia- and RAD3-related (ATR) (Abraham,
2001). These kinases transduce the signal that directly
engages the DNA damage checkpoint.
ATM and ATR appear to have partially overlapping
functions since some common Ser/Thr-Gln-containing
substrates of both kinases have been identified. ATM
responds primarily to double-stand breaks, whereas
ATR responds to many types of DNA damage, including
the bulky DNA lesions caused by UV. Once activated,
ATM phosphorylates the downstream effector kinase
Chk2 on Thr68, and ATR phosphorylates the down-
stream effector kinase Chkl on Ser317 and Ser345
(Abraham, 2001; Guo et al., 2000). In addition, studies
in both Xenopus egg extracts and mammalian cells have
pointed to the existence of a checkpoint pathway that
is independent of ATRWChkl and ATM/Chk2 (Bulavin et
al., 2001; Goldstone et al., 2001; Hirose et al., 2003;
Mikhailov et al., 2004; Stokes and Michael, 2003).
A major mechanism by which Chkl and Chk2 control
the DNA damage response is through the phosphoryla-
tion-dependent inactivation of members of the Cdc25
family of phosphatases, which are positive regulators
of Cyclin/Cdk complexes (Donzelli and Draetta, 2003
and references therein). The Cdc25 family consists of
three different isoforms: Cdc25A, Cdc25B (variants 1,
2, and 3), and Cdc25C. Cdc25A and Cdc25B are thought
to be oncogenes since they are upregulated in many
forms of human cancer (Galaktionov et al., 1995;
Gasparotto et al., 1997). Cdc25A controls both progres-
sion through S phase and entry into, and maintenance
of, mitosis (Busino et al., 2004; Zhao et al., 2002). In
response to DNA damage, Cdc25A is phosphorylated
on several sites, including Ser78 and Ser123, targeting
it for ubiquitin-mediated degradation (Busino et al., 2004
and references therein). Cdc25B and Cdc25C, on the
other hand, are primarily involved in regulating mitotic
entry through their activation of the cyclin-dependent
kinase Cdc2/CyclinB (Donzelli and Draetta, 2003). In re-
sponse to DNA damage, Cdc25B1/Cdc25B2 and Cdc25C
become sequestered away from the nuclear pool of
Cdc2/CyclinB by phosphorylation on Ser309/Ser323
and Ser216, respectively, leading to 14-3-3 binding and
cytosolic retention (Fumari et al., 1997; Giles et al., 2003;
Kumagai and Dunphy, 1999; Peng et al., 1997). The exact
roles of different Cdc25 family members in establishing
this G2/M checkpoint, however, remain a matter of active
debate (Chan et al., 2001; Mailand et al., 2002).
In contrast to the IR-induced DNA damage check-
point, the UV-responsive checkpoint is less well under-
stood. It was recently shown that, in addition to the
ATR-Chkl pathway, the p38 SAPK pathway is also re-
quired for full activation of the DNA damage response
following UV irradiation (Bulavin et al., 2001). We now
demonstrate that MAPKAP kinase-2, a direct down-
stream target of p38 SAPK, is directly responsible for
phosphorylating Cdc25B and C and maintaining the G,,
S, and G2/M checkpoints in response to UV-induced
DNA damage. Thus, MAPKAP kinase-2 constitutes a
third checkpoint kinase, in addition to Chkl and Chk2,
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Figure 1. Substrate Specificity and Kinetic Analysis of Substrate Phosphorylation by p38a SAPK
(A) p38 substrate specificity determined using oriented peptide library screening. Residues displaying the highest selectivity are shown; those
with selection values >1.7 are in bold. MEF2A, myocyte enhancer factor 2; ATF2, activating transcription factor 2; 3PK1, MAP kinase-activated
protein Idnase-3.
(B) Kinetics of in vitro phosphorylation of an optimal p38 peptide (p38tide) and a peptide from p47phox (p47tide) by p38a Idnase.
(C) Kinetics of in vitro phosphorylation of wild-type GST-p47phox, the Ser345-Ala mutant, and the Ser348-Ala mutant. Typical data from
n = 3 experiments is shown.
(D) In vitro phosphorylation of full-length wild-type or mutant p47phox proteins. Samples were analyzed by SDS-PAGE/autoradiography.
(E) Table of kinetic prameters for the reactions in (C).
involved in coordinating the DNA damage response of
higher eukaryotic cells.
Results
Defining the Optimal Phosphorylation Motif
for p38 SAPK
To identify substrates and targets of the p38 SAPK sig-
naling pathway involved in DNA damage responses, the
optimal substrate phosphorylation motif for p38a SAPK
was determined using oriented peptide library screening
(Songyang and Cantley, 1998). Efficient peptide phos-
phorylation by p38 SAPK required a fixed Pro residue
in the Ser+1 position (data not shown), consistent with
the known identification of p38 SAPK as a Pro-directed
MAP kinase. Screening performed with a library con-
taining the degenerate sequence X-X-X-X-Ser-Pro-X-X-
X-X (X denotes all amino acids except Cys, Ser, Thr,
and Tyr) displayed strongest selection for Pro in the
Ser-2 position with weaker selection for other aliphatic
residues (Figure 1A). Additional selection was also ob-
served at the Ser-3, Ser-1, and Ser+2 positions.
To further refine the optimal phosphorylation motif, a
secondary screen was performed based on results from
the initial screen by using a library with Pro fixed in both
the Ser-2 and Ser+1 positions, and Ser, Thr, and Tyr
included in the X positions. This revealed selection for
Gin, Met, and Gly in the Ser-1 position, along with
slightly weaker selection for Pro, Ser, and Thr (Figure
1 A). Gly was the preferred residue in the Ser-3 position,
along with lie, Val, and Tyr. Hydrophobic residues, par-
ticularly aromatic and 3-branched amino acids, were
selected at the Ser+2 position. The resulting optimal
motif for p38a SAPK determined by oriented peptide
library screening closely matches the sequence of
mapped p38 MAPK phosphorylation sites on most,
though not all, known substrates (Figure 1A) (Ben-Levy
et al., 1995; Cheung at al., 2003; El Benna et al., 1996;
McLaughlin et al., 1996; Raingeaud et al., 1995; Wang
and Ron, 1996; Yang et al., 1999)
A peptide containing the optimal p38 SAPK consen-
sus phosphorylation motif GPOSPI, p38tide," was syn-
thesized for kinetic analysis. This peptide was readily
phosphorylated by p38 SAPK in vitro; however, it failed
to display saturable Michaelis-Menton-type kinetics
(Figure 1 B). Instead, the initial velocity increased linearly
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with increasing p38tide concentration up to1400 iM.
This finding suggests that additional interactions be-
sides an optimal phosphorylation motif are likely to be
involved in optimizing p38 SAPK-substrate binding,
such as MAP kinase docking sites (Tanoue et al., 2000).
To search for potential p38 SAPK substrates, particu-
larly those relevant to DNA damage signaling, the Swiss-
Prot database was queried with the p38 SAPK consen-
sus phosphorylation motif using Scansite (Yaffe et al.,
2001) (Supplemental Table SI). Other than GADD153, a
known p38 SAPK substrate, we were unable to identify
any DNA damage response proteins in the top 250 hits.
Database searching did, however, reveal two tandem
near-optimal p38 SAPK phosphorylation sites (Ser345
and Ser348) in p47phox, a cytosolic component of the
NADPH oxidase enzyme. A peptide containing this se-
quence, PGPQSPGSPL, p47tide," was strongly phos-
phorylated by p38 SAPK, but like p38tide, the isolated
peptide displayed linear nonsaturable kinetics (Fig-
ure 1 B).
Wild-type and mutant versions of GST-tagged full-
length p47phox protein, rather than isolated peptides,
were then used as substrates for in vitro phosphorylation
reactions. The wild-type full-length p47phox protein was
rapidly phosphorylated by p38a SAPK (Figures IC and
1 D). Mutation of Ser345-Ala had a more pronounced
effect on p47phox phosphorylation than mutation of
Ser348-Ala, in excellent agreement with the observa-
tion that the Ser345 site is a better match for the optimal
p38 SAPK consensus motif than the Ser348 site. Simul-
taneous mutation of both Ser345 and Ser348 to Ala
eliminated phosphorylation of p47phox by p38 SAPK
altogether. Kinetic analysis revealed classical Michaelis-
Menton behavior for p38 SAPK phosphorylation of the
wild-type p47phox with a Km of 6.0 ILM and a V, of
36.6 nmoVmin/iLg. Mutation of Ser345 to Ala both in-
creased the Km and reduced the V,, while mutation of
Ser348 to Ala primarily increased the Km (Figure 1 E).
This data from isolated peptides and intact proteins
argues that efficient substrate phosphorylation by p38
SAPK requires sequences with reasonable matches to
the optimal substrate motif determined by oriented pep-
tide library screening, and that additional interactions
involving MAPK docking sites are likely to be critical for
strong kinase-substrate interactions. Several docking
motifs have been identified for p38 SAPK, particularly
a short cluster of positively charged amino acid residues
often flanked by hydrophobic amino acids (Roux and
Blenis, 2004; Tanoue and Nishida, 2003). Two se-
quences corresponding to this type of docking motif
are present near the p38SAPK phosphorylation sites in
p47 phox, 3 1 IHQRSRKRLSQ- and 3V1RFLQQRRRQAa.
Mutation of RRRF7 to LLL in the latter motif decreased
the rate of p38a SAPK phosphorylation of p47phox by
over 70% (data not shown). The contribution of amino
acids 311-321, or involvement of alternative p38 SAPK
docking site(s) (cf. Cheung et al., 2003), is not yet known.
Bulavin et al. (2001) implicated p38 SAPK in the DNA
damage-response pathway and reported that p38 SAPK
was directly responsible for generating a 14-3-3 binding
site on Cdc25B (Ser323 in Cdc25B2; Ser309 in Cdc25B1)
in response to UV-C-induced DNA damage. Like
p47phox, Cdc25B contains a potential p38 SAPK dock-
ing motif, 35PVQNKRRRSV3; however, the sequence
flanking Ser323, LXRSPSMP, lacks a Pro in the Ser+1
position and does not resemble the optimal p38 SAPK
motif shown in Figure 1A. As shown in Figure 2A, recom-
binant p38 SAPK readily phosphorylated bacterially pro-
duced Cdc25B in vitro. However, this phosphorylation
did not induce 14-3-3 binding, and a Ser323-Ala mutant
form of Cdc25B was phosphorylated by p38 SAPK
equivalently to the wild-type Cdc25B protein. This data
argues that while Cdc25B may be a p38 SAPK substrate,
this phosphorylation event is not responsible for the 14-
3-3 binding event that results in a G/M checkpoint.
Defining the Optimal Phosphorylation Motif
for MAPKAP Kinase-2
A number of Ser/Thr kinases are activated downstream
of p38 SAPK, including MAPKAP kinases-2, and -3,
MNK1 and MNK2, MSK1 and MSK2, and PRAK (Obata
et al., 2000). In response to UV-B-induced DNA damage,
She et al. (2002) reported that MAPKAP kinase-2 could
phosphorylate p53 on Ser20, the same site that is phos-
phorylated by two well-established checkpoint kinases,
Chkl and Chk2. Both Chkl and Chk2 can also phosphor-
ylate Cdc25 family members to create 14-3-3 binding
sites, suggesting that MAPKAP kinase-2 might share
a similar motif. The optimal substrate phosphorylation
motif for MAPKAP kinase-2 was therefore investigated
using oriented peptide library screening.
Efficient peptide phosphorylation by MAPKAP ki-
nase-2 was only observed with a library containing a
fixed Arg in the Ser-3 position (X-X-X-X-R-X-X-S-X-X-
X-X, where X denotes all amino acids except Cys, Ser,
Thr, or Tyr). A critical step in determining protein kinase
phosphorylation motifs by peptide library screening in-
volves purification of the phosphorylated peptides from
the nonphosphorylated peptide background. In the case
of MAPKAP kinase-2, this was dramatically improved
by conversion of all Glu and Asp residues to their methyl
esters prior to metal-affinity chromatography and se-
quencing (Ficarro et al., 2002). This resulting motif re-
vealed clear amino acid selection at almost all degener-
ate positions (Figure 3A). MAPKAP kinase-2 displayed
strong selection for the hydrophobic residues Leu, Phe,
lie, and Val in the Ser-5 position, and the Ser+1 posi-
tion. Strong selection was also observed for Gin in the
Ser-2 position, and modest selection for Leu in the
Ser-1 position. The motif determined for MAPKAP ki-
nase-2 using oriented peptide library screening is in
remarkably good agreement with the sequence of
mapped MAPKAP kinase-2 phosphorylation sites on
known substrates (Figure 3A, bottom) (Cheng and Lai,
1998; Heidenreich et al., 1999; Huang et al., 1997; Landry
et al., 1992; Rouse et al., 1994; Stokoe et al., 1992,1993;
Werz et al., 2002), which primarily contain Leu, lie, or
Phe in the Ser-5 position; Arg in the Ser-3 position;
Gin, Ser, or Thr in the Ser-2 position; Leu, Val, or Pro
in the Ser-1 position; and hydrophobic residues along
with Glu in the Ser+1 position. The preference for polar
residues Ser and Thr in addition to Gin in the Ser-2
position in known MAPKAP kinase-2 substrates would
not have been detected by oriented peptide library
screening since Ser and Thr were not present in the li-
brary.
To verify the peptide library screening resuits, individ-
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Figure 2. Involvement of MAPKAP Kinase-2 in the Phosphorylation of Cdc25B and Cdc25C after DNA Damage
(A) Phosphorylation of full-length wild-type Cdc25B or a Ser323-.Ala mutant by p38a SAPK or MAPKAP kinase-2. After phosphorylation,
generation of a 14-3-3 binding site on Cdc25B was determined by a 14-3-3-MBP pull-down followed by SDS-PAGE/autoradiography.
(B) Kinetics of MAPKAP kinase-2 phosphorylation and generation of a 14-3-3 binding site on Cdc25B were measured In U20S cells following
20 J/m2 UV Irradiation.
(C) Signaling events in the G¥/M, GI, and S phase checkpoint response were analyzed in GFP sIRNA- or MAPKAP kinase-2 siRNA-treated
U20S cells before and 2 hr after UV-lnduced DNA damage. Equal loading was determined by Western blotting for P3-actin.
ual peptides (MK2tides) containing the optimal MAPKAP
kinase-2 consensus motif LQRQLSI, or mutant versions
with Ala substituted at each position in the motif, were
synthesized and used for kinetic analysis (Figures 3B
and 3C). The optimal MK2tide displayed a K value
2-fold lower than the best MAPKAP kinase-2 peptide
substrate known to date, a sequence derived from
HSP27 (Landry et ai., 1992). Substitution of Ala at each
position in the motif affected K, and V, differently, with
some positions showing primarily a K. effect (i.e., Arg
in the Ser-3 position), while others revealed a primary
effect on V, (i.e., Leu in the Ser-5 position) (Figure
3C). The rank order of importance of key residues is
Arg-3 > Leu-5 I lie+1 > Gln-3. The optimal MK2tide
had neither the lowest K, nor the highest V,, but rather
had the highest V./K ratio, consistent with the fact
that the peptide library screening approach selects sub-
strates on the basis of optimal V1Km, rather than low
K,, or high V. alone (Nishikawa at al., 1997). Combining
the data from oriented peptide library screening, known
substrate sequences, and our kinetic studies, the opti-
mal MAPKAP kinase-2 phosphorylation motif is (Leu/
Phe/lle)-(Xxx)-(Arg)-(Gln/Ser/Thr)-(Leu)-(Ser/Thr)-
(Hydrophobic).
The optimal MAPKAP kinase-2 substrate motif is an
excellent match for the known Ser323 phosphorylation/
14-3-3 binding motif in Cdc25B, as well as the Ser216
phosphorylation/1 4-3-3 binding site in Cdc25C (Figure
3A, Supplemental Table S2). Initial experiments focused
on Cdc25B, since unlike Cdc25C, Cdc25B can be pro-
duced in modest quantities in bacteria, and the Ser323
site in Cdc25B had been previously reported to be a
direct p38 SAPK site. Incubation of recombinant Cdc25B
with purified MAPKAP kinase-2 resulted in significant
Cdc25B phosphorylation and strong binding of the
phosphorylated protein to 14-3-3 (Figure 2A). Mutation
of Ser323-Ala substantially reduced the ability of MAP-
KAP kinase-2 to phosphorylate Cdc25B, and completely
eliminated the ability of Cdc25B to bind to 14-3-3 (Figure
2A). These in vitro results strongly suggest that MAPKAP
kinase-2 is the critical Cdc25/14-3-3 checkpoint kinase
downstream of DNA damage signals relayed by the p38
SAPK pathway.
MAPKAP Kinase-2 Is Critical for the G./M Checkpoint
following UV-lnduced DNA Damage
The importance of MAPKAP kinase-2 in DNA damage
checkpoint function was investigated in U20S cells. Ac-
tivation of MAPKAP kinase-2 in response to UV-C irradi-
ation-induced DNA damage (Figure 4A) was monitored
by its reduced mobility on SDS-PAGE gels, and by immu-
noblotting using a phospho-specific antibody against
pThr344, a site phosphorylated by p38 and required for
MAPKAP kinase-2 activation (Ben-Levy et al., 1995). As
shown in Figure 2B, MAPKAP kinase-2 was activated
within 1 hr of irradiation and remained activated for the
8 hr duration of the experiment. The kinetics of MAPKAP
kinase-2 activation paralleled the ability of Cdc25B from
these cells to bind to 14-3-3. Based on these data, a 2
hr time point was chosen for use in further studies.
RNA interference was used to confirm a direct role
for endogenous MAPKAP kinase-2 in the UV-induced
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Figure 3. Substrate Specificity and Kinetic Analysis of Substrate
Phosphorylation by MAPKAP Kina2se-
(A) MAPKAP kinase-2 substrate specificity was determined by ori-
ented peptide library screeing. HSP27, heat shock protein 27; 5-LO,
5-lipoxygenase; LSP1, lymphocyte-specific protein; SRF, serum re-
sponse factor, GS, glycogen synthase; TH, tyrosine hydroxylase.
(B) Kinetics of in vitro phosphorylation of the optimal MAPKAP ki-
nase-2 peptide (MK2tide) by MAPKAP kinase-2.
(C) Table of kinetic paranmeters for MAPKAP kinase-2 phosphoryla-
tion of wild-type and mutant MK2tides.
DNA damage response. Treatment of U20S cells with
MAPKAP kinase-2-specific siRNA oligonucleotides, but
not with control GFP siRNA oligonucleotides, resulted
in a substantial reduction of MAPKAP Idnase-2 to nearly
undetectable levels by 48 hr after transfection (Figure
2C). No reduction in the levels or UV-C-induced activa-
tion of p38 SAPK, Chkl, or Chk2 was observed in these
cells. Despite the presence of these other active kinases,
siRNA-mediated knockdown of MAPKAP kinase-2
caused a loss of both Cdc25B- and Cdc25C binding to
14-3-3 after UV-C exposure (Figure 2C).
Cell cycle progression in the control GFP and MAP-
KAP kinase-2 knockdown cells following UV-C-irradia-
tion was studied using FACS (Figure 4). In these experi-
ments, cells were irradiated with 20 J/m 2 of UV-C
radiation, allowed to recover for 2 hr, and then placed
in nocodazole-containing media for an additional 16 hr
to cause any cells progressing through the cell cycle to
arrest in mitosis, where they can be stained for the mi-
totic marker phosho-histone H3. Under these condi-
tions, unirradiated cultures of asynchronous GFP
siRNA-transfected cells accumulated in a 4N-DNA-con-
taining peak, with prominent levels of phospho-histone
H3 staining (Figures 4B and 4C), consistent with a noco-
dazole-mediated M phase arrest. In response to UV irra-
diation, control cells displayed a prominent G1, S, and
G2 distribution, with near-complete loss of phospho-
histone H3 staining, indicating intact GI, S, and G2 check-
points (Figures 4D and 4E).
The behavior of the MAPKAP kinase-2 siRNA-trans-
fected cells was dramatically different. In the absence
of UV irradiation, MAPKAP kinase-2 siRNA-transfected
cells, like control GFP siRNA-transfected cells, accumu-
late in a 4N DNA-containing peak with high levels of
phospho-histone H3 staining (Figures 4F and 4G). Fol-
lowing UV-induced DNA damage, however, the MAP-
KAP kinase-2 knockdown cells failed to arrest cell cycle
progression. Instead, these cells proceeded to enter
mitosis to the same extent as unirradiated cells, as
shown by a comparable 4N-DNA peak and similar levels
of phospho-histone H3 staining as those observed in
unirradiated cells (Figures 4H and 41). Together with the
Cdc25B/C:14-3-3 results in Figure 2C, this FACS data
demonstrates that MAPKAP kinase-2 is critical for the
UV-induced Gg/M checkpoint in response to UV irradia-
tion. In contrast to the UV response, summarized in
Figure 4J, the G2/M checkpoint response to ionizing
radiation in MAPKAP kinase-2 knockdown cells is intact
(Figure 4K).
MAPKAP Kinase-2 Is Critical for the 8 Phase
Checkpoint and GI Arrest following
UV-lnduced DNA Damage
The MAPKAP kinase-2 knockdown cells in Figure 4 also
showed a loss of the GI and S phase checkpoints follow-
ing DNA damage, since UV irradiation of asynchronous
cultures resulted in accumulation of the cells in a 4N
DNA-containing peak when the cells were transferred
to nocodazole-containing medium. To investigate the
direct role of MAPKAP kinase-2 in S phase checkpoint
function, control or MAPKAP kinase-2 knockdown U20S
cells were UV irradiated, allowed to recover for 30 min,
and then labeled with BrdU for various times. In the
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absence of irradiation, 42% of the control siRNA-trans-
fected cells showed substantial BrdU incorporation after
12 hr, compared with 53% of the MAPKAP kinase-2
siRNA-transfected cells (Figures 5A and 5B). When the
cells were irradiated with 20 J/m2 of UV light prior to
BrdU labeling, only 3.5% of the control siRNA-trans-
fected cells showed BrdU incorporation at 12 hr. In
marked contrast, 48% of the MAPKAP kinase-2 knock-
down cells continued to incorporate substantial amounts
of BrdU. A similar difference in BrdU uptake between
control siRNA-treated cells and MAPKAP kinase-2
knockdown cells was also seen at shorter times after
irradiation (Figure 5B).
Examination of the FACS profiles 12 hr following UV
irradiation revealed a dramatic decrease in the G1 popu-
lation in the MAPKAP kinase-2 knockdown cells com-
pared with the control GFP siRNA-transduced cells (Fig-
ure 5A, right-most upper and lower FACS profiles). This
loss of the G1 peak, together with the increased percent-
age of cells showing BrdU incorporation at 12 hr versus
2 hr of labeling, implies that endogenous MAPKAP ki-
nase-2 plays important roles in both the inhibition of
DNA synthesis following damage (S phase checkpoint
function), and in the damage-induced arrest of cells in
G1 prior to S phase entry (G1/S checkpoint function).
Loss of the G1/S and S phase checkpoints in MAPKAP
kinase-2 knockdown cells was associated with higher
levels of Cdc25A, decreased levels of p53, and reduced
phosphorylation of p53 on Ser20 following UV irradiation
compared with control siRNA-treated cells (Figure 2C).
The fate of S phase control or MAPKAP kinase-2
siRNA-treated cells in response to UV-C-induced DNA
damage was examined by using FACS. In this experi-
ment, asynchronous cells were mock treated or irradi-
ated with 20 J/m2 of UV-C radiation and then pulse la-
beled with BrdU. The cells showing BrdU uptake were
subsequently analyzed 10 and 20 hr later (Figure 5C).
In both nonirradiated control and MAPKAP kinase-2
knockdown cells, the BrdU pulse-labeled population
showed a late S and G2/M distribution at 10 hr, and a
reappearance of a G1 peak at 20 hr, indicating full transit
through the cell cycle. In response to UV-C irradiation,
control siRNA-treated cells failed to show significant
BrdU uptake upon which to gate for FACS analysis (Fig-
ure 5C, lower left panel). In contrast, the large population
of MAPKAP kinase-2 siRNA-treated cells, which had lost
the S phase checkpoint and incorporated BrdU, went
on to display a greatly reduced G1 peak at 20 hr, with
many cells showing DNA staining 4N (Figure 5C,
bracket in lower right panel), consistent with mitotic
death and exit from the cell cycle.
MAPKAP Kinase-2 Depleted Cells Are More Sensitive
to DNA Damage-Induced Cell Death
The experiments in Figures 4 and 5A-5C indicate that
MAPKAP kinase-2 is involved in each of the cell cycle
Figure 4. MAPKAP Kinase-2 Is Required for G2/M Arrest following
DNA Damage
(A) UV-C irradiation induces DNA damage as revealed by nuclear
foci formation. U2OS cells were mock irradiated or exposed to 20
J/nm of UV-C radiation and immunostained 2 hr later using an anti-
phospho(Ser/Thr) ATM/ATR substrate antibody.
(B-) GFP siRNA- or MAPKAP kinase-2 siRNA-treated U20S cells
were irradiated as in (A), then placed in 50 ng/ml nocodazole-con-
taining media for an additional 16 hr. Cells were analyzed by FACS
for DNA content by PI staining (B, D, F, and H) and for phospho-
histone H3 staining as a marker of mitotic entry (C, E, G, and I).
(J-K) GFP siRNA- or MAPKAP kinase-2 siRNA-treated U20S cells
were either mock treated, exposed to 20 J/m2 of UV-C irradiation
(J), or to 10 Gy of ionizing radiation (K) and analyzed as In (BHI).
Representative results of each experiment are shown.
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Figure 5. MAPKAP Kinase-2 Is Required for S Phase Arrest and Cell Survival following DNA Damage
(A) GFP siRNA- or MAPKAP kinase-2 siRNA-treated U20S cells were mock treated or UV irradiated and allowed to recover for 30 min. BrdU
was added and cells were fixed and analyzed by FACS for DNA content and BrdU incorporation 12 hr later.
(B) Percentage of cells in (A) showing BrdU incorporation at 2 and 12 hr following BrdU addition were measured.
(C) GFP siRNA- or MAPKAP kinase-2 siRNA-treated U20S cells were either mock treated or UV irradiated, allowed to recover for 30 min, then
pulse labeled with BrdU for 30 min. At the indicated times after irradiation the distribution of DNA content was analyzed in the BrdU-
positive population.
(D) GFP sRNA- or MAPKAP kinase-2 siRNA-treated U20S cells were either mock treated or irradiated at the indicated UV-C dose. Cells were
stained with Crystal Violet 48 hr later and visualized. Insets show a magnified view.
(E) Quantitative colony forming assays were performed by plating cells at a density of "100 cells per 35 mm2 dish. Cells were treated as in
(D), and assays were performed in triplicate for each condition.
checkpoints triggered by UV-induced DNA damage. To
determine the effect of MAPKAP kinase-2 depletion on
cell survival, cells were transfected with control siRNA or
MAPKAP kinase-2 siRNA for 48 hr, trypsinized, replated,
and analyzed for colony formation in response to various
doses of UV-C irradiation 12 hr after replating. As shown
in Figures 5D and 5E, MAPKAP kinase-2 knockdown
cells displayed a significant reduction in colony forma-
tion when compared to control-treated cells at all doses
of UV-C irradiation examined. This difference in survival
after UV-C exposure was most pronounced at low to
moderate UV doses.
A Structural Model for MAPKAP Kinase-2
Substrate Slectivity
The optimal phosphorylation motif determined for MAP-
KAP kinase-2 is strikingly similar to that determined for
two other checkpoint kinases, Chkl and Chk2 (Figure
6A; O'Neill et al. [2002]) and data not shown). All three of
these CAMK superfamily members- MAPKAP kinase-2,
....... I
ML-1
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+1 Figure 6. Comparison of Active Site Electro-
F static Potentials and Hydrophobicity for the
F Substrate Binding Cleft of MAPKAP Kinase-,
AktAid, and Chkl
(A) Optimal substrate phosphorylation motifs
sUn -Hfu , l1MM, : nLl M/"IArl' il-
nase-2.
(B) Ribbons representation of the MAPKAP
kinase-2 kinase domain in a similar orienta-
tion as that shown in (C)-(E) (upper), and in
an orthogonal orientation (lower) with stick
representations of the substrate peptide in
the active site cleft. Figure created using Mol-
script (Kraulls, 1991) and Raster3D (Merritt
and Murphy, 1994).
(C) Molecular surface representations of the
Akt/PKB active site (PDB code 106K) using
GRASP (Nicholls et al.. 1993). Electrostatic
potentials (left) are colored red (negative) and
blue (ositive) Hydrophobicity (right) Is shaded
gray, yellow, and green for low, medium, and
high hydrophobic potentials, respectively.
The GSK3 substrate peptide Gly-Arg-Pro-
Arg-Thr-Thr-Ser-Phe-Ala-Glu, with the phos-
pho-acceptor indicated in bold and under-
lined, is shown in stick representation.
(D) Molecular surface representations of the
MAPKAP kinase-2 active site (PDB code
1NY3). Electrostatic and hydrophobic poten-
ullS are GOKr as In ). I nu opnimal suu-
strate peptide Leu-uln-Arg-uIn-Leu-Sr-lle-
Ala is shown in stick representation.
(E) Molecular surface representations of the
Chkl active site (PDB code 1 A8). Electro-
static and hydrophobic potentials are colored
as in (C). Stick representation of the modeled
Cdc25C substrate peptide (Leu-Tyr-Arg-Ser-
Pro-Ser-Met-Pro-Leu) is shown.
The region corresponding to the Ser-5,
Ser-3, and Ser+1 positions of the substrate
peptides in (C), (D), and (E) is indicated by
UasneU ciriUs.
Chkl, and Chk2-strongly select for aliphatic residues
in the Ser-5 position, Arg in the Ser-3 position, and
aromatic/aliphatic residues in the Ser+1 position, along
with additional less stringent selection for particular
amino acids in other positions (Figure 6A). In contrast,
members of the AGC kinase superfamily such as Akt/
PKB and conventional protein kinase C superfamily
members preferentially phosphorylate sequences con-
taining Arg residues in both the Ser-5 and Ser-3 posi-
tions, and play important roles in antlapoptotic signaling
and other signaling events unique to differentiated cell
function, rather than critical roles in cell cycle control.
To investigate the structural basis for substrate motif
selection, we performed molecular modeling studies of
activated MAPKAP kinase-2, using the published MAP-
KAP kinase-2:ADP cocrystal structure (Underwood et
al., 2003) as a base model. The optimal substrate peptide
Leu-GIn-Arg-Gln-Leu-Ser-lle-Ala was modeled into the
kinase active site in an extended confrmation (Figure
6D), and the kinase:substrate complex compared with
the structures of Akt/PKB:AMP-PNP:GSK3-peptide ter-
nary complex (Yang et al., 2002) (Figure 6C) and the
Chkl crystal structure containing a modeled Cdc25C
peptide (Chen et al., 2000) (Figure 6E). Strong selection
for Arg in the Ser-3 position for MAPKAP kinase-2, Akt/
PKB, and Chkl is rationalized by the presence of a
conserved glutamate residue at a similar location in all
three kinases (Glu145 in MAPKAP kinase-2, Glu236 in
Akt/PKB, and Glu91 in Chkl), which in Akt/PKB forms a
bidentate salt bridge with the Ser-3 arginine guanidino
group on GSK3 peptide (Yang et al., 2002). Similarly,
selection for a hydrophobic residue at the Ser+1 posi-
tion is explained by a hydrophobic pocket that is con-
served at this position in all three kinases. The pocket
is lined by Phe310, Pro314, Leu317, and Phe359 in Akt/
PKB and by Met167, Leul71, Val174, Leu178, and
Leu179 in Chkl. The corresponding Ser+1 pocket in
MAPKAP kinase-2 is lined by Pro223, Pro227, Val234,
and Leu235. Within this region, Gly312 in Akt/PKB and
Gly169 in Chkl are replaced by Tyr225 in MAPKAP ki-
nase-2, which may reduce the depth of the MAPKAP
kinase-2 hydrophobic pocket and explain selection for
branched chain aliphatic residues in this position com-
pared with Phe selection by Akt/PKB and Chkl.
The marked contrast between Arg selection at the
Ser-5 position in Akt/PKB with the corresponding se-
lection for hydrophobic residues at this position by
MAPKAP kinase-2 and Chkl is accounted for by the
presence of Glu342 in Akt/PKB at the base of the Ser-5
pocket. This residue is not conserved in MAPKAP ki-
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nase-2 and Chkl and is instead substituted by le255
in MAPKAP kinase-2 and by Ala200 in Chkl. Additional
residues, notably Phel47, Pro189, Pro261, and Leu342
in MAPKAP kinase-2 and, similarly, Phe93, 1e96, Pro98,
Pro133, and Leu206 in Chkl, contribute a significant
hydrophobic character to this region.
Discussion
In this study we have defined the optimal substrate mo-
tifs within the p38 SAPK/MAPKAP kinase-2 axis of sig-
naling using oriented peptide library screening. Our
elucidation of the optimal phosphorylation motif for
MAPKAP kinase-2 expands considerably upon, and is
in good agreement with, a more preliminary motif for
this kinase determined previously (Stokoe et al., 1993).
Similarly, the optimal motif determined for p38 SAPK is
in reasonable agreement with many mapped phosphor-
ylation sites on p38 SAPK substrates. As with all consen-
sus phosphorylation motifs, bona fide substrates match
the optimal motif at some, but not necessarily at all,
positions. Nearly all in vivo p38 MAPK substrates con-
tain at least a minimum core SP motif, though Cohen
and colleagues have recently identified TAB1 as a novel
in vivo substrate of p38 SAPK in which one of the three
mapped p38 SAPK phosphorylation sites lacks the
Ser+1 Pro residue. This suggests that alternative phos-
phorylation and docking motifs may be present on some
p38 SAPK substrates, and/or that local avidity effects
may be important in some cases.
Our data suggests that a crucial role of p38 SAPK in
response to UV-induced DNA damage is the phosphory-
lation and activation of MAPKAP kinase-2, leading to
MAPKAP kinase-2-directed phosphorylation of Cdc25
family members to induce 14-3-3 binding and subse-
quent cell cycle arrest. In this way, MAPKAP kinase-2
performs similar functions after UV-C induced DNA
damage as those performed by Chkl and Chk2 after
exposure of cells to ionizing radiation (Bartek and Lukas,
2003). Recent data suggest that p38 SAPK (and there-
fore MAPKAP kinase-2) may play a similar role in certain
types of chemotherapy-induced DNA damage (Hirose
et al., 2003, 2004; Mikhaliov et al., 2004).
Our finding that MAPKAP kinase-2 is a central check-
point kinase involved in DNA damage responses trig-
gered by UV irradiation allows a different interpretation
of the results of Bulavin et al. (2001), who demonstrated
that inhibition of p38 SAPK by the chemical inhibitor
SB202190, or reduction of p38 SAPK levels using anti-
sense oligonucleotides, blocked the GM checkpoint
response in cells that received the same dose of UV-C
radiation as the cells used in our study. The authors
reported that p38 SAPK directly phosphorylated
Cdc25B and C to generate a 14-3-3 binding site. How-
ever, the experiments in that study were performed us-
ing Flag-tagged p38 SAPK that was immunoprecipitated
from UV-irradiated cells. p38 SAPK and MAPKAP ki-
nase-2 form a tight complex within cells, and in response
to cellular stress, p38 SAPK phosphorylation of MAP-
KAP kinase-2 is required for the cotransport of the p38
SAPK:MAPKAP kinase-2 complex from the nucleus to
the cytoplasm (Ben-Levy et al., 1998; Kotlyarov et al.,
2002). Thus, the p38 SAPK immunoprecipitates used in
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Figure 7. A Unified Model of the Kinase-Dependent DNA Damage
Checkpoint
Parallel pathways in the DNA damage checkpoint signal transduc-
tion network converge on common substrates by signaling to down-
stream kinases with similar phosphorylation motif specificities. +
indicates hydrophobic residues. The dashed line from Chkl to
Cdc25B/C indicates that this phosphorylation event remains contro-
versial in response to Ionizing radiation.
that study likely contained significant amounts of MAP-
KAP kinase-2. Furthermore, the activity of MAPKAP ki-
nase-2 would have been strongly reduced by treatment
with any p38 SAPK inhibitor.
MAPKAP kinase-2 undergoes initial activation in the
nucleus with subsequent export of the active kinase to
the cytoplasm (Ben-Levy et al., 1998). Thus, MAPKAP
kinase-2 is well positioned to function as both a nuclear
initiator of Cdc25B/C phosphorylation in response to
DNA damage and as a maintenance kinase that keeps
Cdc25B/C inhibited in the cytoplasm. A unified model
for kinase-dependent DNA damage checkpoints is pre-
sented in Figure 7. In response to ionizing radiation,
ATM activation of Chk2 and ATR activation of Chkl
leads to phosphorylation of Cdc25 family members on
related sequences corresponding to the checkpoint ki-
nase core "motif" LxRxx[S/TJ]. Similarly, in response
to UV-induced DNA damage, ATR activates Chkl and
p38 SAPK activates MAPKAP kinase-2, leading to phos-
phorylation of the same core motif on Cdc25 family
members. The exact role that different checkpoint ki-
nases play in phosphorylating different Cdc25 phospha-
tases remains incompletely understood. The major role
of Chkl appears to involve phosphorylation of Cdc25A
after IR (Busino et al., 2004 and references therein),
IR r , UV
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whereas Chk2 appears to phosphorylate all three Cdc25
family members. In the absence of Chk2, Chkl appears
to be able to subsume at least part of this function
(Bartek and Lukas, 2003). Our data now suggests that
MAPKAP kinase-2 is the primary effector kinase that
targets Cdc25B/C after UV-C exposure. MAPKAP ki-
nase-2 may also be involved in Cdc25A phosphorylation,
since we observed that the G1and S phase checkpoints
were eliminated in the MAPKAP kinase-2 knockdown
cells.
Given the convergence of optimal substrate motifs
for MAPKAP kinase-2, Chkl, and Chk2, the structural
similarity between the substrate binding cleft in Chkl
and MAPKAP kinase-2, and the functional overlap be-
tween these three kinases in response to DNA damage,
MAPKAP kinase-2 could equivalently be referred to as
'Chk3." Whether MAPKAP kinase-2 plays a similar criti-
cal checkpoint role in the cellular response to altered
chromatin topology and chemically induced DNA dam-
age as that described here in response to UV irradiation
is not known. However, recent reports that p38 MAPK
participates in checkpoint activation following Topo-
isomerase II inhibition, adriamycin-induced double-
strand breaks (Mikhailov et al., 2004), and temozolo-
mide-induced DNA damage mismatch repair (Hirose et
al., 2003) is consistent with such a model. Experiments
to test this are currently in progress. In summary, our
data implicate MAPKAP kinase-2 as a third checkpoint
kinase that functions in parallel with Chkl and Chk2 to
coordinately regulate the DNA damage response.
Experimental Procedures
Protein Production and Purification
Recombinant 14-3-3e/C-MBP (maltose binding protein), 14-3-30/
C-GST (glutathione S-transferase), and p47phox-GST proteins were
produced as described previously (Yaffe et al., 1997). A vector en-
coding Cdc25B2-GST was a gift from B. Gabrielli (University of
Queensland, Australia). Point mutations were generated using the
Stratagene QuickChange Mutagenesis Kit and confirmed by se-
quencing the entire coding regions.
Kinase Motif Screening with Oriented Peptide Ubrares
and In Vitro inase Assay
Combinatorial peptide library screening was performed using re-
combinant purified p38a SAPK, MK2, Chkl, and Chk2 as previously
described (Songyang and Cantley, 1996), with minor modifications.
Kinase reactions were performed in 30 id of kinase reaction buffer
(20 mM HEPES, pH 7.5, 10 mM MgCI2, 3 mM 2-mercaptoethanol,
100 ig/ml BSA, 50 pLM ATP, 10 ipCi P-y-ATP) containing 2.0 pg of
recombinant p47 or Cdc25B substrate protein or the specified
amount of peptide and 0.10 pg of recombinant p38a SAPK or 0.03
pg of recombinant MAPKAP kinase-2 at 30`C for the indicated time.
Additional details are provided in the Supplemental Data, which can
be found at http//www.moecule.org/cgVcontent/full 7/1/37/DC1/.
Tissue Culture and Transfections
U20S cells were maintained and propagated in DMEM supple-
mented with 10% fetal bovine serum (FBS), L-glutamine, and penicil-
lin/streptomycin. siRNA oigonucleotides corresponding to MAP-
KAP kinase-2 sense strand 5'-UGACCAUCACCGAGUUUAUdTdT-3'
and antisense strand 5'-AUAAACUCGGUGAUGGUCAdTdT-3' and
to GFP sense strand 5'-UCCCGGCUAUGUGCAGGAGdTdT-3' and
antisense strand 5'-CUCCUGCACAUAGCCGGGAdTdT-3' were
purchased from Dharmacon. sIRNAs were used according to the
manufacturer's uggested protocol and transfected into cells using
Lipofectamine 2000 (GIBCO Invitrogen).
14-3 Pull-Down Asays, mmunoblotting,
and Immunofluorcence
U20S cells were lysed In lysis buffer: 50 mM Tris/HCI, pH 7.8, 150
mM NaCI, 1.0% NP-40, 5 mM EDTA, 2 mM DTT, 8 pg/ml pepstatin,
8 pg/ml aprotinin, 8 g/ml leupeptin, 2 mM NaVO4, 10 mM NaF,
and 1 p.M microcystin for 20 min at 40C. Clarified lysates (0.5-2 mg
protein) were incubated with 20 ILI glutathione beads or amylose
beads containing 10-20 pIg 14-3-3-GST or 14-3-3-MBP, respec-
tively, for 120 min at 4C. Following washing, lysates and bead
bound proteins were analyzed by SDS-PAGE, followed by transfer
to PVDF membranes, and Immunoblotted with the Indicated anti-
bodies. For Immunofluorescence experiments, U20S cells were
seeded onto 18 mm' coverslips, irradiated or mock treated, fixed,
extracted, and immunostained as described previously (Clapperton
st al., 2004).
FACS Anlysis
UV rradiation was performed at 254 nm (UV-C) using a Stratalinker
2400 (Stratagene). U20S cells were fixed in 70% ethanol overnight
at -20°C, perneabilized with PBS containing 0.2% Triton X-100 for
20 min at 4C, blocked with 2% FBS in PBS, and incubated with 1 p9g
of anti-phospho-histone H3 per 10 cells for 60 min on ice. Following
washing, cells were incubated with FrTC-conjugated goat anti-rabbit
antibody (diluted 1:500) for 30 min on ice, washed, and resuspended
in PBS containing 50 pg/ml P for 20 min immediately prior to
FACS analysis.
For BrdU incorporation experiments, cells were incubated with
30 iLM BrdU for the indicated times, then fixed and permeabilized
as above. Cells were denatured In 2 N HCI for 20 min at room
temperature, neutralized with 0.1 M Na2B407 (pH 8.5), blocked with
2% FBS in PBS, and Incubated with a murine anti-BrdU antibody
for 60 min on ice. Following washing, cells were incubated with
FITC-conjugated goat anti-mouse antibodies and PI as above. Anal-
ysis was performed using a Becton Dickinson FACS machine with
CellQuest software.
Structural Modeling
Activated MAPKAP kinase-2 (phosphorylated on Thr222) was mod-
eled using the crystal structure of the ADP complex (Underwood et
al., 2003) with the activation loop (residues 213-241) deleted and
rebuilt using the corresponding region (residues 299-328) from the
structure of activated Akt/PKB in complex with AMP-PNP and
GSK3-peptide (Yang et al., 2002) as a template. An optimal peptide
(Leu-Gln-Arg-Gln-Leu-Ser-lle-Ala) w s modeled in the active site
based on the GSK3-peptide. A substrate peptide (Leu-Tyr-Arg-Ser-
Pro-Ser-Met-Pro-Leu, residues 211-219 of human Cdc25C) in the
Chkl active site was similarly modeled using the GSK3-peptide as
a template and manually adjusted to resemble the published model
(Chen et al., 2000). Structures were superimposed using ALIGN
(Cohen, 1997) and SUPERIMPOSE (Diederichs, 1995). Manual ad-
justments of the models were made using XFIT from the XtaMew
suite (McRee, 1999).
Supplemental data including additional data and detailed Experi-
mental Procedures used in this work are available online at http://
www.molecule.org/ogVcontent/fulV7/1/37/DC1/.
Acknowledgments
We thank Joe Budmann, Irma Alercon-Rangel, Timmy Ho, Drew
Lowery, and Duaa Mohammad fortechnical and editorial assistance,
and Steve Smerdon for helpful discussions. We apologize to authors
whose work we were unable to site due to space limitations. This
work was funded by a David Koch Graduate Student Fellowship to
I.A.M., a Jane Coffin Childs Memorial Fund postdoctoral fellowship
to D.L, and NIH grant GM60594 and a Burroughs-Wellcome Career
Development Award to M.B.Y.
Received: July 21, 2004
Revised: October 5, 2004
Accepted: October 27, 2004
Published: January 6, 2005
MAPKAP Kinase-2 Is a DNA Damage Checkpoint Kinase
47
References
Abraham, R.T. (2001). Cell cycle checkpoint signaling through the
ATM and ATR kinases. Genes Dev. 15, 2177-2196.
Bartek, J., and Lukas, J. (2003). Chkl and Chk2 kinases in check-
point control and cancer. Cancer Cell 3, 421-429.
Ben-Levy, R., Leighton, IA., Doze, Y.N., Attwood, P., Morrice, N.,
Marshall, C.J., and Cohen, P. (1995). Identification of novel phos-
phorylation sites required for activation of MAPKAP kinase-2. EMBO
J. 14, 5920-5930.
Ben-Levy, R., Hooper, S., Wilson, R., Paterson, H.F., and Marshall,
C.J. (1998). Nuclear export of the stress-activated protein kinase
p38 mediated by its substrate MAPKAP kinase-2. Curr. Biol. 8,1049-
1057.
Bulavin, D.V., Higashimoto, Y., Popoff, I.J., Gaarde, WA, Basrur,
V., Potapova, O., Appeila, E., and Fomace, A.J., Jr. (2001). Initiation
of a G2/M checkpoint after ultraviolet radiation requires p38 kinase.
Nature 411, 102-107.
Busino, L., Chiesa, M., Draetta, G.F., and Donzelli, M. (2004). Cdc25A
phosphatase: combinatorial phosphorylation, ubiquitylation and
proteolysis. Oncogene 23, 2050-2056.
Chen, P., Luo, C., Deng, Y., Ryan, K., Register, J., Margosiak, S.,
Tempczyk-Russell, A., Nguyen, B., Myers, P., Lundgren, K., et al.
(2000). The 1.7 A crystal structure of human cell cycle checkpoint
kinase Chkl: Implications for Chk1 regulation. Cell 100, 681-692.
Chen, M.S., Hurov, J., White, L.S., Woodford-Thomas, T., and Piw-
nica-Worms, H. (2001). Absence of apparent phenotype in mice
lacking Cdc25C protein phosphatase. Mol. Cell. Biol. 21, 3853-3861.
Cheng, T.J., and Lai, Y.K. (1998). Identification of mitogen-activated
protein kinase-activated protein kinase-2 as a vimentin kinase acti-
vated by okadaic acid in 9L rat brain tumor cells. J. Cell. Biochem.
71, 169-181.
Cheung, P.C., Campbell, D.G., Nebreda, AR., and Cohen, P. (2003).
Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha.
EMBO J. 22, 5793-5805.
Clapperton, J.A., Manke, I.A., Lowery, D.M., Ho, T., Haire, LF., Yaffe,
M.B., and Smerdon, S.J. (2004). Structure and mechanism of BRCA1
BRCT domain recognition of phosphorylated BACH1 with implica-
tions for cancer. Nat. Struct. Mel. Biol. 11, 512-518.
Cohen, G.E. (1997). ALIGN: a program to superimpose protein coor-
dinates, accounting for insertions and deletions. J. Appl. Crystallogr.
30, 1160-1161.
Dlederichs, K. (1995). Structural superposition of proteins with un-
known alignment and detection of topological similarity using a six-
dimensional search algorithm. Proteins 23, 187-195.
Donzelli, M., and Draetta, G.F. (2003). Regulating mammalian check-
points through Cdc25 inactivation. EMBO Rep. 4, 671-677.
El Benna, J., Faust, R.P., Johnson, J.L., and Babior, B.M. (1996).
Phosphorylation of the respiratory burst oxidase subunit p47phox
as determined by two-dimensional phosphopeptide mapping. Phos-
phorylation by protein kinase C, protein kinase A, and a mitogen-
activated protein kinase. J. Biol. Chem. 271, 6374-6378.
Ficarro, S.B., McCleland, M.L., Stukenberg, P.T., Burke, D.J., Ross,
M.M., Shabanowitz, J., Hunt, D.F., and White, F.M. (2002). Phospho-
proteome analysis by mass spectrometry and its application to Sac-
charomyces cerevisiae. Nat. Biotechnol. 20, 301-305.
Fumari, B., Rhind, N., and Russell, P. (1997). Cdc25 mitotic inducer
targeted by chkl DNA damage checkpoint kinase. Science 277,
1495-1497.
Galaktionov, K., Lee, A.K., Eckstein, J., Draetta, G., Meckler, J.,
Loda, M., and Beach, D. (1995). CDC25 phosphatases as potential
human oncogenes. Science 269, 1575-1577.
Gasparotto, D., Maestro, R., Piccinin, S., Vukosavljevic, T., Barzan,
L, Sulfaro, S., and Boiocchi, M. (1997). Overexpression of CDC25A
and CDC25B in head and neck cancers. Cancer Res. 57, 2366-2368.
Giles, N., Forrest, A., and Gabrielli, B. (2003). 14-3-3 acts as an
intramolecular bridge to regulate cdc25B localization and activity.
J. Biol. Chem. 278, 28580-28587.
Goldstone, S., Pavey, S., Forrest, A., Sinnamon, J., and Gabrielli, B.
(2001). Cdc25-dependent activation of cyclin A/cdk2 is blocked in
G2 phase arrested cells independently of ATWMATR. Onogene
20, 921-932.
Guo, Z., Kumagai, A., Wang, S.X., and Dunphy, W.G. (2000). Require-
ment for Atr in phosphorylation of Chkl and cell cycle regulation
in response to DNA replication blocks and UV-damaged DNA in
Xenopus egg extracts. Genes Dev. 14, 2745-2756.
Heidenreich, O., Neininger, A., Schratt, G., Zinck, R., Cahill, M.A.,
Engel, K., Kotyarov, A., Kraft, R., Kostka, S., Gaestel, M., et al.
(1999). MAPKAP kinase 2 phosphorylates erum response factor
in vitro and in vivo. J. Bioi. Chem. 274,14434-14443.
Hirose, Y., Katayama, M., Stokoe, D., Haas-Kogan, DA, Berger,
M.S., and Pieper, R.O. (2003). The p38 mitogen-activated protein
kinass pathway links the DNA mismatch repair system to the G2
checkpoint and to resistance to chemotherapeutic DNA-methylating
agents. Moi. Cell. Biol. 23, 8306-8315.
Hirose, Y., Katayama, M., Berger, M.S., and Pieper, R.O. (2004).
Cooperative function of Chki and p38 pathways in activating G2
arrest following exposure to temozolomide. J. Neurosurg. 100,
1060-1065.
Huang, C.K., Zhan, L, Ai, Y., and Jongstra, J. (1997). LSP1 is the
major substrate for mitogen-activated protein kinase-activated pro-
tein kinase 2 in human neutrophils. J. Biol. Chem. 272, 17-19.
Kotlyarov, A., Yannoni, Y., Fritz, S., Leass, K., Telliez, J.B., Pitman,
D., Lin, LL., and Gaestel, M. (2002). Distinct cellular functions of
MK2. Mel. Cell. Biol. 22, 4827-4835.
Kraulis, P.J. (1991). MOLSCRIPT: a program to produce both de-
tailed and schematic plots of protein structures. J. Appl. Crystaiiogr.
24, 946-950.
Kumagai, A., and Dunphy, W.G. (1999). Binding of 14-3-3 proteins
and nuclear export control the ntracellular ocalization of the mitotic
inducer Cdc25. Genes Dev. 13, 1067-1072.
Landry, J., Lambert, H., Zhou, M., Lavole, J.N., Hickey, E., Weber,
LA, and Anderson, C.W. (1992). Human HSP27 is phosphorylated
at serines 78 and 82 by heat shock and mitogen-activated kinases
that recognize the same amino acid motif as S6 kinase II. J. Biol.
Chem. 267, 794-803.
Maliand, N., Podtelejnikov, A.V., Groth, A., Mann, M., Bartek, J., and
Lukas, J. (2002). Reguiation of G(2)/M events by Cdc25A through
phosphorylation-dependent modulation of its stability. EMBO J.
21, 5911-5920.
McLaughlin, M.M., Kumar, S., McDonnell, P.C., Van Hom, S., Lee,
J.C., Livi, G.P., and Young, P.R. (1996). Identification of mitogen-
activated protein (MAP) kinase-activated protein kinase-3, a novel
substrate of CSBP p38 MAP kinase. J. Biol. Chem. 271, 8488-8492.
McRee, D.E. (1999). XtaiVew/Xfit: a versatile program for manipulat-
ing atomic coordinates and electron density. J. Struct. Biol. 125,
156-165.
Merritt, EA, and Murphy, M.E.P. (1994). Raster3D version 2.0. A
program for photorealistic molecular graphics. Acts Crystallogr. D
Bid. Crystallogr. 50, 869-873.
Mikhallov, A., Shinohara, M., and Rleder, C.L. (2004). Topoisomerase
II and histone deacetylase inhibitors delay the G2/M transition by
triggering the p38 MAPK checkpoint pathway. J. Ceill Biol. 166,
517-526.
Nicholls, A., Bharadwaj, R., and Honig, B. (1993). GRASP: graphical
representation and analysis of surface properties. Biophys. J. 64,
Al 66.
Nishikawa, K., Toker, A, Johannes, F.J., Songyang, Z., and Cantley,
L.C. (1997). Determination of the specific substrate sequence motifs
of protein kinase C isozymes. J. Biol. Chem. 272, 952-960.
Obata, T., Brown, G.E., and Yaffe, M.B. (2000). MAP kinase pathways
activated by stress: the p38 MAPK pathway. Crit. Care Med. 28,
N67-N77.
O'Neill, T., Giarratani, L, Chen, P., lyer, L, Lee, C.H., Boblak, M.,
Kanai, F., Zhou, B.B., Chung, J.H., and Rathbun, GA (2002). Deter-
mination of substrate motifs for human Chkl and hCdsl/Chk2 by the
oriented peptide library approach. J. Biol. Chem. 277,16102-16115.
Peng, C.Y., Graves, P.R., Thoma, R.S., Wu, Z., Shaw, A.S., and
Molecular Cell
48
Piwnica-Worms, H. (1997). Mitotic and G2 checkpoint control: regu-
lation of 14-3-3 protein binding by phosphorylation of Cdc25C on
serine-216. Science 277,1501-1505.
Raingeaud, J., Gupta, S., Rogers, J.S., Dickens, M., Han, J., Ulevitch,
R.J., and Davis, R.J. (1995). Pro-inflammatory cytokines and environ-
mental stress cause p38 mitogen-activated protein kinase activation
by dual phosphorylation on tyrosine and threonine. J. Biol. Chem.
270, 7420-7426.
Rouse, J., Cohen, P., Trigon, S., Morange, M., Aionso-LUamazares,
A., Zamanillo, D., Hunt, T., and Nebreda, A.R. (1994). A novel kinase
cascade triggered by stress and heat shock that stimulates MAP-
KAP kinase-2 and phosphorylation of the small heat shock proteins.
Cell 78, 1027-1037.
Roux, P.P., and Blenis, J. (2004). ERK and p38 MAPK-activated
protein kinases: a family of protein kinases with diverse biological
functions. Microbiol. Mol. Biol. Rev. 68, 320-344.
She, .B., Ma, W.Y., and Dong, Z. (2002). Role of MAP kinases
in UVB-induced phosphorylation of p53 at serine 20. Oncogene
21, 1580-1589.
Songyang, Z., and Cantley, L.C. (1998). The use of peptide library
for the determination of kinase peptide substrates. Methods Mol.
Biol. 87, 87-98.
Stokes, M.P., and Michael, W.M. (2003). DNA damage-induced repli-
cation arrest in Xenopus egg extracts. J. Cell Bol. 163, 245-255.
Stokoe, D., Campbell, D.G., Nakielny, S., Hidaka, H., Leevers, S.J.,
Marshall, C., and Cohen, P. (1992). MAPKAP kinase-2; a novel pro-
tein kinase activated by mitogen-activated protein kinase. EMBO J.
11, 3985-3994.
Stokoe, D., Caudwell, B., Cohen, P.T., and Cohen, P. (1993). The
substrate specificity and structure of mitogen-activated protein
(MAP) kinase-activated protein kinase-2. Blochem. J. 296, 843-849.
Tanoue, T., and Nishida, E. (2003). Molecular recognitions in the
MAP kinase cascades. Cell. Signal. 15, 455-462.
Tanous, T., Adachi, M., Moriguchi, T., and Nishida, E. (2000). A
conserved docking motif in MAP kinases common to substrates,
activators and regulators. Nat. Cell Blol. 2, 110-116.
Underwood, K.W., Parris, K.D., Federico, E., Mosyak, L, Czerwinski,
R.M., Shane, T., Taylor, M., Svenson, K., Uu, Y., Halao, C.L., et al.
(2003). Catalytically active MAP KAP kinase 2 structures in complex
with staurosporine and ADP reveal differences with the autoinhibited
enzyme. Structure (Camb) 11, 627-36.
Wang, X.Z., and Ron, D. (1996). Stress-induced phosphorylation and
activation of the transcription factor CHOP (GADD1 53) by p38 MAP
Kinase. Science 272, 1347-1349.
Werz, O., Szellas, D., Steinhilber, D., and Radmark, 0. (2002). Arachi-
donic acid promotes phosphorylation of 5-lipoxygenase at Ser-271
by MAPK-activated protein kinase 2 (MK2). J. Biol. Chem. 277,
14793-14800.
Yaffe, M.B., Rittinger, K., Volinia, S., Caron, P.R., Aitken, A., Leffers,
H., Gamblin, S.J., Smerdon, S.J., and Cantley, L.C. (1 997). The struc-
tural basis for 14-3-3:phosphopeptide binding specificity. Cell 91,
961-971.
Yaffe, M.B., Leparc, G.G., Lai, J., Obata, T., Volinia, S., and Cantley,
LC. (2001). A motif-based profile scanning approach for genome-
wide prediction of signaling pathways. Nat. Biotechnol. 19, 348-353.
Yang, S.H., Galanis, A., and Sharrocks, A.D. (1999). Targeting of p38
mitogen-activated protein kinases to MEF2 transcription factors.
Mol. Cell. Biol. 19, 4028-4038.
Yang, J., Cron, P., Good, V.M., Thompson, V., Hemmings, BA,
and Barford, D. (2002). Crystal structure of an activated Akt/proteln
kinase B temary complex with GSK3-peptide and AMP-PNP. Nat.
Struct. Biol. 9, 940-944.
Zhao, H., Watkins, J.L., and Piwnica-Worms, H. (2002). Disruption of
the checkpoint kinase 1/cell divsion cycle 25A pathway abrogates
ionizing radiation-induced S and G2 checkpoints. Proc. Nati. Acad.
Si. USA 99, 14795-14800.
Zhou, B.B., and Elledge, S.J. (2000). The DNA damage response:
putting checkpoints in perspective. Nature 408, 433-439.
ARTICLES
nature
structural &
molecularbiology
Structure and mechanism of BRCA1 BRCT domain
recognition of phosphorylated BACH 1 with implications
for cancer
Julie A Clappertonl, 3 , Isaac A Manke 2 ,3, Drew M Lowery2 , Timmy Ho2 , Lesley F Haire', Michael B Yaffe2 &
Stephen J Smerdon'
Germline mutations in the BRCA 1 tumor suppressor gene often result in a significant increase in susceptibility to breast and
ovarian cancers. Although the molecular basis of their effects remains largely obscure, many mutations are known to target the
highly conserved C-terminal BRCT repeats that function as a phosphoserine/phosphothreonine-binding module. We report the
X-ray crystal structure at a resolution of 1.85 A of the BRCA1 tandem BRCT domains in complex with a phosphorylated peptide
representing the minimal interacting region of the DEAH-box helicase BACH1. The structure reveals the determinants of this
novel class of BRCA1 binding events. We show that a subset of disease-linked mutations act through specific disruption of
phospho-dependent BRCA1 interactions rather than through gross structural perturbation of the tandem BRCT domains.
The breast cancer susceptibility gene product, BRCA1, has important
roles in cell cycle control, transcriptional regulation, chromatin
remodeling and the response to DNA damage'". BRCA1 is a large,
modular protein of 1,863 residues containing an N-terminal RING
domain, a central region rich in SQ and TQ dipeptide pairs and tan-
dem BRCT (BRCA1 C-terminal) domains. BRCA1 interacts with
many protein partners at different stages of the cell cycle, or after geno-
toxic stress. For example, BRCA1 interacts with the DNA helicase
BACH 1 during S and G2 phases in normally cycling cells5 '6, whereas
BRCA1 interacts with a subset of ATM and ATR substrates in response
to DNA damage7. In both S phase and irradiated or mutagen-treated
cells, BRCA1 localizes to distinct nuclear foci thought to represent sites
of DNA damage8,9 where BRCA1 is thought to function, at least in
part, as a scaffold for the assembly of DNA repair complexes.
Mutations in BRCA1 occur in 50% of women with inherited breast
cancer and up to 90% of women with combined breast and ovarian
cancer""' 3. Most frameshift and deletion mutants truncate all or part
of the BRCT repeats, whereas >70 missense mutations lie within the
BRCT domains themselves (http://research.nhgri.nih.gov/projects/
bic/). BRCT domains are c structures that occur singly or as
multiple repeats in several proteins in addition to BRCA1 that are
involved in cell cycle regulation and DNA damage responses' 4 15 .
Composed of 80-100 amino acids, BRCT domains are generally
thought to function as protein-protein recognition modules'5. The
molecular basis of BRCT function, and how cancer-causing mutations
in the BRCA1 BRCT domains act at the structural level, however,
remain unresolved, despite considerable structural, biochemical and
mutagenic analysis'l5' 7-20. It has been suggested that mutational
effects are manifested through structural destabilization; however,
several mutations are located on the protein surface, indicating that
they may specifically affect BRCT interactions with other BRCA1-
associated targets.
We recently discovered that a subset of tandem BRCT domains,
including those of BRCA1, function as phosphoserine/phosphothreo-
nine (pSer/pThr)-binding modules, suggesting that some BRCT-
mediated interactions with proteins involved in DNA damage and cell
cycle control are regulated by protein phosphorylation7. Oriented
peptide library screening of tandem BRCT domains revealed phospho-
dependent binding specificity extending from the pSer/pThr(+ ) to the
pSer/pThr(+5) position, with particularly strong selection for aromatic
or aromatic/aliphatic residues in the pSer/pThr(+3) position7 " 6. High-
affinity phosphopeptides selected by in vitro-oriented library screens
blocked the interaction of the tandem BRCT domains of BRCA1 and the
transcriptional regulator PTIP with ATM- and ATR-phosphorylated
substrates 7 . Similar findings were reported in a study6 demonstrating
that the BRCT domain repeat mediates interaction with the DEAH-box
helicase BACH 1 through a specific phosphoserine (pSer990) located in
a region (residues 888-1063) previously shown to be sufficient for
BRCA1-BACH1 binding5'6. The tumor suppressor function of BRCA1
may directly depend on this interaction as its disruption is sufficient to
abrogate the G2-M checkpoint after DNA damage 6 6 .
To determine the structural basis for phosphopeptide binding and
phosphopeptide-motif selection, and to investigate alternative struc-
tural mechanisms underlying BRCT mutations and cancer predisposi-
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Figure 1 Structure of the tandem BRCT domain-BACH1 phosphopeptide complex. (a) Ribbc
representation of the tandem BRCT domains in complex with the pSer-containing BACH 1 pe
(yellow stick representation). The BACH 1 phosphopeptide binds at the interface between the
BRCT repeats. The secondary-structure elements in BRCT2 are labeled with primes to diffen
them from the secondary-structure elements in BRCT1. The BRCT interdomain linker is gree
the 3 10-helix are not labeled. (b) Electron density map (2F o- F,) covering the BACH 1 phosp
tion, we solved the high-resolution X-ray crystal structure of the tan-
dem BRCT repeats bound to a BACHI phosphopeptide. We provide
here a molecular rationale for phosphospecific binding, and show that
a set of cancer-associated BRCT mutations eliminate phosphopeptide
binding in vitro and BACHI phosphoprotein binding in vivo, or alter
the phosphopeptide recognition motif for the tandem BRCT domains,
revealing a structural basis for mutation-associated loss of BRCA1
function.
RESULTS
Structure of the BRCA1 BRCT-BACH1 complex
The tandem BRCT domains bound to the interacting phosphopeptide
from BACH1 (residues 986-995) was crystallized and its structure
solved at a resolution of 1.85 A by X-ray diffraction (Fig. 1). Phases
were determined by molecular replacement using the previously
determined structure of the unliganded tandem BRCT domains (PDB
entry IJNX) as a search model' 7 (see Table 1 and Methods). Difference
Fourier maps revealed well-defined electron density for the phospho-
peptide, allowing modeling of eight residues corresponding to BACH 1
Ser988-Lys995. Each BRCT repeat forms a compact domain (Fig. la)
in which a central, four-stranded P-sheet is packed against two
a-helices, al and a3, on one side and a single a-helix, a2, on the
other. The two domains pack together through interaction between a2
of BRCT1 and the al'-a3' pair of BRCT2. A linker region connecting
the two BRCT domains contains a B-hairpin-like structure, 3L, and a
short helical region, aL, which forms part of the interface through
interactions with a2 of BRCT1 and the N-terminal end of a3' from
BRCT2. Overall, the structure of the tandem BRCT domain-
phosphopeptide complex is similar to that of the unliganded domains
(r.m.s. deviation -0.4 A for all Ca atoms). However, superposition of
the individual BRCT repeats reveals that phosphopeptide binding is
associated with a slight relative rotation of each BRCT domain and a
translation of BRCT1 helix al toward the cleft between the domains.
The BACH1 phosphopeptide binds in an
extended conformation to a groove located at
mso the highly conserved interface between the
N- and C-terminal BRCT domains (Figs. la
and 2a), consistent with the requirement of
both domains for efficient phosphopeptide
binding7"16. This mode of binding is distinct
from that observed in the phospho-
independent interaction between p53 and the
tandem BRCT domains of 53BP-I, which
Phe993 occurs primarily through the linker
region21' 22. Our structure clearly shows that
the phospho-dependent interactions that are
necessary and sufficient for formation of the
BACH l-BRCA1 complex occur on the oppo-
site side of the BRCT-BRCT interface from
those involved in the interaction between p53
and 53BP- 1.
BRCT-phosphopeptide specificity
ons The binding of tandem BRCT domains to
ptide library-selected peptides in vitro7 16 and to
two phosphorylated BACH 1 in vivo6 is dominated
entiate
n. Areas of by the presence of a pSer/pThr and a phenyl-
alanine three residues C-terminal to it
(Phe(+3)). This is confirmed by our struc-
ture, which shows that the BACH I1 pSer990
phosphate moiety binds to a basic pocket
through three direct hydrogen-bonding interactions involving the side
chains of Ser1655 and Lysl702, and the main chain NH of GlyI656
(Fig. 3a). All three of these residues are located in BRCTI and all are
absolutely conserved in BRCA1 homologs. Ser1655 and Gly1656 are
situated within the loop preceding al and are brought near to the
phosphate moiety as a result of the conformational change that occurs
upon phosphopeptide binding. Notably, a S1655F mutation has been
identified in a single breast cancer patient, although its link to disease
has not been confirmed. In addition to these direct interactions, the
phosphate and some peptide main chain atoms are also tethered
through networks of water molecules, many of which are tetrahedrally
hydrogen-bonded (Fig. 3a). Indirect protein-solvent-phosphate con-
tacts are unusual in phospho-dependent protein-protein interactions
but have been observed previously in structures of phosphopeptide
complexes of the human Plkl Polo-box domain2 3'2 4.
The Phe(+3) peptide side chain fits into a hydrophobic pocket at the
BRCT interface consisting of the side chains of Phe1704, Met1775 and
Leu1839 from both BRCT domains (Figs. 3a and 4a). This finding
rationalizes the strong selection for aromatic amino acids in the +3
position of the binding motif seen in peptide library experiments716 ,
as well as the observation that a BACHI F993A mutation eliminates
BRCA1-BACHL binding6. Additional hydrogen bonds with the main
chain N and O atoms of Phe(+3) are supplied by main and side chain
atoms from Arg1699, a site of mutation also associated with cancer
predisposition. The phosphorylated Ser990 of BACH 1 is preceded by
an arginine in the -3 position and followed by a proline in the + 1 posi-
tion, suggesting potential Ser990 phosphorylation by either basophilic
and/or proline-directed kinases. The tandem BRCT domains are also
known to interact with pSQ-containing motifs characteristic of PI
3-kinase-like kinases such as ATM and ATR7. In the tandem
BRCT-BACH1 phosphopeptide cocrystal structure, there are no
direct interactions between the Pro(+1) side chain and the
BRCT domains. Instead, this residue participates in only a single
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water-mediated hydrogen bond involving its carbonyl oxygen
(Fig. 3a), consistent with the idea that various types of protein kinases
can generate tandem BRCT phospho-binding motifs. The Lys(+5) side
chain makes two salt-bridging interactions with residues in BRCT2
(Fig. 3a), consistent with the lysine selection observed in this position
by spot blot and peptide library experiments7"16.
Cancer-associated BRCT mutations
Residues that form or stabilize the phosphopeptide-binding surface
and the domain-domain interface are among the most highly con-
° served portions of the molecule in BRCA1 orthologs from humans,
E primates, rats and mice (Fig. 2b). Notably, these regions correlate
t strongly with the location of cancer-associated mutations (Fig. 2a).
Some cancer-associated mutations may disrupt the global BRCT fold
whereas others are more likely to specifically interfere with ligand bind-
ing15"' 8 2 1. About 80 tumor-derived mutations have been identified in
the tandem BRCT domains, though only a few of these have been sub-
L sequently confirmed to result in cancer predisposition, includingi D1692Y, C1697R, R1699W, A1708E, S1715R, G1738E, P1749R,
· M1775R, 53821nsC (a frameshift mutation that results in a stop codon
at position 1829) and Y1853X (which truncates the C-terminal 11
residues). Most of these cluster at or near the phosphopeptide-
f interacting surface (Fig. 2a). Two of these mutated residues, Argl699
and Met1775, directly interact with residues in the phosphopeptide0.
Z (Fig. 3a). Two others, Pro1749 and Gly1738, are located at the BRCTI-
BRCT2 interface beneath the molecular surface and their effects are
L probably mediated through alterations in the relative orientation of the
._ tandem BRCT motifs that our structure suggests are necessary for
. phospho-dependent interactions with partner proteins.
To verify the phosphoserine phosphate interactions observed in the
L X-ray structure and to investigate the effects of the most common
tumor-derived point mutations, we investigated the binding of a panel
% of site-directed mutant tandem BRCT domains to the interacting
Z region of BACH1. We determined binding by measuring the ability of
in vitro-transcribed and translated proteins to bind to either phospho-
eJ rylated or nonphosphorylated biotinylated peptides (Fig. 3b). Wild-
type tandem BRCT domains clearly bound to phosphorylated but not
nonphosphorylated peptides, whereas mutation of the conserved
Ser1655 and Lysl702, alone or in combination, completely abolished
the interaction. Five genuine cancer-linked mutations, P1749R,
G1738E, M1775R, Y1853X and 5382InsC, all resulted in complete loss
of phosphopeptide binding. The R1699W mutation is cancer-linked
and a second mutation, R1699Q, has been detected in breast cancer
patients but has not yet been directly correlated to disease predisposi-
tion. We surmised that the glutamine side chain might still participate
in main chain hydrogen bonding to the peptide; this was, indeed, the
only tandem BRCT domain mutant that retained a small degree of
binding in our assays. Notably, the R1699Q mutant largely lost
phospho-specificity, and instead bound to both phosphorylated and
nonphosphorylated peptides.
To investigate the in vivo binding to endogenous BACH1 of tan-
dem BRCT domains with cancer-predisposing mutations, we trans-
fected U2OS cells with a vector encoding the C-terminal 550 amino
acids of BRCA1 containing a myc tag and an SV40 nuclear localiza-
tion sequence as described25. Interaction between the wild-type tan-
dem BRCT domains and full-length BACH1 was easily detected
(Fig. 3c). In contrast, no in vivo interaction was observed between
BACH I and mutant tandem BRCT domains that disrupt phosphate
binding or cause predisposition to breast and ovarian cancer. All of
these cancer-associated mutant proteins were expressed at compara-
ble levels when transfected into mammalian cells26 (Fig. 3c),
a M1775R S1655F
.S1 715R
/ R1699Q I
Y1853X C1697R
b
Back
Figure 2 BRCT cancer-linked mutations and sequence conservation in
relation to the BACH1 phosphopeptide-binding site. (a) Molecular surface
representation of tandem BRCT domains. Cancer-associated mutations
S1655F, D1692Y, C1697R, R1699Q, S1715R, M1775R and Y1853X
cluster near the phosphopeptide-binding site. BRCT1 is blue, BRCT2 is gray,
and the mutations are red, except for S1655F, which is green, as its cancer
predisposition has not been confirmed by pedigree analysis. (b) Comparison
of the front and back views of the molecular surface showing the clustering
of residues (pink) conserved in human, chimp, mouse, rat, chicken and
Xenopus laevis BRCA1 tandem BRCT domains. The BACH1 peptide binds
in a conserved phosphopeptide-binding roove.
suggesting that gross structural destabilization is unlikely to account
for their cancer proclivity.
Interpretation of the structural effects of the M1775R mutation is
simplified because the X-ray crystal structure of the M 1775R tandem
BRCT domain mutant has been determined (PDB entry IN50)' 8 ,
revealing a nearly identical structure to that of the wild-type protein
with an average r.m.s. deviation of 0.35 A for all Ca atoms.
Superposition of the mutant structure with that of our BACHI com-
plex shows that the guanidine portion of the substituent arginine side
chain extrudes into the tandem BRCT cleft, where it occupies the
binding site for the essential Phe(+3) of the phosphopeptide
(Fig. 4a,b). In this case, loss of phosphopeptide binding in vitro and
BACH1 binding in vivo seem to be attributable to the severe steric
clash of the Arg1775 side chain with an important determinant of
phospholigand specificity and affinity. The M1775R mutant protein
does, however, bind weakly to a BACHI phosphopeptide in which
Phe(+3) is mutated to aspartate or glutamate (Fig. 4c). This is consis-
tent with the introduction of a basic residue at the pSer(+3)-binding
site and with the observation that this mutation creates new anion-
binding sites in the M1775R crystal structure 8 . Thus, in addition to
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Figure 3 Functional effects of tandem BRCT domain mutations. (a) Schematic representation of protein-peptide contacts between tandem BRCT domains
and the BACH 1 phosphopeptide. Dashed lines, hydrogen bonds; pink crescents, van der Waals interactions; green circles, water molecules. (b) The wild-type
and mutant myc-tagged tandem BRCT domain constructs containing the indicated mutations were analyzed for binding to a bead-immobilized optimal
tandem BRCT domain-interacting phosphopeptide, YDIpSQVFPF, or its nonphosphorylated counterpart. The weak phospho-independent binding of the
R1699Q mutant was observed using ten-fold more sample input than was used in the other lanes. (c) U20S cells transfected with wild-type and mutant
myc-tagged tandem BRCT domain constructs were analyzed for association with endogenous BACH 1.
disrupting the native BRCA I-BACH1 interaction, this mutation may
also result in the formation of inappropriate BRCT interactions.
. Phosphopeptide binding and nuclear foci formation
Subcellular localization and nuclear foci formation by wild-type, phos-
w phopeptide-binding mutant S1655A K1702M, and cancer-associated
Z mutant M1775R BRCT domains were studied before and after DNA
a damage in unsynchronized U20S cells (Fig. 5). To maximize visualiza-
c tion of nuclear foci, the cells were permeabilized with buffers contain-
§ ing 0.5% (v/v) Triton X-100 before fixation and immunostaining2 7. In
unextracted cells, the wild-type BRCT domains and both of the mutant
o Extraction of the unirradiated cells before fixation caused almost com-
plete loss of BRCT domain staining in all cases (Fig. 5a). Under these
conditions, <5% of the wild-type and M1775R tandem BRCT-
containing cells exhibited five or more nuclear foci, and no foci were
observed with the S1655A K1702M double mutant. When the cells were
irradiated with 10 Gy of y-irradiation, and permeabilized, fixed and
stained 2 h later, nearly all of the cells containing the wild-type tandem
BRCT domains demonstrated sharp punctate nuclear foci that largely
colocalized with the staining pattern of an antibody against the
pSer/pThr-Gln epitope that recognizes ATM- and ATR-phosphorylated
substrates (Fig. 5b). In contrast, the S1655A K1702M mutant showed
only faint staining with a very fine granular pattern that completely
failed to colocalize with pSer/pThr-Gln staining. This failure of foci for-
mation and pSer/pThr-Gln colocalization is strong evidence that the
phospho-binding function of the tandem BRCT domains is critical for
normal subcellular localization after DNA damage. The M1775R
mutant protein that binds wealdy to phosphopeptides with a different
specificity than the wild-type BRCT domains also formed punctate
nuclear foci, although these were slightly reduced in number and
showed less colocalization with pSer/pThr-Gln staining foci than the
Figure 4 The Phe(+3) position of the BACH1
phosphopeptide is essential for tandem BRCT
domain binding specificity. (a) Phe1704,
Metl775 and Leu1704 from tandem BRCT
domains form a hydrophobic pocket to
accommodate the Phe(+3) position of the
BACH1 phosphopeptide. (b) Superposition of
the crystal structure of the M1775R tandem
BRCT domain mutantl8 with the wild-type
BACH 1-phosphopeptide complex reveals that
this mutation occludes the BACH 1 Phe(+3)
position. (c) Wild-type (WT) tandem BRCT
domains and the M1775R mutant binding to a
BACH 1 phosphopeptide spot array. The M 1775R
mutant spot blot was carried out using ten times
the amount of protein and was exposed to film for
a substantially longer amount of time than the
wild-type protein.
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Figure 5 Localization of the BRCT domains to nuclear phosphoproteins. (a) Localization of wild-type, M1775R or K1702M S1655A mutants of myc-tagged
tandem BRCT domains in unirradiated U20S cells before (left panels) or after (right panels) extraction using Triton X-100-containing buffers. Bars, 25 pm.
(b) Localization after Triton X-100 extraction as in a at 2 h after exposure of cells to 10 Gy of y-radiation. Extracted cells were also stained using an anti-
pSer/pThr-Gln epitope that recognizes the phosphorylation motif generated by the DNA damage-response kinases ATM and ATR. Bars, 10 pm.
wild-type protein. This localization might result from synergistic weak
binding to alternative nonoptimal phosphorylated ligands present in
high abundance in nuclear foci after DNA damage, as has been
observed for other phosphopeptide-binding domain interactions28.
DISCUSSION
The structure of the tandem BRCAI BRCT domain-phosphopeptide
complex described here is the highest-resolution X-ray structure of any
BRCT domain structure solved to date, and provides an enhanced
structural framework for investigating the molecular basis of breast and
ovarian cancer. The structure reveals why tandem BRCT repeats, rather
than single BRCT domains, are required for binding to pSer/pThr-con-
taining phosphopeptides with high affinity and specificity; motif recog-
nition is mediated by residues contributed by both domains across the
domain-domain interface. In addition, the structure rationalizes the
observation that the BRCT domains do not bind to phosphotyrosine-
containing sequences7, as the phosphate recognition pocket seems too
shallow to accept a bulky phenyl ring. Despite the fact that not all tan-
dem BRCT domains seem to bind phosphopeptides, several residues
involved in the binding are relatively conserved. Structures of addi-
tional BRCT-phosphopeptide complexes will be necessary to better
understand negative determinants of binding.
The tandem BRCT-phosphopeptide structure, in combination with
biochemical and cell biological analysis, shows that some pro-
oncogenic mutations in the BRCA1 C-terminal domains directly dis-
rupt phosphopeptide binding or perturb the BRCT interface that forms
the phospho-dependent binding surface. Similar conclusions have been
reached in a study36 reporting the structure of the tandem BRCT
domains bound to an alternative phosphopeptide determined from ori-
ented peptide library screening7 , and the unliganded structures of the
M1775R and V1809F mutants in an accompanying paper in this issue36.
Like the BRCT domains in PTIP, the BRCT domains in BRCA1 are
sufficient for nuclear foci formation in response to DNA damage,
and the phospho-binding function seems to be involved in this
phenomenon. Four genuine cancer-linked mutations, P1749R,
G1738E, 5382InsC and Y1853X, all result in loss of phosphopeptide
binding. A fifth mutation, M 1775R, binds weakly to phosphopeptides
with altered motif specificity, and can still form nuclear foci after DNA
damage; however, it completely loses the ability to interact with wild-
type BACH1. These effects of the Pro1749 and Met1775 lesions con-
firm previous observations that these mutations are sufficient to
abrogate BRCA1-BACH1 interactions in vivo5. Because BACH1 muta-
tions are also associated with the development of cancer2 9, these find-
ings suggest that loss of this BRCA1-BACH1 interaction may be the
critical event responsible for cancer predisposition6 2 9.
Despite the fact that mutations in BRCA1 ultimately predispose
women to cancer, wild-type BRCAI paradoxically constitutes a target
for anticancer therapy. Given the importance of BRCAI in homo-
logous recombination and DNA repair4 3 - 32, disruption of the
phosphoserine-binding function would be expected to cause
enhanced sensitivity to chemotherapy and radiation2 6, as has been
observed in BRCAl-null murine embryonic stem cells31. The struc-
tural delineation of the phosphoserine-binding surface provides a new
target for rational drug design.
METHODS
Protein cloning, expression and purification. For crystallization experiments,
human BRCTs (residues 1646-1859) were expressed as glutathione
S-transferase (GST) fusions in pGEX-4TI (Amersham Pharmacia Biotech) in
Escherichia coli BL21 at 18 °C. The GST was removed by 48-h treatment with
thrombin before gel filtration. Synthetic peptides were prepared by W. Mawby
(University of Bristol). A BRCT clone (residues 1313-1863) in pcDNA3 con-
taining a N-terminal myc tag and a SV40 nuclear localization sequence was a
gift from R. Scully (Beth Israel Deaconess Medical Center) and D. Livingston
(Dana-Farber Cancer Institute)25 , and was used for the coimmunoprecipita-
tion and immunofluorescence assays. Mutations were generated using the
Stratagene QuikChange mutagenesis kit, and verified by sequencing. The
pGEX-BRCT clone (residues 1633-1863) has been described7 and was used for
the peptide filter array. Induction of recombinant GST-BRCT domain protein
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Table 1 Data collection and refinement statistics
Data collection
Resolution range (A)
Completeness (%)
Total observations
Unique reflections
Average I / a(l)
Rsym (%)a
l
o:5Ei2
L.UC0I0.
Refinement
Resolution (A)
No. of reflections (free)
Rwork (%)b
Rfe (%)b
No. of protein atoms
No. of water atoms
R.m.s. deviations
Bonds (A)
Angles (°)
15.0-1.85
93.9
165,151
19,219
35.6
5.4
15.0-1.85
18,225 (911)
20.6
22.2
1,750
157
0.01
1.35
aRsym = ¥1<!> - jl I 1<1> where Ij is the intensity of the th reflection and <> is the
average intensity. bR0, = hk1 IF - F1 hkI F, where Rfm is equivalent to Rw but is
calculated for a randomly chosen 5% of reflections omitted from the refinement process.
was done at 37 °C for 3 h in the presence of 0.4 mM IPTG. The GST-BRCT
domains were isolated from bacterial lysates using glutathione agarose, fol-
lowed by elution with 40 mM glutathione, 50 mM Tris-HCl, pH 8.1, and dialy-
c sis into 50 mM Tris-HCl, pH 8.1, 300 mM NaCl.
a
9 Crystallization and structure determination. Crystals were grown at 18 'C by
microbatch methods. The BACH1 phosphopeptide (SRST-pS990-PTFNK) was
.L mixed with the BRCTs in a 1.5:1 stoichiometric excess and concentrated to
0.35 mM in a buffer containing 50 mM Tris-HCI, pH 7.5, 0.4 M NaCI and
3 mM DTT. Crystals grew from 50 mM MES, pH 6.5, 0.1 M (NH4)2SO4 and
Z 13% (w/v) PEG 8K. Crystals belonged to the trigonal space group P3221
(a = b = 65.8 A, c = 93.1 A, a = = 90.0°, y = 120.0°) with one complex in the
° asymmetric unit. Data were collected from flash-cooled crystals at 100 K on a
o Raxis-lI detector mounted on a Rigaku RU200 generator. Diffraction data were
integrated and scaled using DENZO and SCALEPACK33. The structure was
solved by molecular replacement using the coordinates of PDB entry IJNX17 as
a model with AmoRe34. Subsequent refinement was carried out using
REFMAC5 (ref. 34) and manual model building in O35. Figures were
constructed using PyMOL (http://www.pymol.org).
Peptide binding. An optimal phosphopeptide for binding the BRCTs was deter-
mined by oriented peptide library screening as described7 . This peptide was
synthesized in both its phosphorylated and nonphosphorylated forms with a
biotin group at the N terminus using N-a-FMOC-protected amino acids and
standard BOP-HOBt coupling chemistry. These peptides were conjugated to
streptavidin-coated beads (Sigma-Aldrich). The wild-type and mutant BRCT
domain-containing constructs (residues 1313-1863) were transcribed and
translated in vitro in the presence of 3 5S]methionine using the TNT kit
(Promega). The bead-immobilized peptides (10 P! beads) were added to 10 !ld
of the in vitro-translated 35S-labeled protein pool in 150 1I binding buffer
(50 mM Tris-HCI, pH 7.6, 150 mM NaCI, 0.5% (v/v) NP-40, 1 mM EDTA,
2 mM DTT, 8 !ag ml-' pepstatin, 8 g ml-' aprotinin, 8 jig m11 leupeptin,
800 ILM Na3VO4, 25 mM NaF). After incubation at 4 °C for 3 h, the beads were
washed three times with 200 KIl binding buffer before analysis by SDS-PAGE
(12.5% (w/v)) and autoradiography.
Peptide filter array. An ABIMED peptide arrayer with a computer-controlled
Gilson diluter and liquid handling robot was used to synthesize peptides onto
an amino-PEG cellulose membrane using N-a-FMOC-protected amino acids
and DIC-HOBT coupling chemistry. The membranes were blocked in 5%
(w/v) milk in Tris-buffered saline containing 0.1% (v/v) Tween-20 (TBS-T) for
lh at room temperature, incubated with 0.025 M GST-BRCTs or 0.25 ILM
MI775RGST-BRCTs (residues 1633-1863) in 5% (w/v) milk, 50mM Tris-HCl,
pH 7.6, 150 mM NaCl, 2 mM EDTA, 2 mM DTT for 1 h at room temperature
and washed four times with TBS-T. The membranes were then incubated with
anti-GST-conjugated HRP (Amersham) in 5% (w/v) milk and TBS-T for I h at
room temperature, washed five times with TBS-T, and binding analyzed by
ECL (Perkin-Elmer).
Coimmunoprecipitation of BRCTs and BACH1. U20S cells were grown to
50% confluence in 100-cm2 dishes and transfected with the myc-tagged wild-
type or mutant BRCT constructs (residues 1313-1863) using FuGene6 trans-
fection reagent (Roche) according to manufacturer's protocol. Cells were
collected 30 h after transfection, lysed in lysis buffer (50 mM Tris-HCI, pH 7.6,
150 mM NaCI, 1.0% (v/v) NP-40, 5 mM EDTA, 2 mM DTT, 8 !xg ml-' AEBSF,
8 lxg ml' aprotinin, 8 ttg ml l1 leupeptin, 2 mM Na3VO4, 10 mM NaF and the
phosphatase inhibitors microcystin and okadaic acid). Lysates containing equal
amounts of protein (3 mg) were incubated with 3 td of a mouse anti-myc (Cell
Signaling) for 2 h at 4 °C, and then 10 !xl of protein G-Sepharose beads (Sigma-
Aldrich) were added and samples incubated for an additional 2 h at 4 °C. Beads
were washed four times with lysis buffer, and bound proteins were eluted in
SDS-PAGE sample buffer, analyzed on 6% (w/v) PAGE, transferred to PVDF
membrane, and detected by blotting with rabbit anti-BACHl (a gift from
D. Livingston). A portion of the lysates were also run and blotted with anti-
BACH1 and anti-myc to further ensure equal protein loading.
Immunofluorescence and microscopy. U20S cells were seeded onto 18-mm2
coverslips and transfected with the BRCT construct (residues 1313-1863) and
various mutants using FuGene6 transfection reagent (Roche) according to the
manufacturer's protocol. At 30 h after transfection, the cells were either treated
with 10 Gy ionizing radiation or mock-irradiated and allowed to recover for
120 min. Cells were fixed in 3% (v/v) paraformaldehyde and 2% (w/v) sucrose
for 15 min at room temperature and permeabilized with a 0.5% (v/v) Triton
X-100 solution containing 20 mM Tris-HCl, pH 7.8, 75 mM NaCI, 300 mM
sucrose, and 3 mM MgCI2 for 15 min at room temperature. When necessary,
proteins were extracted after IR treatment as described2 7 . In brief, cells were
incubated with extraction buffer (10 mM PIPES, pH 6.8, 100 mM NaCI,
300 mM sucrose, 3 mM MgCI2, 1 mM EGTA, 0.5% (v/v) Triton X-100) for
5 min on ice followed by incubation with extraction stripping buffer (10 mM
Tris-HCI, pH 7.4, 10 mM NaCI, 3 mM MgCI2 , 0.5% (v/v) Triton X-100) for
5 min on ice followed by successive washes in ice-cold PBS. Slides were fixed as
above, stained with primary antibodies at 37 °C for 20 min, then stained with a
anti-mouse or anti-rabbit secondary antibody for 20 min (Molecular Probes) at
37 °C. Primary antibodies used were mouse anti-myc (Cell Signaling) and rab-
bit anti-(pSer/pThr)Gln (Cell Signaling). Images were collected on a Axioplan2
microscope (Carl Zeiss) and processed using OpenLab (Improvision).
Coordinates. The atomic coordinates and structure factors have been deposited
in the Protein Data Bank (accession code IT1 5).
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Our results provide support for a role of
kin selection in favoring helping behavior
within cooperative vertebrates. Moreover, we
show that the importance of kin selection
varies across species, consistent with the pre-
dictions of Hamilton's rule (6). Specifically,
preferential helping of relatives is more com-
mon in species where helping provides a
greater benefit. It should be noted that our
results do not imply that the direct fitness
benefits of helping are unimportant or show
anything about the relative importance of di-
rect and indirect fitness benefits. Ideally, the
next step would be an equivalent study on the
effect size of direct fitness benefits.
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BRCT Repeats As
Phosphopeptide-Binding Modules
Involved in Protein Targeting
Isaac A. Manke, Drew M. Lowery,* Anhco Nguyen,* Michael B. Yaffet
We used a proteomic approach to identify phosphopeptide-binding modules
mediating signal transduction events in the DNA damage response pathway.
Using a library of partially degenerate phosphopeptides, we identified tandem
BRCT (BRCA1 carboxyl-terminal) domains in PTIP (Pax transactivation domain-
interacting protein) and in BRCA1 as phosphoserine- or phosphothreonine-
specific binding modules that recognize substrates phosphorylated by the ki-
nases ATM (ataxia telangiectasia-mutated) and ATR (ataxia telangiectasia- and
RAD3-related) in response to y-irradiation. PTIP tandem BRCT domains are
responsible for phosphorylation-dependent protein localization into 53BP1-
and phospho-H2AX (y-H2AX)-containing nuclear foci, a marker of DNA dam-
age. These findings provide a molecular basis for BRCT domain function in the
DNA damage response and may help to explain why the BRCA1 BRCT domain
mutation Met1 77 - Arg, which fails to bind phosphopeptides, predisposes
women to breast and ovarian cancer.
Signal transduction by protein kinases in eu-
karyotes results in the directed assembly of
multiprotein complexes at specific locations
within the cell (1). This process is particularly
evident after DNA damage, where activation
of DNA damage response kinases results in
the formation of protein-protein complexes at
discrete foci within the nucleus (2). In many
cases, protein kinases directly control the for-
mation of these multiprotein complexes by
generating specific phosphorylated-motif se-
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quences; modular binding domains then rec-
ognize these short phospho-motifs to mediate
protein-protein interactions (3, 4).
We used a proteomic screening approach
(5) to identify novel modular pSer- or pThr-
binding domains involved in the DNA damage
response. In cells exposed to y-irradiation, the
kinases ATM and ATR phosphorylate tran-
scription factors, DNA repair proteins, protein
kinases, and scaffolds on Ser-Gln and Thr-Gln
motifs (6). We therefore constructed an orient-
ed phosphopeptide library biased to resemble
the motif generated by ATM and ATR (7, 8)
(Fig. IA). This library and its nonphosphoryl-
ated counterpart were immobilized and
screened against -96,000 in vitro translated
polypeptides (960 pools each containing - 100
transcripts) (Fig. A).
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Pool EE II contained the strongest phos-
phopeptide-binding clone, EEl 1-9, encoding the
C-terminal 70% of human PTIP (Fig. 1B). PTIP,
originally identified as a transcriptional regula-
tory protein, appears to also play a critical role in
the DNA damage response pathway (9-11). Hu-
man PTIP contains four BRCT domains, known
protein-protein interaction modules that are
present in many DNA damage response and cell
cycle checkpoint proteins (12). A construct con-
taining only the tandem third and fourth BRCT
domains displayed strong and specific binding to
the (pSer/pThr)-Gln library (Fig. IB). Con-
A ATMIATR-mof library
vs. library screen
Pool
Piay
Waryy
ADN
structs of PTIP lacking both of these domains
either failed to bind or lacked phosphopeptide
discrimination. Moreover, neither the third nor
the fourth BRCT domain alone bound to phos-
phopeptides, which suggests that the tandem C-
terminal BRCT domains finction as a single
module that is necessary and sufficient for phos-
pho-specific binding.
BRCT domains are often found in tandem
pairs [(BRCT)2] or multiple copies of tandem
pairs, and the BRCAI (BRCT)2 domains be-
have as a single stable fragment in limited
proteolysis and x-ray crystallographic studies
Sib akcetk
of clone EEl
CF4 EE10 EE11 EE12
B
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(13). Like those of PTIP, the (BRCT)2 do-
mains of BRCA1, but not the individual
BRCT domains alone, displayed phospho-
specific binding (Fig. 2A). However, little if
any phospho-binding was seen for (BRCT) 2
modules from the human DNA damage-
response proteins 53BPI and MDC1, Sac-
charomyces cerevisiae Rad9p, or the PTIP
N-terminal pair, which suggests that the
phosphopeptide-binding function is present
in only a subset of (BRCT) 2 domains.
We used oriented peptide library screening to
determine the optimal phospho-binding motifs
on 10%
114 R"kkIes a Ric chrl m 0r2 Rcts mcT4 kWtAt IpdQ S Mw
..-f df 9~= aiiill _ -
-.... UI - ili -"
-.4, _ * -_ .
N-- m a -23
'l01 4 m 13
rTIP 367' 1- * .14
Fig. 1. Identification of pSer- or pThr-binding domains with an ATM/ATR-motif
library versus an expression library screen. (A) An oriented (pSer/pThr) phosphopeptide
library, biased toward the phosphorylation motifs of ATM and ATR, was immobi-
lized on Streptavidin beads. The library [pSQ = biotin-ZGZGGAXXXB(pS/
pT )QIXXXAKKK] and its nonphosphorylated counterpart (SQ) were screened against
in vitro translated, [35S]Met-labeled proteins. Notation code: (pS/pT), 50% pSer
and 50% pThr; Z, aminohexanoic acid; B, a biased mixture of the amino acids Ala (A), lie, Lys (K), Met, Asn, Pro, Ser, Thr, and Val; J, a biased
mixture of 25% Glu and 75% X, where X denotes all amino acids except Cys, His, Lys, and Arg (21); G, Gly; Q, Gin. In each panel, the first and
second lanes show binding of proteins within the pool to the phosphorylated (pSQ) and nonphosphorylated (SQ) libraries, respectively.
Identification of PTIP, denoted by arrow and asterisk, occurred through progressive subdivision of the EE1 1 pool to a single clone. The uppermost
band is a fusion artifact of PTIP with vector sequences resulting in translation initiation at an upstream start codon in the vector. (B) Deletion
mapping of the phospho-binding domain of PTIP. Truncations of PTIP were assayed for selective binding to the pSQ library as in (A). BRCT
domain boundaries were determined from sequence alignments (22).
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Fig. 2. Comparison of the (BRCT)2 domains and determination of the
optimal phosphopeptide-binding motifs. (A) PTIP, BRCA1, BRCA1
M1775R, MDC1, 53BP1, and Rad9p (BRCT)z domains were assayed for
binding as in Fig. 1A. The peptide libraries used were pSQ (Fig. 1A),
pS = biotin-ZGZGGAXXXXpSXXXX-XAKKK; pSXXF = biotinZGZGGA
XXXXpSXXFX-XAYKKK (pS, pSer; pT, pThr; Z, aminohexanoic acid; X,
all amino acids except Cys). Domain boundaries: PTIP, as indicated in
Fig. 1; BRCA1 BRCT1 and BRCT2, amino acids 1633 to 1863; BRCT1
I
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31
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alone, amino acids 1633 to 1740; BRCT2 alone, amino acids 1741 to
1863; MDC1, amino acids 1874 to 2089; 53BP1, amino acids 1622 to
1972; Rad9p, amino acids 985 to 1309. (B) Strong selection by the
PTIP-(BRCT)z and BRCA1-(BRCT)z domains for Phe (F) at the (pSer/
pThr)-Gln +3 position (7.0 or 7.5), respectively (table S1) (21). Bar
graphs show the relative abundance of each amino acid at a given
cycle of sequencing versus its abundance in the starting peptide
library mixture (23).
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for the C-terminal (BRCT)2 domains of PTIP
and BRCA1 (Fig. 2B) (table SI ). PTIP-(BRCT) 2
and BRCA-(BRCT) 2 displayed strongest bind-
ing to similar but not identical motifs, with ex-
tremely strong selection in the (pSer/pThr) +3
position for aromatic and aliphatic residues, or
aromatic residues, respectively. More moderate
selection was also observed at other positions,
particularly (pSer/pThr) +2 and +5. We de-
-IR
fined an optimal (BRCT)2-binding peptide
(BRCTide) as Tyr-Asp-Ile-(pSer/pThr)-Gln-
Val-Phe-Pro-Phe and verified motif data with
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Fig. 3. Association of PTIP and BRCA1 (BRCT)2
domains with DNA damage-induced phospho-
proteins through their phosphopeptide-binding
pockets. (A) Lysates from U20S cells before or 2
hours after 10 Gy of -y-irradiation were incubated
with GST-PTIP-(BRCT)2. Bound proteins were de-
tected by immunoblotting with an antibody to
the (pSer/pThr)-Gln motif generated by ATM and
ATR. The interaction was disrupted by incubation
with the pSQ peptide library, but not with the SQ
peptide library or an unrelated pTP library (5). (B)
Interaction of the PTIP-(BRCT)2 domain with
phosphoproteins was disrupted by treatment of
U2OS cells with caffeine (5 mM) before irradia-
tion or by incubating the beads with BRCTtide
(7pT), but not by its nonphosphorylated counter-
part (7T). (C) (BRCT)2 domains of PTIP interact
with 53BP1 after DNA damage. Endogenous
53BP1 from irradiated U2OS cells was precipitat-
ed with GST-PTIP-(BRCT)2 and detected by im-
munoblotting with an antibody to 53BP1. U2OS
cells were transfected with HA-tagged 53BP1,
and the interaction with GST-PTIP-(BRCT)2 was
analyzed as in (A) and (B). Treatment of the cell
lysates with lambda phosphatase also abolished
the interaction. (D) Lysates from U20S cells
before or after irradiation were incubated with
GST-BRCA1-(BRCT)2 and analyzed as in (B). In
these experiments, the pSer version of BRCT-
tide (7pS) and its nonphosphorylated counter-
part (7S) were used.
C
Fig. 4. Full-length PTIP forms DNA damage-induced foci and colocalizes with (pSer/pThr)-Gln
proteins, 53BP1, and y-H2AX. All cells shown were either treated with 10 Gy of y-irradiation or
mock-irradiated 24 hours after transfection, allowed to recover for 2 hours, stained, and analyzed
by immunofluorescence microscopy. (A) U2OS cells were transfected with a full-length GFP-PTIP
construct (PTIP-FL residues 1 to 757). (B) U20S cells were transfected with a PTIP deletion
construct in which the last two BRCT domains had been removed (PTIP-ABRCT, residues 1 to 549).
(C) U2OS cells were transfected with a PTIP construct containing only the last two BRCT domains
[(BRCT)2, residues 550 to 757].
24 OCTOBER 2003 VOL 302 SCIENCE www.sciencemag.org
A
a
fpTO
X ppro
EDTA
IRA
a-U
41^A
B
638
in
- a-IP"Tl~p a
.~~t; .lu~I
the use of a solid-phase array of immobilized
phosphopeptides (fig. SI).
Isothermal titration calorimetry showed
that the optimal pSer-containing peptide
bound to the C-terminal (BRCT)2 of PTIP
with a dissociation constant of 280 nM, and
to the (BRCT) 2 of BRCAI with a dissocia-
tion constant of 400 nM (table S2). Substitu-
tion of pThr for pSer reduced the affinity of
the peptide for PTIP-(BRCT) 2, although
binding was still observed. Substitution of
pTyr, Ser, or Thr for pSer abrogated binding,
which confinned that (BRCT)2 modules are
pSer- or pThr-specific (fig. S).
After treatment of U20S human osteosar-
coma cells with 10 Gy of y-irradiation, both
PTIP-(BRCT)2 and BRCAI-(BRCT) 2 bound
distinct phosphoproteins, as detected by im-
munoblotting with a phospho-specific anti-
body to the (pSer/pThr)-Gln motif generated
by ATM and ATR (Fig. 3, A, B, and D).
Binding to (BRCT)2 was inhibited by incu-
bation with specific phosphopeptides but not
by nonphosphorylated peptides. Pretreatment
of the cells with caffeine to inhibit the activ-
ity of ATM and ATR before irradiation also
largely eliminated binding (14).
In response to y-irradiation, 53BP1 under-
goes multisite phosphorylation by ATM and
forms nuclear foci (15-17). We found that
53BP 1 bound to the C-terminal PTIP-(BRCT) 2
only after irradiation, and in a phosphorylation-
dependent manner (Fig. 3C). In addition, in
vivo association of full-lenglh FLAG-tagged
PTIP with hemagglutinin (HA)-tagged 53BP1
increased after irradiation (18).
The binding of (BRCT)2 domains to
ATM- or ATR-phosphorylated substrates
could localize PTIP to sites of DNA damage
in vivo. In the absence of DNA damage, PTIP
tagged with green fluorescent protein (GFP-
PTIP) was diffusely nuclear with a small
amount of cytosolic staining (Fig. 4). Two
hours after irradiation, PTIP localized into
discrete nuclear foci with (pSer/pThr)-Gln
phosphoepitopes, 53BP1, and y-H2AX (Fig.
4A). PTIP lacking the C-terminal (BRCT)2
did not form foci (Fig. 4B). The isolated
C-terminal (BRCT) 2 was diffusely nuclear in
the absence of DNA damage, but relocalized
into these nuclear foci after irradiation (Fig.
4C). Inhibition of ATM and ATR by caffeine
before irradiation reduced the number and
altered the appearance of full-length PTIP
foci, and caused loss of colocalization with
y-H2AX (fig. S2). These findings strongly
suggest that PTIP functions as a key compo-
nent of the DNA damage response and may
provide a molecular rationale for the early
embryonic lethality of PTIP knockout mice
with extensive unrepaired DNA ends (10).
(BRCT) 2 selection for aromatic and aliphatic
residues in the (pSer/pThr) +3 positions ex-
ceeds their selection for Gin in the + 1 position.
Thus, only a subset of ATM- and ATR-phos-
phorylated substrates are likely to bind with
high affinity, and other kinases might also gen-
erate (BRCT) 2-binding motifs. The important
role for (BRCT)2 domains as pSer- or pThr-
binding modules is emphasized by the finding
that -80% of germline mutations in BRCAI
result in C-terminal truncations involving the
BRCT region, predisposing women to breast
and ovarian cancer (12). Interestingly, a BRCA I
cancer-associated mutation in the (BRCT)2
module that ablates critical BRCA1 protein in-
teractions (19), Met""'7 5 Arg (M1775R), fails
to bind phosphopeptides (Fig. 2A), even though
the M 1775R crystal structure is nearly identical
to that of the wild-type (BRCT) 2 (20). Agents
that interfere with DNA damage signaling sen-
sitize tumor cells to killing by radiation and
chemotherapy. Thus, the phosphopeptide-bind-
ing pocket of (BRCT) 2 modules may constitute
a target for anticancer drug development.
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The BRCT Domain Is a
Phospho-Protein Binding Domain
Xiaochun Yu,' Claudia Christiano Silva Chini,' Miao He,Z
Georges Mer,3 Junjie Chen'*
The carboxyl-terminal domain (BRCT) of the Breast Cancer Gene 1 (BRCA1) protein
is an evolutionarily conserved module that exists in a large number of proteins from
prokaryotes to eukaryotes. Although most BRCT domain-containing proteins par-
ticipate in DNA-damage checkpoint or DNA-repair pathways, or both, the function
of the BRCT domain is not fully understood. We show that the BRCA1 BRCT domain
directly interacts with phosphorylated BRCA1-Associated Carboxyl-terminal He-
licase (BACH1). This specific interaction between BRCA1 and phosphorylated
BACH1 is cell cycle regulated and is required for DNA damage-induced checkpoint
control during the transition from G2 to M phase of the cell cycle. Further, we show
that two other BRCT domains interact with their respective physiological partners
in a phosphorylation-dependent manner. Thirteen additional BRCT domains also
preferentially bind phospho-peptides rather than nonphosphorylated control pep-
tides. These data imply that the BRCT domain is a phospho-protein binding domain
involved in cell cycle control.
The BRCT domain was first identified as
-100-amino acid tandem repeats at the C-
terminus of the tumor-suppressor gene prod-
uct BRCAI, in which the germline mutations
lead to -50% familial breast cancer. A large
number of proteins also contain single or
multiple BRCT motifs, and many of them
appear to function in DNA-damage check-
point control and DNA repair (1, 2).
The BRCT domains are important for the
tumor-suppressor function of BRCA1. Most
BRCAI mutations cause truncated BRCA1 gene
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